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The catabolic process of macroautophagy occurs constitutively in eukaryotic cells at a 
basal level and can become upregulated during periods of stress to recycle nutrients 
and promote cell survival. The role of this process in disease states is starting to be 
explored, particularly in cancers where the rapid growth and proliferation of cells 
generates a stressful environment. During the course of this study I investigated the 
role of autophagy in the aggressive brain cancer glioblastoma multiforme (GBM), 
focussing on the regulation of cellular signalling pathways that are known to drive 
oncogenesis. Specifically, I find that autophagy is required for tumour formation in an 
in vivo KRasG12D-driven mouse model of GBM, correlating in vitro with the 
suppression of senescence and stimulation of pro-growth signalling pathways. 
Additionally, autophagy is seen to promote anchorage-independent growth in a panel 
of cell line models of GBM, as well as being required for maintenance of cell 
signalling activities upon anchorage loss. Further exploration of cellular signalling 
activities revealed that the knockout of autophagy gene expression significantly 
reduces ligand-induced signalling from receptor tyrosine kinases, such as the 
epidermal growth factor receptor (EGFR), which is frequently mutated in GBM. The 
endocytic trafficking of EGFR is found to be perturbed in autophagy-deficient cells, 
with the receptor accumulating in early endosomes rather than maturing into recycling 
endosomes and returning back to the plasma membrane for renewed activation. 
Mechanistically, autophagy players localise to endosomal structures, which appear 
morphologically disrupted upon loss of autophagy gene expression, thereby 
suggesting that autophagy may directly regulate endosomal homeostasis. Together, 
these results support a role for autophagy in facilitating the oncogenic cell signalling 
that drives GBM. 
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4 Lay Summary 
Glioblastoma multiforme is a particularly aggressive brain cancer with a poor 
prognosis for patients. To develop better therapies there is an urgent need to 
understand more about the basic biology of these tumours. Previous work has shown 
that the aberrations that generate tumours increase the activity of signals in the cell 
that induce their uncontrollable division. Here we find that autophagy (literally 
meaning ‘self eating’), a process traditionally believed to simply be a way to break 
down and recycle unwanted cell components, has a novel function of regulating these 
tumour-associated signals. Our findings demonstrate that autophagy is required for 
glioblastoma tumour formation in mice by maintaining the ability of cells to divide. 
Further investigations reveal that autophagy aids the proper movement of growth 
messages through the cell, which enhances their potency. If this knowledge can be 
utilised to halt tumourigenic signals then it may be possible to attack an Achilles heel 
of glioblastoma multiforme.  
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7 Abbreviations 
3-MA  3-Methyladenine 
AP-2  Adaptor protein 2 
APPL1 Adaptor protein phosphotyrosine-interacting with PH domain and 
leucine zipper 
ATG  Autophagy-related 
BafA1  Bafilomycin A1 
BSA  Bovine serum albumin 
CDKN  Cyclin-dependent kinase inhibitor 
CIE  Clathrin-independent endocytosis 
CME  Clathrin-mediated endocytosis 
CSC  Cancer stem cell 
DAPI  4’,6’-diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle’s media 
EEA1  Early endosome antigen 1 
ECM  Extracellular matrix 
EGF(R) Epidermal growth factor (receptor) 
ER  Endoplasmic reticulum 
ErbB  Erythroblastic oncogene B 
ERK  Extracellular signal-related kinase 
ESCRT Endosomal sorting complexes required for transport 
FBS  Foetal bovine serum 
FIP200 FAK-interacting protein of 200kDa 
FGF(R) Fibroblast growth factor (receptor) 
Gal  Galectin 
GAP  GTPase-activating protein 
GBM  Glioblastoma multiforme 
GEF  GTPase-effector protein 
Grb2  Growth factor receptor bound 2 
GTPase Guanosine triphosphatase 
HCQ  Hydroxychloroquine 
HER2  Human epidermal growth factor receptor 2 
HGF  Hepatocyte growth factor 
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hr  Hour 
IF  Immunofluorescence 
IL  Interleukin 
IRS1  Insulin receptor substrate 1 
IGF-1(R) Insulin growth factor-1 (receptor) 
KRas  Kirsten Ras 
LAMP  Lysosomal-associated membrane proteins 
LC3  Microtubule-associated protein 1A/1B-light chain 3 
MAPK  Mitogen-activated protein kinase 
min  Minute 
mTOR(C1,C2)Mammalian target of rapamycin (complex 1, complex2) 
MVB  Multivesicular body 
NDP52 Nuclear dot protein 52 
NF-1  Neurofibromin 1 
OIS  Oncogene-induced senescence 
OPTN  Optineurin 
PDK1  Protein-dependent kinase 1 
PE  Phosphatidylethanolamine 
PI  Propidium iodide 
PI(3)P  Phosphatidylinositol-3-phosphate 
PI3KC3 Phosphatidylinositol-3-kinase catalytic subunit type 3 
pRb  Retinoblastoma protein 
RCAS/tv-a Replication-competent avian Sarcoma-leukosis LRT splice 
acceptor/tumour virus A 
ROS  Reactive oxygen species 
RTK  Receptor tyrosine kinase 
SASP  Senescence-associated secretory phenotype 
SEM  Standard error of the mean 
sgRNA Single guide RNA 
siRNA  Small intefering RNA 
SOS  Son-of-sevenless 
STAT  Signal transducer and activator of transcription 
TBC  Tre2-Bub2-Cdc16  
TBK1  TANK-binding kinase 1 
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Tfn(R)  Transferrin (receptor) 
Tp53  Tumour protein 53 
ULK1  UNC51-like serine/threonine kinase 1 
UVRAG UV radiation resistance-associated gene 
VEGF(R) Vascular endothelial growth factor (receptor) 
WIPI2  WD repeat domain phosphoinositide interacting 2 





8.1 The Autophagy Pathway 
First coined by Christian de Duve fifty-five years ago, the term ‘autophagy’ finds its 
roots in Greek, roughly translating as ‘self-eating’1. Since then, it has been revealed 
that autophagy can have far-reaching impacts on different organelles and cellular 
pathways and is finely tuned by a vast array of signals to tailor its rate to the specific 
needs of the cell. Several different modes of autophagy are known, although as much 
of the field focuses on macroautophagy this process has become synonymous as 
autophagy. Macroautophagy is the process of encapsulation of cellular components, 
such as proteins and organelles, in double-membrane vesicular structures, called 
autophagosomes, which can then fuse with the lysosome where the contents are 
degraded. Other forms include microautophagy (direct uptake of materials into the 
lysosome via membrane invaginations) and chaperone-mediated autophagy (assisted 
translocation of proteins through the lysosomal membrane)2,3. During the course of 
this study, I have focussed on the process of macroautophagy, which I shall hereafter 
refer to as autophagy.  
On the organism level, autophagy has been seen to be critical during development and 
for tissue homeostasis, whilst its deregulation has been associated with a myriad of 
different pathologies. Mice deficient in autophagy cannot survive long after birth and 
loss of autophagy selectively in neurons results in the early onset of 
neurodegenerative disease4–6. Indeed, numerous studies of the the role of autophagy in 
neurodegeneration have suggested its function may be instrumental in preventing this 
disease5. Furthermore, a wealth of research has also focussed on the influence of 
autophagy on cancer, although the results are seemingly conflicting and certainly 
context-dependent7. To make sense of the findings from mouse models, however, we 
must look at the cellular level. Therefore, I shall begin by introducing the molecular 
machineries that mediate the process of autophagy. 
8.1.1 Pathway Overview 
Much of what is currently known regarding the essential components of autophagy 
was uncovered in a series of studies in yeast, with the earliest elegant experiments 
performed by Yoshinori Ohsumi, earning him the 2016 Nobel Prize for Medicine and 
Physiology8–10. He established that the products of autophagy-related (ATG) genes 
22 
co-ordinate a series of events that generate an autophagosome. Fortunately, autophagy 
is well conserved between yeast and mammalian cells and therefore much of this 
knowledge has been transferred between eukaryotes. Here I shall summarise what is 
known regarding key regulators of the mammalian autophagy pathway (Figure 8.1). 
Autophagy occurs constitutively in cells but can be upregulated in situations of stress, 
such as amino acid depletion or low oxygen levels. The signals that sense these 
stressors are co-ordinated by the upstream UNC51 like serine/threonine kinase 
(ULK1) and phosphatidylinositol-3-kinase catalytic subunit type 3 (PIK3C3) 
complexes to stimulate autophagy.  
 
Figure 8.1 Overview of the Autophagy Pathway 
ATG proteins catalyse the production of phosphatidylinositol-3-phosphate and the conjugation of LC3 
to phosphatidylethanolamine. This facilitates the production of the pre-autophagosomal membrane that 
encapsulates cellular components. Following a membrane expansion step, the fully formed 
autophagosome vesicle can fuse with the lysosome, where contents are then degraded and recycled 
back into the cell. 
These complexes can cross-activate each other by a series of post-translational 
modifications and result in the production of phosphatidylinositol-3-phosphate 
(PI(3)P), a lipid essential to recruit downstream autophagy players (as described in 
more detail section 8.1.3). Additionally, the mammalian ATG8 family members 
(gamma-aminobutyric acid receptor-associated proteins (GABARAP, GABARAPL1, 
and GABARAPL2) and microtubule-associated protein 1A/1B-light chain 3 proteins 
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(LC3A, LC3B, and LC3C)) are prepared for conjugation to the lipid 
phosphatidylethanolamine (PE) through proteolytic cleavage by ATG4 cysteine 
protease family members, which exposes a glycine at their C-termini. By pairing with 
ATG10, ATG7 can catalyse the ubiquitin-like conjugation of ATG12 to ATG5, which 
then binds to each molecule in a homodimer of ATG16L1, thereby producing the 
(ATG12-ATG5-ATG16L1)2 complex. Next, ATG7 can function alongside ATG3 and 
the (ATG12-ATG5-ATG16L1)2 complex to facilitate the enzymatic addition of 
ATG8 proteins to PE11.  
Following these initiation steps, ATG8+/PI(3)P+ membranes then undergo an 
expansion step enabled by membrane contributions from several sources. Electron 
microscopy has revealed that a wide variety of organelles can undergo some form of 
contact with autophagosomes, and therefore could be sources of membrane for 
autophagosome biogenesis12. However, the best-established site for autophagosome 
biogenesis is the ‘omegasome’ cradle that is formed by a highly curved branch from 
the endoplasmic reticulum (ER)13. Following completion of this expansion step, the 
fully formed autophagosome can then undergo fusion with the lysosome, where acidic 
hydrolases degrade the autophagosomal contents. In this manner, autophagosomes 
can act as shuttles to the lysosome.  
8.1.2 The ULK1 Complex: Mediation of Autophagy by mTORC1 Signalling 
The mammalian target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2) are 
considered ‘master regulators’ of anabolic metabolism. mTORC1 is composed of 
mTOR, mLST8, and Raptor, whilst mTORC2 contains mTOR, mLST8, mSIN1, and 
Rictor14. mTORC1 can sense oxygen tension, mitogenic signalling, and the 
abundance of nutrients, such as amino acids, and subsequently co-ordinates the rates 
of synthetic and degradation processes according to the available resources14,15. For 
example, relinquishment of mTORC1-mediated inhibition ULK complex is required 
for the upregulation of autophagy during times of hypoxia or amino acid depletion16. 
ULK, originally identified in yeast as Atg1, functions in a complex consisting of: 
ATG13, FAK family kinase-Interacting Protein of 200 kDa (FIP200), ATG101, and a 
ULK family member (of which, ULK1 and ULK2 are apparently functionally 
redundant)17. Several reports concurrently described the regulation of this complex by 
mTORC1, which occurs via several residues on ULK1 and ATG13 that are targeted 
by the kinase activity of mTORC116,18,19. Furthermore, mTORC1 prevents the TNF 
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receptor-associated factor 6 (TRAF6)-mediated addition of Lys63 ubiquitin chains to 
ULK1 by disrupting the autophagy and Beclin-1 regulator 1 (AMBRA1)-TRAF6 
complex, thereby resulting in the destabilisation of ULK1. 
It has been uncovered that mTORC1 is activated on the lysosomal membrane, in a 
mechanism that is mediated by the v-ATPase and the amino acid sensors Sestrin2, 
CASTOR1, and SLC38A9, as well as activation from Rheb and Rags 1 and 2, which 
are responsive to nutrient levels15,20–22. It is currently a point of active research how 
the mTOR complexes are spatially and temporally co-ordinated with downstream 
targets that are not themselves localised on the lysosome, such as ULK118,23,24.  
The mechanism by which the ULK complex initiates autophagy is becoming 
increasingly understood. For example, studies have found that the complex that 
catalyses PI(3)P production at pre-autophagosomes, PIK3C3, is one of the targets for 
this kinase .  
8.1.3 The PIK3C3 Complex: An Intersection for Autophagy Regulation 
The core components of the PIK3C3 complexes are PIK3C3, also known as vacuolar 
protein sorting 34 (VPS34) (often used synonymously to refer to the holoenzyme), 
VPS15, and Beclin-125. For its activity at autophagosomes it complexes with 
ATG14L1 (complex 1), whereas at endosomes it associates with UVRAG (complex 
2)25. PIK3C3 can generate PI(3)P either on endosomal membranes or at sites of 
autophagosome biogenesis on the ER, such as at ER-mitochondria contact sites, by 
phosphorylating phosphoinositol (PI)13,26,27. Interestingly, the endocytic and 
autophagic PIK3C3 complexes have differing abilities to act on vesicles of different 
sizes: whilst both can act on smaller, more curved vesicles, only the endocytosis-
specific complex can phosphorylate PI on less curved vesicles corresponding to the 
larger size of endosomes relative to pre-autophagosomal/omegasomal structures28.  
PI(3)P is essential for the formation of the autophagosome. Following the activity of 
PIK3C3 complex 1, downstream autophagy effectors are then recruited to PI(3)P, 
such as double-FYVE-containing protein 1 (DFCP1) and WD-repeat protein 
interacting with phosphoinoside family member 2 (WIPI2) 13,29,30. Although current 
understanding of the process suggests that this primarily occurs from omegasome 
cradles at the ER, other membrane structures have also been seen to be involved in 
autophagosome nucleation13,24,31,32. The duality of PIK3C3 in these different 
complexes presents an opportunity to induce autophagy and endocytosis distinctly 
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according to upstream cues, such as mitogenic signalling (explored in greater detail in 
section 8.2.4)33. 
8.1.4 Regulation of LC3 Lipidation and Autophagosome Maturation 
Once the ULK and PIK3C3 complexes have been stimulated to set the scene, LC3 
lipidation is then undertaken. The conjugation of LC3/GABARAP proteins to the 
lipid PE is generally considered the hallmark of autophagosome formation. Therefore, 
autophagosome biogenesis relies not only on stimulation of the function of upstream 
players but also requires the activation of enzymes that facilitate the lipidation of 
LC3/GABARAP family proteins. As I frequently ablate the expression of players that 
mediate the lipidation of LC3B in the course of this study, here I shall describe what 
has been gleaned from studies that have primarily focussed on that isoform. 
Parallels have been drawn between LC3 lipidation and the system of enzymes that 
catalyse the conjugation of ubiquitin to its targets. In autophagy, the enzymes that 
catalyse the conjugation of the ubiquitin-like ATG12 and LC3/GABARAP proteins to 
targets are comparable to E1, E2, and E3 ubiquitination enzymes. The regulation of 
this lipidation process is explored below. 
8.1.4.1 Preparation of LC3 
Lipidation of LC3B can only occur once the 22 amino acids from the C-terminus of 
pro-LC3B are cleaved off by an ATG4 family member, generating ‘LC3-I’, which 
exposes a glycine for conjugation to PE34. Current evidence suggests that there is 
some degree of redundancy between ATG4 A, B, C, and D isoforms, with ATG4B 
being the most broad-acting catalyst across the LC3/GABARAP families35. 
Additionally, ATG4 can catalyse LC3B deconjugation and so, when overexpressed, it 
can inhibit autophagosome formation36,37. Therefore, ATG4 has the intriguing ability 
to both promote and inhibit autophagic flux.  
Post-translational modifications can modulate the activity of this protease. Firstly, 
oxidative conditions, sensed by a reactive cysteine residue at position 81, are required 
for ATG4 activity, whilst reducing conditions can inhibit the protein via a key 
disulphide bond between cysteines 338 and 39438,39. Therefore, oxidising conditions 
promote ATG4 function and autophagic flux. Furthermore, a recent paper has 
revealed that ATG4 is also modulated by the phosphorylation of serine 383 by Golgi 
resident protein mammalian STE20-like protein kinase 4 (MST4), which promotes its 
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activity40. These reports demonstrate that autophagosome biogenesis can be regulated 
by the cellular status at several different points, right down to the final catalytic steps. 
8.1.4.2 The Lipidation of LC3 
The lipidation of LC3 requires the same E1-like function of ATG7 at two distinct 
steps: it catalyses the link between ATG3 and the glycine in LC3-I as well as 
facilitating the coupling of ATG12 to ATG5, which binds ATG16L1.  
The (ATG12-ATG5-ATG16L1)2 complex can be recruited to PI(3)P-positive WIPI2-
labelled pre-autophagosomal structures via interactions between ATG16L1 and 
WIPI2 as well as FIP20029,41. ATG12 can then recruit ATG3 to catalyse the bond 
between LC3 and PE, producing LC3-II, which facilitates the closure of the 
autophagosome. This step may be regulated by the physical properties ATG3 itself, 
which preferentially binds to highly curved membranes of the pre-autophagosome 
lipid bilayer42. 
Interestingly, ATG16L1 is dispensable for LC3 lipidation in vitro but is required in 
cells, thereby suggesting that ATG16L1 is required for targeting of the ATG12-ATG5 
to pre-autophagosomal structures in the cell43. Although it has been reported that the 
localisation of ATG16L1 at pre-autophagosomes requires clathrin-mediated 
endocytosis from the plasma membrane, the molecular mechanism that mediates its 
trafficking is unknown44. Indeed, even the subcellular localisation of ATG16L1 is 
currently under dispute (see section 8.2.3.3).  
Regulation of the LC3 lipidation machinery is suggested by observations that 
although ATG7 constitutively catalyses the formation of ATG12-ATG5 complexes in 
the cytoplasm, the conjugation of LC3 to PE occurs in a highly selective and 
controlled manner specifically at sites of autophagosome formation. This implies that 
either re-localisation or activation of these players must occur upon autophagy 
induction. Furthermore, whilst it is known that PI(3)P is important for the recruitment 
of upstream players, such as WIPI2, that then bind members of the LC3 lipidation 
machinery, it is not currently understood how certain PI(3)P pools are specified for 
autophagy. The majority of PI(3)P in the cell is found at early endosomes and yet it is 
a specific ER-localised PI(3)P pool that is generally believed to be responsible for the 
initiation of autophagy13. It is unknown how this spatial selectivity is achieved. These 
are exciting questions in the autophagy field, the answers to which may be 
enlightening in the search for a specific autophagy inhibitor. 
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8.1.4.3 Formation of the Autolysosome 
Following its completion, the autophagosome is delivered to the lysosome, generating 
the autolysosome, where acidic hydrolases degrade its contents. Microtubule 
networks regulate trafficking to facilitate sorting nexin 17 (SNX17)/soluble n-
ethylmaleimide sensitive factor attachment protein 29 (SNAP29)/vesicle associated 
membrane protein 8 (VAMP8)-regulated fusion of autophagosomal and lysosomal 
membranes45,46. Although this process is still incompletely understood, it is known 
that fusion requires the activity of the late endosomal regulator Rab7. Rab7 is 
regulated by its corresponding guanine nucleotide exchange factor (GEF) Mon1-
Ccz1, as well as the homotypic vacuole fusion and protein sorting (HOPS) 
complex47,48. Further investigation has revealed that Pleckstrin homology domain 
containing protein family member 1 (PLEKHM1) plays a key role in this process by 
bringing LC3-containing structures into contact with the HOPS complex, Rab7, and 
SNX1749. It seems, therefore, that autophagosome-lysosome fusion involves many of 
the same players and regulators that are required in the endolysosomal pathway. 
In addition to its role early in autophagosome biogenesis, ATG14L1 is also required 
for the final step of autophagosome-lysosome fusion, with homodimers of the protein 
engaging SNX17/SNARE19/VAMP850. Furthermore, ATG14L1 facilitates 
production of the lipid PI(4,5)P2 by type Iγ phosphatidylinositol phosphate kinase i5 
(PIPKIγi5) at the interface between the ER and late endosomes51. This has the dual 
function of firstly significantly stabilising the PIK3C3 complex 1 and secondarily 
promoting fusion of autophagosomes with the lysosome by facilitating PI(4,5)P2 
production. Therefore, ATG14L1 has been seen to be key at both the very early 
embryonic stages of autophagosome biogenesis and the final fusion step with the 
lysosome to instigate degradation. 
Intriguingly, a recent study from the Mizushima group observed that although LC3 
lipid conjugation vastly increases the efficiency of degradation of autophagosomal 
structures, it is not strictly required for the process to occur52. This is indeed logical in 
terms of reaction kinetics and it demonstrates that LC3 lipidation is not necessarily 
the complete story of autophagy. 
8.1.5 Specific Cargoes Are Targeted by Autophagy 
For many years autophagy was thought to capture largely random sections of the 
cytoplasm and deliver them to the lysosome to regenerate cellular building blocks 
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under conditions of stress53. However, a considerable amount of recent evidence has 
revealed that autophagy actually utilises targeted cargo receptors to ensnare specific 
cargo. Some of these targeting mechanisms are outlined here. 
8.1.5.1 Xenophagy 
Autophagy targets can be marked out for degradation by post-translational 
modifications, such as ubiquitination. Ubiquitin-binding autophagy receptors such as 
sequestosome 1 (SQSTM1)/p62, nuclear dot protein 52 (NDP52), and Optineurin 
(OPTN) then recognise ubiquitinated cargoes and link them to the autophagy 
machinery54–56.  
These cargoes include bacteria, which are cleared from cytosolic and endosomal 
compartments of cells as part of the innate immune response to limit infection, in a 
process called xenophagy. Bacteria, such as Shigella, Salmonella, and Listeria, trigger 
the activation of nucleotide-binding oligomerisation domain (NOD)-like receptors 
and Toll-like receptors (TLRs) by recognition of pathogen-associated molecular 
patterns (PAMPs)54,56,57. The bacterium is then labelled with ubiquitin, which can be 
recognised by the autophagy machinery. In one example, ubiquitinated Salmonella is 
recognised by OPTN56. TANK-binding kinase 1 (TBK1), which is activated by TLR 
signalling, then phosphorylates OPTN and induces its binding to LC3 thereby 
facilitating the entrapment of the bacterium in the autophagosome. 
The targeting of vesicular-resident bacteria for autophagic degradation is mediated 
upstream by galectins. Galectins are a family of proteins that recognise modified 
sugars found either on bacterial coats or on the inner face of endosomal membranes, 
which are exposed upon disruption of endomembranes by bacteria. Although 
galectins-3, -8, and -9 have all been described to localise to vesicles harbouring the 
Salmonella bacterium, galectin-8 is believed to be the primary means by which this 
bacterium is cleared58. This is mediated by the binding of galectin-8 to NDP52, which 
then binds LC3 on the autophagosome surrounding the bacterium. Interestingly, 
LC3C is the only Atg8 family member that can bind NDP52 and therefore may play a 
central role in xenophagy and immunity59. 
8.1.5.2 Organellar Autophagy 
Due to common upstream autophagic targeting mechanisms, selective removal of the 
mitochondria by autophagy may parallel the clearance of bacteria during xenophagy. 
This is intriguing considering that current research suggests that both bacteria and 
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mitochondria evolved from similar prokaryotic ancestors. However, unlike 
xenophagy, ‘mitophagy’ is generally believed to maintain the health of the 
mitochondrial network rather than destroying it. Disruption of autophagy leads to the 
accumulation of damaged mitochondria that can leak reactive oxygen species causing 
significant damage to other cellular components, such as lipids, proteins, and DNA60. 
As a result, loss of mitophagy may promote mutagenesis, altered metabolism, or cell 
death.  
Although it is now recognised that alternative mitophagy mechanisms may exist 
under basal conditions, inducing damage experimentally has revealed that a 
PINK1/Parkin-mediated process can target mitochondria for degradation by 
autophagy. Firstly, following depolarisation of its membrane, the ubiquitin kinase 
PINK1 binds to the mitochondrion61. The E3 ubiquitin ligase Parkin is then recruited 
and phosphorylated by PINK1. Parkin subsequently assembles ubiquitin chains on a 
variety of mitochondrial outer membrane proteins, which are themselves then 
subjected to phosphorylation by PINK1 at serine 65. These phospho-ubiquitin chains 
enhance Parkin binding and activity at the mitochondria, thereby acting as part of a 
positive feedback loop. TBK1 then acts in concert with OPTN, NDP52, and p62 to 
recognise phospho-ubiquitin, recruit LC3, and facilitate the sequestration of the 
mitochondrion into an autophagosome55,61. Defects in this process have been strongly 
linked to pathologies, such as Parkinson’s disease and amyotrophic lateral sclerosis 
(ALS), although the precise causes and molecular mechanisms are still currently 
unknown61,62.  
Mitochondria are not the only organelle to be selectively degraded by autophagy, 
however; lysosomes, ribosomes, and the endoplasmic reticulum have all been shown 
to be targeted to autophagosomes. For example, leaking lysosomes can be cleared by 
autophagy to prevent the exposure of the cell to acidic conditions, cathepsins, and 
other such hydrolases63–65. These damaged membranes are recognised by galectins 
and are enriched in ubiquitin and p6265. Removal of such endo-lysosomal damage not 
only maintains lysosomal homeostasis to protect against cell death but also helps 
defend against invading pathogens that propagate in the lysosome65,66.  
Similarly, exciting data from the Sabatini group has shown that ‘ribophagy’ is also 
required for cell survival. This is facilitated by the recruitment of LC3B to ribosomes 
upon amino acid starvation by the cargo receptor nuclear fragile X mental retardation-
interacting protein 1 (NUFIP1)67. The selective degradation of ribosomes during 
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starvation replenishes pools of arginine, lysine, and nucleosides in the cell. However, 
it is not currently known which cues induce the localisation of NUFIP1 to ribosomes 
upon amino acid depletion. It is possible that it is not an ubiquitin-mediated process, 
however, as these are not damaged or aberrant structures being degraded, but rather 
normal healthy organelles. 
Additionally, further to its role in generating the omegasome autophagosome 
precursor, the ER network can itself be targeted by autophagy. The ER-resident 
proteins FAM134B, SEC62, cell cycle progression gene 1 (CCPG1), and reticulon 3 
(RTN3) can act as receptors that mediate the degradation of the ER by binding to 
components of the autophagy machinery, including LC3B and FIP20068–70. In this 
way, ‘ER-phagy’ can conserve the gross structure and function of the organelle, as 
well as hastening the resolution of ER stress to maintain cell homeostasis. This is an 
emerging field and it is intriguing to consider what other key ER functions may rely 
its autophagic turnover.  
8.1.5.3 Specific Proteins Can Be Targeted By Autophagy 
In addition to organelles, specific proteins can also be targeted to autophagosomes for 
degradation. In this regard autophagy works hand-in-hand with the proteasome to 
mediate the degradation of ubiquitinated proteins. Some diverse examples of proteins 
that are degraded by autophagy include the tyrosine kinase Src, the naïve cytokine 
pro-interleukin (IL)-1β, and the redox regulator Keap171–73.  
However, it is still unclear whether many other proteins could actually be regulated 
by autophagy under specific conditions. For example, Xu et al. showed that EGFR 
can be degraded by autophagy in an EGFR inhibitor-resistant lung cancer cells treated 
with the triterpene molecule celastrol74. The degradation of EGFR by autophagy 
promoted cell death in this instance; thereby suggesting that autophagy may be 
required to enhance the effects of some chemotherapeutic agents. 
 
8.2 Endocytic Trafficking, Receptor Tyrosine Kinase Signalling, 
and Autophagy 
During the course of research into the molecular regulation of autophagy, it has been 
found that autophagy and the endocytic pathway overlap at a multitude of points. 
These connections regulate autophagosome biogenesis and may also impact the 
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function of endosomes, such as the endocytic trafficking of receptor tyrosine kinases 
(RTKs). These concepts are explored in this section, although many open-ended 
questions remain, particularly with regards to the potential impact of autophagy on 
endosomes. 
8.2.1 Introduction to the Endosomal Pathway 
Cells can respond to extracellular conditions either by relaying signals from receptors 
on the membrane directly to intracellular networks or by taking up plasma membrane 
proteins or extracellular materials into single-membraned vesicles called endosomes. 
These vesicles can harbour diverse cargoes including invading bacteria and viruses, 
growth factor-RTK complexes, and nutrients such as glucose75–77.  
Endocytosis begins at the plasma membrane where different machineries can be 
engaged to create membrane invaginations that can bud off as endosomal vesicles. 
The uptake of targets in membrane-bound vesicles allows the internalisation of 
proteins with hydrophobic transmembrane domains and regulates their transport to 
specific intracellular compartments. Mechanisms for uptake include 
macropinocytosis, clathrin-mediated endocytosis (CME) or clathrin-independent 
endocytosis (CIE). Each of these three processes has specific sets of regulatory 
machineries and different triggers. For example, high doses of EGF ligand result in 
EGFR CIE whereas lower quantities of EGF engage CME81. Whilst CME promotes 
recycling of EGFR to the plasma membrane for continued activation, CIE directs the 
receptor to the lysosome, thereby ablating signalling. Therefore, protein activities can 
be differentially regulated by CME and CIE. 
CME is considered a highly selective process and is the best characterised mechanism 
of endocytosis. Surrounding cargoes that undergo CME is a localised concentration of 
PI(4,5)P2 that recruits lipid-binding adaptor proteins, such as adaptor protein 2 (AP-
2). These membrane-targeted adaptor proteins, as well as other CME-regulators such 
as Epsin, induce the curvature of the pit structure79,80. Adaptor proteins also connect 
the target cargo to clathrin; a triskelion complex composed of heavy and light chains, 
which is assembled into a multimeric coat around cargoes (Figure 8.2A1,B1). 
Dynamin then acts around the neck of the bud to pinch it off and allow its entry into 
the cell as a clathrin-coated vesicle (Figure 8.2A2,B2). The coat complex then 
disassembles and adaptor protein phosphotyrosine interacting with PH domain and 
leucine zipper 1  (APPL1) is recruited to membranes containing active receptors and 
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PI(4,5)P2. This is known as the pre-early endosome (Figure 8.2A3)81. The GTP-bound 
form of the small guanosine triphosphatase (GTPase) Rab5 is then recruited to the 
vesicle, following which the endocytosis-specific complex of PIK3C3 (PIK3C3-
Beclin-1-UVRAG) generates PI(3)P82. The early endosome is then marked with early 
endosome antigen 1 (EEA1), which has binding domains for both Rab5 and PI(3)P83.  
Figure 8.2 Clathrin-Mediated Endocytosis 
A: A simplified diagram representing the process of clathrin-mediated endocytosis, from the formation 
of PI(4,5)P2-containing pits at the plasma membrane that are coated in clathrin triskelions (1), to 
maturation into PI(3)P-positive early endosomes (4), B: Electron microscope image obtained by myself 
where different stages of clathrin-mediated endocytosis can be clearly seen and are labelled with 
numbers according to part A. Scale bar represents 500µm 
Early endosomes mature into other endosomal classes (Figure 8.3). The regulation of 
endosomal maturation and trafficking are key to propagate or dampen the activity of a 
variety of different cargoes taken up from the plasma membrane and thereby 
influences a variety of cellular functions. 
Whilst protein moieties that associate with different discrete endosomal 
compartments, such as members of the Rab superfamily, have been relatively well 
documented, the regulation of endosomal lipid composition has received sporadic 
attention. Whilst the synthesis and role of PI(3)P at early endosomes has been 
explored in some detail over more than two decades, phosphatidylinositol (PI) species 
at other endosomal compartments are only now starting to be elucidated25,83. These 
lipid moieties are important in facilitating the binding of the correct endosomal 
regulators, such as membrane remodelling proteins, to each compartment and 
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therefore the so-called ‘phosphoinositol switch’ is becoming recognised as a critical 
regulator of endosomes84,85. Therefore, during the ensuing sections, I shall describe 
both protein and PI markers of each endosomal compartment. 
8.2.1.1 Late Endosome to Lysosome Trafficking 
En route to the lysosome for degradation, cargos from the plasma membrane undergo 
transition through late endosomes that are marked by Rab7 and the lipid PI(3,5)P2, 
which is generated by PIKfyve86–89. These late endosomes can either exist as a single 
vesicle or can undergo membrane invaginations, mediated by the endosomal sorting 
complexes required for transport (ESCRT) proteins, to form multivesicular bodies 
(MVBs)90. The ESCRT complex is recruited first by ESCRT 0, which binds PI(3)P on 
endosomes as well as their ubiquitinated cargo91. ESCRT I, which also has cargo-
binding function, is then recruited to ESCRT 092. ESCRT II then binds both ESCRT I 
and PI(3)P, thereby further anchoring the complex to the membrane. Finally, ESCRT 
III components assemble to induce membrane scission and pinch off the bud into the 
lumen of the endosome. Therefore, whilst the surface of MVBs is believed to be 
primarily decorated with PI(3,5)P2, the intraluminal vesicles that are formed inside the 
body are PI(3)P -positive93. 
Late endosomes and MVBs then go on to fuse with the lysosome. The lysosomal 
vesicle is the final stop of the endolysosomal pathway and carries out the breakdown 
of cargoes, thereby terminating their signal. The lysosomal enzymes that catalyse 
these degradation reactions are hydrolases that function specifically in the acidic 
conditions that are found in this organelle (roughly pH 5)94. This prevents any 
inadvertent activity against cytosolic components, which, if left uncontrolled, could 
lead to cell death63. To achieve such a low pH, lysosomes employ vacuolar ATP-
dependent proton pumps (v-ATPases) to transport protons against their concentration 
gradient into the lysosome95. The resulting vesicle can be recognised by the presence 
of lysosomal-associated membrane proteins 1 and 2 (LAMP1 and LAMP2), which are 
believed to make up approximately half of the membrane protein content of 
lysosomes96. 
8.2.1.2 Regulating Recycling to the Plasma Membrane 
Instead of being degraded, some cargoes can be recycled back to the plasma 
membrane. The recycling of these cargoes can occur via either ‘fast’ or ‘slow’ 
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mechanisms. The more rapid system utilises Rab4 to return distal early endosomes 
directly back to the plasma membrane, whereas the slower Rab11-mediated system 
sends cargo via the perinuclear region, thereby providing a degree of spatial, 
temporal, and molecular regulation97. Rab11-positive recycling endosomes have been 
observed to form both from the Golgi apparatus, which is primarily localised near the 
nucleus, and from early/sorting endosomes98. The generation of these recycling 
endosomes relies on a dynamin-mediated tubulation and pinching off of membrane 
containing the specified cargoes99,100. Furthermore, recent work has elucidated that 
during the generation of recycling endosomes a characteristic PI conversion occurs: 
PI(3)P is dephosphorylated to PI, which is then phosphorylated to produce PI(4)P that 
can be further modified to PI(4,5)P2101,102.  
The recycling of plasma membrane cargoes facilitates renewed activation of pathways 
without requiring additional protein synthesis, which is therefore faster and more 
energy-efficient for the cell. 
8.2.1.3 Retrograde Endocytic Transport 
Early endosomes can also undertake a retrograde route that sends cargo through the 
Golgi apparatus and ER. The cargo can then be exocytosed from the cell, returned to 
the plasma membrane, or delivered to a different cellular compartment, such as the 
lysosome. The transport of proteins through this route and controlled by the 
‘retromer’ complex, composed of VPS26, VPS29, and VPS35, as well as a cargo-
recognition complex103,104. Following the docking of the core retromer complex, SNX 
membrane remodelling proteins and the actin-polymerising WASH complex produce 
budding structures from PI(3)P-positive early endosomal membrane105.  
The retromer can be critical in the regulation of cell and organelle homeostasis. For 
example, the retromer mediates the endosome-Golgi retrieval of the cation-
independent mannose-6-phosphate receptor (CI-M6PR)103,106. This is required for CI-
M6PR function in delivering lysosomal proteins from the Golgi to the lysosome and 
thereby is critical for lysosomal function.  
Further to these cytoplasmic trafficking events, it is now understood that the 
retrograde endocytic pathway can also be used to target proteins to the nucleus, in a 
mechanism that seems to require co-operation with nuclear pore proteins such as 
importin-β or members of the Sad1/unc-84 protein-like (SUN) family107,108. This 
therefore provides a mechanism to relay signals from the extracellular environment 
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directly to DNA regulation machinery in the nucleus (for details of this function see 
section 8.2.2.4). There is not much known regarding the exact mechanisms that 
regulate endosome-nucleus transport, but it is currently the subject of rigorous 
investigation, particularly with regards to cancer109. 
 
 
Figure 8.3 Summary of RTK Trafficking Through the Endolysosomal System 
Following ligand binding at the plasma membrane, RTKs can be trafficked through different 
endosomal compartments or be transported to the nucleus. These events are mediated by different Rab 
family members, which can act as markers for each compartment, and generate a signalling response, a 
few of the key outputs of which (Akt and ERK) are summarised here. 
 
8.2.2 Introduction to Receptor Tyrosine Kinase Signalling  
One class of cargo that can be trafficked by endocytosis are the receptor tyrosine 
kinases (RTKs) transmembrane proteins. In this section, I will explain how these 
receptors are activated and endocytosed, then how they relay their activities to 
intracellular signalling cascades. 
8.2.2.1 Receptor Tyrosine Ligand Binding  
RTKs at the plasma membrane bind specific ligands from the extracellular milieu. 
Receptors then undergo conformational changes that result in asymmetric 
dimerization and cross-phosphorylation of the intracellular tyrosine kinase domains of 
the receptor (Figure 8.4). For example, phosphorylation of tyrosines 1,068 and 1,173 
in the C-terminal domain of EGFR are reliably used as markers for its activation110. 
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RTKs can be activated in response to growth factor ligands that induce a variety of 
cellular responses, including the stimulation of cell growth and anchorage-
independence or the repression of cell death77. To prevent over-activation of tyrosine 
kinase signalling cascades the cell has developed a variety of regulatory mechanisms 
for RTKs. However, although extensively studied, detailed understanding of 
signalling pathways downstream from RTKs is considerably confounded by the 
regulatory complexities and capabilities for crosstalk between different components. 
Here I shall describe some example signalling pathways that are known to lie 
downstream of RTKs such as EGFR. 
8.2.2.2 Ligand Binding Induces Post-Translational Modification of RTKs 
It is known that RTK signalling is co-ordinated by the binding of adaptors containing 
Src homology (SH) or phospho-tyrosine-binding (PTB) domains to phosphorylated 
residues of activated receptors77. Several of these adaptors, such as growth factor 
receptor-bound protein-2 (GRB2) and insulin-receptor substrate 1 (IRS1), can 
simultaneously bind to the same activated receptors, providing multiplexing and 
synchronisation of downstream pathway activities. The particular domains present in 
each adaptor protein mediate the assembly of these complexes at RTKs. For example, 
in addition to a PTB domain, IRS1 also harbours a PH domain that anchors it to the 
plasma membrane at sites of PI(4,5)P2 enrichment surrounding activated RTKs111,112. 
IRS1 is then phosphorylated, following which proteins containing SH2 and SH3 
motifs, such as GRB2 and the p85 subunit of class I phosphatidylinositol-3 kinase 
(PI3K), are recruited to phospho-tyrosine residues112,113.  
It is known that certain protein tyrosine phosphatases (PTPs) can act on RTKs, 
thereby altering their protein conformation and inactivating their kinase activity. 
These phosphatases are themselves regulated both temporally and spatially. For 
example, induction of EGFR activity by EGF binding induces the inactivation of 
PTP1B by its oxidation114,115. This oxidation peaks at approximately ten minutes after 
EGF binding, then drops to baseline levels after approximately forty minutes, thereby 
allowing for a controlled window of EGFR signalling activity. PTPs are also 
regulated spatially to physically separate areas of RTK activation and inactivation. 
For example, PTP1B is constitutively localised to the endoplasmic reticulum where, 
at specific contact sites with endosomes, it can regulate the inactivation of most RTKs 
following their activation at the plasma membrane116. 
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As well as phosphorylation, RTKs can be modified by ubiquitination, which induces 
their trafficking to lysosomes and therefore inhibits their signalling capacity117,118. 
 Ubiquitin marks can act as binding sites for Hrs or ESCRT components, thereby 
promoting the sequestration of RTKs into MVBs that are destined for lysosomal 
delivery92,118. Interestingly, the degree RTK of ubiquitination, as mediated by the E3 
ubiquitin ligase Cbl, appears to be conferred by the strength of ligand stimulation, as 
is the decision to be taken up by either CME or CIE78,119. Therefore, RTKs that are 
stimulated by a high concentration of ligand are prone to higher ubiquitination and 
CIE, and vice versa.  
Figure 8.4 Schematic Diagram of Receptor Tyrosine Kinase Activation 
1. Inactive RTK monomers reside in the plasma membrane. 2. Ligand binds dimers of RTKs on their 
extracellular domains, causing a corresponding conformational change in the intracellular domains to 
activate the kinase and induce cross-phosphorylation in the C-termini. 3.  RTKs activate cellular 
signalling pathways and engage the endocytic machinery to facilitate their uptake. 
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8.2.2.3 PI3K/Akt, mTOR, and MAPK Signalling Cascades 
The assembly of adaptor proteins at RTKs nucleates the binding of cellular signalling 
factors. For example, through its interaction with IRS1, PI3K can then mediate the 
production of PI(3,4,5,)P3 on the plasma membrane from PI(4,5)P2 that then recruits 
the serine/threonine kinase Akt that can then be activated by phosphorylation. 
Phosphoinositide-dependent protein kinase-1 (PDK1) adds a phosphate group to 
threonine 308 of Akt, which is sufficient for low levels of activity but to achieve 
maximal activity serine 473 also needs to be phosphorylated, which can be catalysed 
by TORC2 or possibly by autophosphorylation120–122. Activated Akt then feeds into a 
variety of different pathways including nuclear factor-κB (NF-κB) signalling, 
glycogen synthase kinase-3β (GSK3β)-mediated glucose metabolism, repression of 
the cell cycle inhibitors Tp53 and p27, or activation of mTORC1 and 2 complexes. 
Furthermore, whilst mTORC2 can directly phosphorylate Akt, mTORC2 can be 
cross-activated by mTORC1 thereby feeding into Akt activity123,124.  
Alternatively to IRS1, GRB2 also sits at the top of an arm of RTK signalling. This 
RTK adaptor is one of the best characterised, primarily owing to its connection to Ras 
signalling, which has attracted much attention due to its frequent over-activity in 
cancers125. GRB2 is composed of a central SH2 domain and two SH3 domains, which 
facilitate its binding to Son of sevenless (SOS) at the plasma membrane. SOS is a 
guanine nucleotide exchange factor (GEF) for Ras, which is anchored in membranes 
by prenylation and palmitoylation126. Activated guanosine triphosphate (GTP)-bound 
Ras then triggers a series of kinase reactions from Raf to MEK and on to ERK77. This 
cascade, known as the mitogen-activated protein kinase (MAPK) pathway, is then 
capable of instigating pro-growth, pro-survival, and proliferation programmes127. 
There is a significant degree of crosstalk between the pathways downstream of active 
RTKs. For example, the MAPK pathway can directly feed into the PI3K/Akt/mTOR 
pathway by the phosphorylation and activation of the p110 subunit of PI3K by Ras128. 
Following their activation, RTKs become internalised into endosomes where they can 
be differentially trafficked according to a variety of factors, including receptor 
identity, cell type, and ligand potency and abundance (e.g. for EGFR: high EGF vs. 
low EGF vs. transforming growth factor α)78,129. As described above, endosomal 
trafficking can result in the transport of the receptor to late endosomes/the lysosome, 
the Golgi/ER, recycling endosomes/the plasma membrane, or the nucleus. Although 
there is a significant body of evidence showing that ligand-bound RTKs can signal 
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from early endosomal membranes, it is starting to become clear that this may be 
dependent on the pathway. For example, whilst MAPK constituents may be able to 
signal efficiently from either the plasma membrane or endosomes, Akt is considered 
to primarily signal from the plasma membrane, where PI3K is located, or potentially 
in APPL1-positive pre-early endosomes130–134. 
8.2.2.4 Nuclear Functions of RTKs 
In addition to cytoplasmic signalling pathway activities, the nuclear functions of 
RTKs are also beginning to be investigated in greater detail. Many of these studies 
focussed on EGFR, which represents a good prototype on which to develop this 
model. In the nucleus it can act as a co-transcriptional activator in concert with 
transcription factors such as STAT proteins and E2F1, to induce the expression of 
genes such as CYCLIN D1, C-MYC, and AURORA-A109. The presence of RTKs like 
EGFR in the nucleus is therefore generally believed to be a positive stimulus for cell 
growth and survival, with obvious implications in pathologies like cancer135–137. 
However, the mechanism for nuclear translocation of RTKs is not yet completely 
understood; whilst some evidence supports a Golgi-ER-nucleus retrograde transport 
route, other studies suggest that early endosomes can directly fuse with the nuclear 
membrane107,138–141. What is clear from these studies, however, is that nuclear RTK 
translocation depends on its endocytosis and trafficking via functional early 
endosomes, rather than representing a population of receptors that directly enter the 
nucleus from the cytoplasm following synthesis. Interestingly, studies undertaken thus 
far have not addressed how these receptors are processed following their nuclear 
uptake: whilst we know that endosomal RTKs can be directed either back to the 
plasma membrane or degraded in the lysosome, it is unclear what the eventual fate of 
these nuclear receptors is. 
8.2.3 Autophagy Players Functionally Localise to Different Endosomal 
Compartments 
Numerous recent studies have described the localisation of autophagy proteins at 
endocytic compartments. Furthermore, autophagy and endocytosis are both vesicular 
processes that have been reported to rely on some common upstream regulators, such 
as certain Rab GTPase-activating proteins (GAPs). Here I shall outline what is 
currently known regarding the various endosomal localisations of different autophagy 
players and the resulting functional impact on autophagosome biogenesis. 
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8.2.3.1 ATG9 Trafficking 
One of the most active areas of research in the autophagy field involves the 
investigation of the source of membrane during the expansion of the pre-
autophagosome. Different groups have proposed that membranes from mitochondria, 
Golgi apparatus, ER, or endosomes can contribute to autophagosome biogenesis. 
ATG9 is the only known transmembrane autophagy player and so has been looked to 
by many as the dictator of autophagosome membrane source. Indeed, ATG9 has been 
seen to localise with several different compartments that can act as membrane sources 
during autophagosome biogenesis, including the Golgi and recycling endosomes31,142–
145. Upon autophagy induction, ATG9 re-localises to sites of autophagosome 
formation, potentially mediated by the activity of the ULK1 complex24,142,145.  
Unexpectedly, the production of Golgi-derived ATG9 vesicles has been seen to rely 
on PI(3)P-binding capability of the endocytosis-specific PIK3C3 complex containing 
UVRAG146. Under untreated conditions UVRAG regulates transport between the 
Golgi and the ER to maintain Golgi morphology. Upon autophagy induction by 
rapamycin or nutrient depletion, UVRAG is required for ATG9 vesicle production 
and maximal LC3 lipidation. This contrasts to the established understanding of the 
PIK3C3 complexes as the UVRAG-containing complex is thought to function solely 
in early endosomal PI(3)P production whereas the ATG14-containing complex was 
believed to function at the ER for autophagosome biogenesis. 
Furthermore, recently it has been shown that ATG9 and ATG16L1 traffic to sites of 
autophagosome biogenesis from recycling endosomes, mediated by membrane re-
modellers SNX18 and Dynamin-2147. The importance of recycling endosomes is 
emphasised by the requirement for Rab11 activity to induce maximal autophagic flux 
in this context24. 
8.2.3.2 The Role of Tre2/Bub2/Cdc16 (TBC) Domain-Containing Proteins in 
Autophagy 
The core autophagy player LC3 has been seen to interact with several 
Tre2/Bub2/Cdc16 (TBC) domain-containing Rab GAP proteins, most likely through 
LC3-interacting region (LIR) motifs148. Although the functional relevance of these 
associations has not yet been completely elucidated, several studies have yielded 
compelling results.  For example, LC3 can interact with TBC1D25, which functions 
in autophagy by acting as a GAP for Rab33B, an ATG16L1 binding partner149. 
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Additionally, LC3 binds TBC1D2 and co-ordinates Rab7 GTP binding, thereby 
regulating autophagosome-lysosome fusion steps, although the reciprocal influence 
on late endosomal function is unclear150. Interestingly, TBC1D2 has also seen to 
localise to Rab11-positive recycling endosomes150.  
Furthermore, it has been shown that the interaction of some TBCs with various 
autophagy players can impact both endocytic trafficking as well as the autophagy 
pathway. This has been shown in the case of TBC1D5, which interacts with and 
inhibits the function of the retromer complex at endosomes under fed conditions148. 
However, following autophagy induction LC3 displaces the retromer and instead 
targets TBC1D5 to autophagosomes. Therefore, autophagy induction can have a 
direct impact on endosomal processes. Moreover, as described in section 8.2.1.3, the 
retromer promotes the activity lysosomal hydrolases thereby providing an additional 
retromer-mediated interdependency between autophagy and endocytosis. The 
interplay between the retromer and autophagy was then further explored by Popovic 
and Dikic, who demonstrated that TBC1D5 is trafficked with AP-2 and ATG9 from 
clathrin coated pits at the plasma membrane through to early endosomes, where 
TBC1D5 inhibits the retromer complex144. Functionally, autophagic degradation of 
TBC1D5 is important to facilitate the proper trafficking of the glucose transporter 
GLUT1 from early endosomes back to the plasma membrane instead of being 
targeted to the lysosome151.  
Additionally, the ULK1 complex has been observed to interact with TBC1D14 at 
recycling endosomes, which inhibits its role in autophagy24. Following the induction 
of autophagy, TBC1D14 translocates to the Golgi complex, leaving ULK1 free to 
participate in autophagy. TBC1D14 also binds active Rab11 and mediates recycling 
endosomal tubulation, which negatively impacts autophagosome biogenesis.  
Together these studies demonstrate that, similarly to other cellular vesicular 
pathways, autophagy relies on the regulation of certain Rab GTPases and it is now 
beginning to emerge that this may reciprocally influence endosomal trafficking.  
8.2.3.3 The Localisation of ATG16L1 
The localisation of ATG16L1 is proving to be somewhat contentious. On the one 
hand, the Rubinsztein and Simonsen laboratories have documented ATG16L1 co-
localisation with Rab11-positive recycling endosomes and recycling transferrin 
receptor (TfnR)31,44,152. In these reports, ATG16L1 co-operates with ATG9 at 
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recycling endosomes to mediate autophagosome formation. Furthermore, ATG16L1 
has been seen to tether to these recycling endosomes via PI(3)P-binding protein 
WIPI2, which co-immunoprecipitates with Rab11153. However, Li et al. found that 
although transiently overexpressed ATG16L1 co-localised with Rab11, its 
endogenous counterpart did not localise to recycling endosomes154. Further, this 
transiently overexpressed protein did not co-localise with its autophagy complex 
partner ATG12, and instead actually inhibited GFP-LC3 puncta formation. It remains 
to be seen how these observations of ATG16L1 and recycling endosome connections 
can be aligned, whether it be dependent on cell type, treatment conditions, or antibody 
variations.  
Alternatively, ATG16L1 has been reported to interact with components of the CME 
machinery at the plasma membrane, which is required for its eventual delivery to sites 
of autophagosome biogenesis44. Additionally, ATG16L1 has been seen to bind the 
endosomal regulator Annexin A2; an interaction which facilitates the formation of 
autophagosomes155. However, whether the interaction between autophagy proteins 
and the CME components has an impact on CME endocytosis has not been explored. 
Despite being documented at both the plasma membrane and at recycling endosomes, 
ATG16L1 has not been observed in the interim; i.e. at early endosomes31,44. One 
possibility is that ATG16L1 does not traffic through endosomes but instead 
independently localises at clathrin-coated pits and at recycling endosomes. 
Alternatively, there may just be a low level of ATG16L1 transport between the 
plasma membrane and recycling endosomes, or the localisation may be extremely 
transient. This option seems more feasible given that trafficking from the plasma 
membrane through early endosomes to recycling endosomes has previously been 
observed for ATG931. 
 
Together, the studies described above draw attention to an intricate interplay between 
the processes of autophagy and endocytosis. However, explicit evidence documenting 
a reliance of endosomal homeostasis on autophagic flux remains elusive. 
8.2.4 Receptor Tyrosine Kinase Signalling Can Regulate the Autophagy 
Machinery 
Although some studies have shown that ligand activation of some RTKs (such as 
AXL, ERBB3/ERBB4, TRKA, Ephrin, and VEGFR) can promote autophagy, 
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stimulation of others (including EGFR, HER2, and FGFR1) can inhibit components 
of the autophagy machinery156–162. Crucially, mTORC1, mTORC2, and Akt lie 
downstream of RTK activation, and these kinases are known to directly phosphorylate 
and inhibit autophagy regulators, with the mTORC1-ULK1-PIK3C3 axis being 
perhaps the best known. Alternatively, Akt can phosphorylate serines 234 and 295 on 
Beclin-1, causing its association with the scaffold and cytoskeletal proteins 14-3-3 
and Vimentin, and thereby preventing its localisation to sites of autophagosome 
biogenesis. This is likely to be reinforced by Akt-mTORC1 crosstalk that would also 
inhibit ULK1 (see section 8.1.2) and thereby prevent Beclin-1 activation. Moreover, 
mTOR, operating via Raptor and Rictor, has also been shown to influence Beclin-1 
protein stability, although this mechanism has not been fully explored163.  
In addition to engaging mTOR and Akt, the RTK EGFR also directly phosphorylates 
Beclin-1 following EGF binding33. This displaces it from the PIK3C3 complex and 
recruits Rubicon thereby inhibiting the activity of the complex. On the other side of 
the coin, in the absence of ligand binding, inactive EGFR can act to promote Beclin-
1/PIK3C3 activity by recruiting Rubicon, LAPTM4B, and the exocyst constituent 
Sec5, consequently promoting autophagy164.  
Overall, these regulatory interactions and modifications mediated by 
RTK/mTORC1/Akt signalling reduces the production of PI(3)P, which then ablates 
the recruitment of downstream autophagy players and autophagosome formation. In 
this way, mitogenic signalling pathways can limit cellular catabolism when conditions 
are permissive for growth and division.  
Additionally, RTKs can modulate autophagic flux by the regulating the transcription 
of autophagy and lysosomal proteins, primarily via the forkhead transcription factors 
(FoxO), signal transducers and activators of transcription 3 (STAT3), and 
transcription factor EB (TFEB). Whilst FoxO and TFEB promote autophagy gene 
expression and are repressed by RTK signalling, STAT3 is activated by RTKs and 
acts to inhibit the expression of autophagy regulators165–169. 
8.2.5 The Putative Role of Autophagy in Receptor Tyrosine Kinase Signalling 
The switch between the catabolism mediated by autophagy and the anabolism induced 
by mitogenic RTKs has attracted much attention in the past ten years. However, 
recent studies are also revealing an unexpected synergy between autophagy proteins 
and RTK signalling. These investigations are of particular interest with regards to 
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cancer where both autophagy and RTK activities are associated with increased 
malignancy and resistance to therapies.  
8.2.5.1 Autophagy and the c-Met Receptor 
Several groups have reported a co-operation between autophagy-related gene 
expression and the promotion of signalling from the HGF/c-Met receptor in cancer 
cell lines. Barrow-McGee and colleagues utilised a variety of cell lines in suspension 
to show that non-canonical ATG13-independent ‘autophagy-related endomembranes’ 
act as platforms for c-Met signalling to promote cell survival and ultimately 
tumourigenicity170. Additionally, as part of screen of RTK activities in autophagy-
deficient colorectal cancer cells, c-Met appeared to be reliant on ATG7 and ATG5 
expression to achieve maximal signalling171. These studies also found that c-Met 
localises to autophagy-related structures that are positive for LC3. Furthermore, 
autophagy has been seen to increase HGF expression and c-Met/JNK/STAT3 
signalling, which promotes stemness in cirrhotic livers that increases 
hepatocarcinogenesis172. 
8.2.5.2 Autophagy and the Epidermal Growth Factor Receptor 
With regards to EGFR signalling, there have been some conflicting reports of the 
effect of autophagy. Whilst several groups have shown that EGFR is not regulated by 
autophagy inhibition and that EGFR does not localise with autophagy proteins, others 
have shown that EGFR and LC3 can co-localise24,51,52. Additionally, although EGF-
induced Akt and ERK phosphorylation were not influenced by autophagy loss in 
several studies, Martinez-Lopez et al. reported that autophagy-related structures 
assemble components of the MAPK cascade and facilitate their EGF-mediated 
activation171,173,174.  
In its capacity as an endosomal PI(3)P regulator, the autophagy-related protein 
Beclin-1 acts to dampen EGFR signalling by facilitating the switch from pre-early 
endosomes to early endosomes, where the tyrosine kinase activity is inhibited82. As 
Beclin-1 is re-distributed between its autophagosomal and endosomal PIK3C3 
complexes during starved or fed conditions, respectively, the induction of autophagy 
may conversely sequester Beclin-1 from endosomes and thus enhance EGF-induced 
signalling25.  
Alternatively, the non-receptor tyrosine kinase Ack1 localises to autophagosomes 
under conditions of ligand withdrawal, thereby sequestering it from its function at 
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early endosomes where it acts to prevent EGFR lysosomal targeting175. Conversely, 
upon EGF treatment, Ack1 re-localises to early endosomes to support oncogenesis by 
promoting EGFR activity. 
Additionally, autophagy has been suggested to be required for the mitochondrial 
delivery of EGFR, with autophagy stimuli inducing the translocation of EGFR to 
mitochondria176. This is dependent on the activity of the PIK3C3/Beclin-1 complex, 
as 3-methyladenine (3-MA) treatment or siRNAs knockdown of Beclin-1 inhibited 
the process. The mitochondrial load of EGFR correlated with increased survival and 
was depleted upon cell death induction by etoposide treatment. Interestingly, in a later 
study also by the Jiang group  mitochondrially localised EGFR was shown to be 
independent of its endocytosis177. 
 
These emerging studies highlight an intriguing reliance of RTK signalling on the 
expression of key autophagy proteins and even on autophagosomal membranes 
themselves.  
 
8.3 Autophagy and Cancer 
Cancer is a particularly challenging disease to treat, not only due to the high 
variability between different tumour types but primarily because of its incredibly 
dynamic behaviour. Therefore, a major aim has become to understand whether cancer 
cells may have a targetable weak point. As a constitutive pathway that has been seen 
to promote several key hallmarks of cancer, such as elevated cell metabolism and 
survival, autophagy has garnered significant attention178. However, the current studies 
of autophagy in cancer have provided somewhat conflicting evidence, with both pro- 
and anti-tumourigenic properties described7. Here I shall explore some of these 
studies and how this knowledge has been applied so far in attempting to target 
autophagy for cancer treatment.  
8.3.1 The Context-Dependent Role of Autophagy in Cancer  
Autophagy has been implicated in processes such as cellular signalling, metabolism, 
and ROS production/DNA damage: all of which have been implicated in either 
cellular transformation and tumour maintenance. It is suggested that autophagy can 
act a double-edged sword with regards to cancer: whilst the lack of autophagy seems 
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to predispose cells to oncogenic transformation, the formation of a malignant tumour 
requires the metabolic support conferred by autophagy7. This is complicated by 
contradictory reports that rely on the use of non-autophagy-specific inhibitors such as 
hydroxychloroquine (HCQ) or 3-MA. In this section I aim to outline some of the data 
and hypotheses currently being put forward in this rapidly expanding field. 
8.3.1.1 Autophagy Proteins Inhibit Cellular Transformation and Beclin-1 is an 
Archetypal Tumour Suppressor 
A putative role for autophagy as a tumour suppressor pathway was heralded by early 
work carried out by the Levine group. A seminal study in 1999 revealed that the 
heterozygous loss of Beclin-1 resulted in the increased formation of tumours in a 
mouse model of breast cancer thereby suggesting a role as a tumour suppressor179.  
However, despite much further investigation since then, the impact of the PIK3C3 
complex on cell transformation remains somewhat unclear.  
In more recent work by the Levine group, both EGFR and Akt were shown to directly 
phosphorylate and inhibit Beclin-133,180. This was substantiated by introducing acidic 
mutations into Beclin-1 to mimic its phosphorylation by EGFR resulting in autophagy 
suppression and enhanced tumourigenecity of transformed fibroblasts. Conversely, 
preventing the phosphorylation of Beclin-1 by Akt inhibited tumour formation. On 
the other side of the coin, enhanced binding between Beclin-1 and Rubicon during 
EGF stimulation may promote EGFR lysosomal degradation by relieving Rab7 from 
its inhibitory interaction with Rubicon181.  
Another intriguing study showed that the action of the Beclin-1/PIK3C3/UVRAG 
endocytosis-specific complex plays a key role as a tumour suppressor. This is 
conferred by its function in generating early endosomal PI(3)P, which then recruits 
effectors such as EEA1182. This facilitates the maturation of signalling receptors, like 
IGF-1R and EGFR, from signalling-competent to signalling-defective compartments, 
which limits oncogenic potential in a breast cancer cell line model. This highlights the 
possibility that the role of Beclin-1 in cancer may be at least partly attributable to its 
function in the endocytic pathway. 
8.3.1.2 Autophagy Facilitates Progression from Benign Phenotypes  
A variety of studies have demonstrated that ablating the expression of key autophagy 
players promotes tumourigenesis or tumour maintenance in several different cancers. 
This has been primarily attributed to the role of autophagy in supporting elevated 
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metabolic activity and resolving cell stresses that are induced by oncogenic 
transformation. In one example, the formation of tumours in a Polyoma Virus middle 
T-antigen mouse mammary model (MMTV-PyVT) was greatly inhibited when 
FIP200 was deleted183. Similarly, tumours in a Palb2 deletion-driven breast cancer 
model required Beclin-1 expression to form efficiently in Tp53 wild type but not 
Tp53-deficient background184. Autophagy has also been implicated in facilitating 
tumourigenesis driven by aberrant MAPK activity in the context of constitutively 
active BRaf. In a BRafV600E melanoma model, mitophagy ablated oxidative stress and 
kept senescence at bay whereas BRafV600E-induced adenomas fail to progress into 
adenocarcinomas when ATG7 is lost185,186. 
Furthermore, several studies have investigated the connection between oncogenicity 
and ATG gene expression in different tumour types. In pancreatic cancer, increased 
Atg gene expression correlated with elevated autophagy/lysosomal gene expression 
signature187. Glioblastoma stem cells also exhibit elevated expression of autophagy 
regulators DNA damage regulated autophagy modulator 1 (DRAM1) and p62188. 
Additionally, in 2016 the Ketteler laboratory undertook a comprehensive analysis of 
the expression of autophagy genes across a variety of cancers189. The authors found 
that overall core autophagy player expression was not significantly changed in most 
cancers, although some mutations were observed in prostate cancers. Given that 
cancer cell genomes have a high mutagenic rate as a whole, this negative result may 
be suggestive of a requirement for autophagy gene function in tumourigenesis. 
However, the modulation of autophagy is believed to occur primarily at the protein 
level rather than by transcription regulation (see section 8.1). Therefore, the frequency 
of autophagy gene mutation rate in tumours is not necessarily an accurate read-out of 
the importance of autophagy in tumourigenesis. 
8.3.1.3 Autophagy and Ras: A Special Relationship? 
There are three main steps involved in tumour formation: firstly cells must acquire an 
oncogenic mutation that drives cell growth and proliferation, then they overcome their 
inherent cell cycle inhibition mechanisms that protect against cancer, and finally the 
transformed cells must maintain this phenotype in the face of any exogenous ‘stop’ 
signals or immune attack. Sitting atop the MAPK signalling cascade, overactive Ras 
can represent a strong first step, but then does autophagy help or hinder either of the 
consecutive steps required for transformation? Many cancer models using oncogenic 
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Ras as a driving mutation have documented a critical interplay with autophagy, 
particularly with regards to metabolism and senescence (also see section 8.3.1.2). The 
molecular mechanisms that underpin this have been investigated in some depth and 
shall be reviewed here.  
Whilst there have been a multitude of studies regarding autophagy and Ras 
transformation, their cellular relationship still remains unclear. One study of Ras 
oncogene-induced senescence (OIS) in IMR90 primary fibroblasts showed that 
autophagy promotes OIS, with the knockdown of essential autophagy genes resulting 
in delayed senescence onset190. This observation was bolstered mechanistically by 
additional work showing that autophagy facilitates the degradation of components of 
the nuclear lamina during Ras OIS and preventing this promotes oncogenic 
transformation191. Furthermore, the autophagy-related protein ATG12 has been seen 
to repress the malignant growth of cells expressing oncogenic Ras by engaging BCL-
2 family members and instigating cell death, although this appears to be independent 
of its function in autophagy192,193.  
However, in other contexts autophagy has been seen to promote Ras-induced 
transformation, such as in mouse embryonic fibroblasts (MEFs), where loss of ATG5 
or ATG3 sensitises cells to senescence194. In this model, the authors found that cells 
can escape HRasV12-induced senescence by expressing a high level of ATG5-ATG12 
and that the exogenous expression of ATG5 increases the ability of cells to avoid 
senescence. These findings are supported by experiments undertaken by Lock and 
colleagues showing that autophagy promotes glycolytic metabolism that is required 
for the malignant growth of mammary epithelial cells195.  
From these studies we are starting to see that the influence of autophagy on in vitro 
transformation may be different according to the cellular context. However, in mouse 
models there appears to be a greater consensus that autophagy is required for the 
growth of a variety of Ras-driven tumours; including pancreatic, kidney and lung 
cancer models196–200. In these mouse models, mechanistic data has implicated 
autophagy in the deregulation of metabolic pathways196–198,200. For example, in a 
KRasG12D lung cancer model, autophagy was required for lipid fatty acid oxidation 
that promoted the formation of malignant adenomas and carcinomas rather than 
benign oncocytomas200. The disparities between mouse models and cell culture 
studies may be explained by the differing conditions that cells are exposed to. 
Oncogenic Ras-transformed cells may have an increased reliance on autophagy for 
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tumourigenic growth in vivo due to the sub-optimal growth conditions experienced, 
whereas cultured cells grow adhered in a monolayer with nutrients in excess. 
Alternatively, these opposing results may be due to the different cellular contexts, 
such as the presence of other mutations. Indeed, one elegant study by Rosenfeldt et al. 
was able to show that Tp53 status dictated the response to Ras transformation201. 
8.3.2 The Interplay of Autophagy, Senescence, and Cancer 
The studies outlined above have revealed a conflicting array of data regarding the role 
of autophagy in cancer. This is similarly found with regards to the interplay of 
autophagy with senescence, where the use of different model systems has made 
comparison of variable results difficult to interpret. Below I shall summarise the 
findings of these studies and put them into the context of tumourigenesis. 
8.3.2.1 Introduction to Senescence 
The process of senescence is defined as an irreversible arrest of the cell cycle. This 
renders cells incapable of responding to mitogenic growth factors or replicating their 
DNA. Cell cycle arrest can instigate tissue re-modelling, prevent or promote 
malignant transformation, and mediate the clearance damaged aged cells by the 
immune system. A characteristic set of hallmarks is used to define senescence  
(Figure 8.5). This includes the increase in cell cycle arrest markers, such as p16 
(cyclin-dependent kinase inhibitor (CDKN) 2A/p16INK4a), p21 (CDKN1A), p27 
(CDKN1B/KIP1), Tp53 (TP53), or Retinoblastoma protein-1 (pRb/RB1)202–205. 
Although previously understood to be separate pathways (p21/Tp53 or p16/pRb/p27), 
new research is showing that there is in fact an extensive cross-talk between the two 
pathways. 
Tp53 was the earliest tumour suppressor protein to be characterised and has been 
dubbed ‘the guardian of the genome’ due to its ability to reduce DNA mutagenesis206. 
Since then, much has been elucidated regarding the cellular pathways that regulate or 
are regulated by Tp53. Engaging Tp53 can either halt cell growth or promote 
apoptosis, as well as influence other tumour-regulatory factors depending on cell 
status207. For example, DNA damaging agents, such as γ-radiation, activate Tp53/p21 
and inhibit cell division, thereby preventing the propagation of cells with radiation-
modified DNA, which might be tumourigenic208.  
First discovered in connection with the development of the eye cancer retinoblastoma, 
pRb represses the cell cycle by inhibiting E2F transcription factors and cyclin/cyclin-
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dependent kinase 2 (CDK2) complexes that promote expression of key cell cycle 
progression regulators205,209,210. The retinoblastoma protein family, composed of 
pRb/p105, p107, and pRb2/p130, are characterised by a common ‘small pocket’ 
domain, but each family member can undertake several unique roles, particularly with 
regards to the establishment of senescence209. This is attributable to the fact that these 
pocket proteins appear to regulate different subsets of genes211. These proteins are 
active (i.e. replication repressive) when hypophosphorylated, with their 
phosphorylation mediated by CDKs during the cell cycle210. The activity of pRb is 
intimately connected with that of p27 as these proteins are able to activate one another 
in a positive feedback loop to reinforce cell cycle inhibition204,205. Interestingly, in 
addition to regulation by CDKs, it has been found that the pro-growth regulator Akt 
can phosphorylate and inhibit p27 activity, thereby blocking pRb/p27 cell cycle 
regulation212–214. Similarly, Akt inhibits Tp53 by phosphorylating and activating the 
Tp53 ubiquitin ligase MDM2, thereby destabilising Tp53215.  
In addition to these cell cycle regulators, other cellular markers are used to test for the 
establishment of senescence. The use of multiple markers of the senescent phenotype 
is important to rule out that alternative forms of cell cycle arrest may be occurring. 
One of the most frequently used hallmarks of senescence is the staining for β-
galactosidase at pH 6.0216. This enzyme is elevated in senescent cells due to the 
presence of enlarged lysosomal compartments, where β-galactosidase activity is 
detected217. Additionally, senescent cells harbour regions of dense heterochromatin at 
proliferation-promoting genes, known as senescence-associated heterochromatic foci 
(SAHF)218 as well as having significant increase in DNA damage markers, such as 
γH2AX219,220. In oncogene-induced senescence this damage is caused by the inability 
of DNA to efficiently replicate at the speed dictated by the signals from the oncogene, 
such as constitutively active Ras, whilst in replicative senescence it occurs at the ends 
of eroding telomeres. A more recently characterised feature of senescent cells is the 
secretion of a pro-inflammatory senescence-associated secretory phenotype 
(SASP)221. The SASP is composed of cytokines and chemokines, such as members of 
the interleukin family, which promote senescence in both a paracrine and autocrine 
manner. These factors can then recruit immune cells, which can either mediate 
senescent cell clearance or promote the growth of neighbouring cells.  
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8.3.2.2 Autophagy and Senescence 
Autophagy has been connected to senescence in a variety of different contexts. 
Autophagy may regulate senescence through crosstalk with tumour suppressor 
pathways or maintaining cellular homeostasis. Observations by Young et al. 
demonstrated increased LC3-II generation during the initiation of senescence190. 
Additionally, Tp53 has been shown to upregulate the expression of ULK1 and 
ATG13, which promoted autophagic flux during DNA damage222. Furthermore, Kang 
et al. have found that autophagy is required for the generation of the SASP223. 
Specifically, autophagy degrades the transcription factor GATA4, and so ablates its 
action in promoting the expression of NF-κB effectors that induce the production of 
SASP factors such as IL-6, IL-8, and tumour necrosis factor α (TNFα).  
Together, these studies highlight an interesting and possibly context-dependent effect 
of autophagy in the establishment and maintenance of senescence. Autophagy loss 
may make the cell more susceptible to senesce due to the accumulation of damaged 
components, such as mitochondria. Alternatively, autophagy can regulate senescence 
inducers by degradation. However, there is little known regarding the impact of 
autophagy loss on the induction of senescence outside the context of OIS, particularly 
with regards to the maintenance of tumours or their therapeutic targeting. 
 
 
Figure 8.5 Diagram of the Cellular Hallmarks of Senescence 
Engaging cell cycle inhibitors blocks cell replication, whilst SASP factors both reinforce the phenotype 
of the senescent cell and induce senescence in neighbouring cells. Senescence induction can be 
accompanied by DNA damage markers and senescence-associated β-galactosidase. 
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8.3.3 Autophagy Suppresses Anoikis During Anchorage-Independent Growth 
As well as its role in cell cycle inhibition by senescence, the influence of autophagy 
on cell survival or death decisions has also been of particular interest in cancer 
biology. For some time the concept of ‘autophagic cell death’ garnered much interest 
but, as eloquently described in a review by Levine and Kroemer, the survival 
pathways that are promoted by autophagy mean it is more likely to be activated in a 
futile attempt to ablate cell death rather than being the causative mechanism224. 
Indeed, during oncogenic transformation, autophagy is primarily reported to support 
metabolism and cell survival225. From the extensive research undertaken in this field, 
I shall focus specifically on outlining the findings most pertinent to this study, which 
relate to ability of autophagy to prevent cancer cell death during anchorage loss.  
To prevent inappropriate growth away from their intended niche, when normal cells 
detach from the extracellular matrix (ECM) they undergo a caspase-mediated form of 
cell death called ‘anoikis’ (a Greek derivation meaning ‘homeless’)226. A key property 
of cancer cells is to avoid anoikis and grow in conditions of anchorage loss227. 
Anoikis is evaded by a plethora of adaptations, including oncogenic transformation, 
an epithelial-to-mesenchymal transition (EMT), and acquisition of stemness by 
expressing transcription factors generally associated with a more developmentally 
naïve state228–233. However, overcoming initial cell death triggers is only the 
beginning for cancer cells- they must then maintain the activity of signalling and 
metabolic pathways to survive and proliferate during prolonged anchorage loss.  
In order to compensate for the loss of integrin-mediated, anchorage-induced 
signalling, cancer cells employ oncogenic signalling cascades. The activation of 
receptors such as IGF1-R, EGFR, c-MET, NOTCH, or ERBB2 by their ligands or by 
oncogenic mutation can instigate a series of phosphorylation reactions that result in 
anchorage-independent growth170,228,229,234,235. The key kinases that relay these signals 
are Akt and ERK, the activities of which have been seen to be crucial for anchorage-
independent growth in wide variety of contexts from breast, prostrate, and ovarian 
cancers to head and neck squamous cell carcinoma228,229,235–237. Additional reports 
show that alternative MAPK signalling axes may also be utilised to stimulate cell 
survival, such as TGFβ-activated kinase 1 (TAK1/MAP3K7), which induces non-
canonical WNT signalling238.  
Detachment from the ECM and reduction in cell signalling causes a catastrophic 
disruption of glucose uptake and ATP production as well as an increase in reactive 
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oxygen species (ROS)239,240. The metabolism of non-anchored cells is particularly 
sensitive to ROS and their removal is therefore vital for anchorage-independent 
growth239. To override this, cancer cells can either upregulate the expression of 
detoxifying enzymes, such as superoxide dismutase 2 (SOD2)241, or perturb metabolic 
pathways to generate reducing species that can quench ROS242. The deficit in ATP 
production caused by detachment can be overcome in cancer cells by increasing 
mitochondrial neobiogensis or upregulating metabolic programmes such as the 
pentose-phosphate pathway, for example by reducing pyruvate dehydrogenase kinase 
4 (PDK4) expression240,243.  
One pathway that has been seen to both regulate cell signalling and supply additional 
metabolic demand in detached cells is autophagy. For the past decade, autophagic 
flux has been known to be important to avoid anoikis and promote cell proliferation 
following anchorage loss244. Induced by ROS and PERK signalling from the 
endoplasmic reticulum, detachment-induced autophagy is hypothesised to promote 
metabolism, via the supply of amino acids, as well as contributing to cell 
survival170,245. Furthermore, autophagy proteins are required for the recognition and 
lysosomal degradation of detached cells engulfed by the ‘cell-in-cell’ entosis 
phenomenon246,247. The outcome of entotic cell degradation is currently unclear, with 
some evidence suggesting that it may clear potentially tumourigenic detached cells, 
whilst others argue it can result in pro-oncogenic aneuploidy and provide a source of 
nutrients for a prospective cancerous host cell to survive246,248.  
8.4 Glioblastoma Multiforme 
As described above, autophagy has been identified as a potential therapeutic target in 
several different cancer types, but perhaps one of the most promising opportunities is 
in the treatment of glioblastoma multiforme (GBM). These tumours exist in 
conditions that are known to strongly upregulate autophagy, such as hypoxia, and 
preliminary studies suggest that GBM cells require autophagy for rapid oncogenic 
growth and in the development of resistance against treatment strategies. To put this 
into context, I shall first introduce the defining features of GBM biology before 
discussing the role autophagy may play in its tumourigenesis. 
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8.4.1 Pathological Features 
GBM is a devastating brain cancer that confers an extremely poor patient prognosis. 
These rapidly growing, high-grade tumours have a high lethality rate, even when 
treated with a combination of chemotherapy, radiotherapy, and surgery, with 1-, 2-, 3-
, and 4-year survival estimated at 58%, 20%, 10%, and 7%, respectively249. The 
defining histological characteristics of glioblastoma include foci of necrotic cells 
surrounded by hypercellular zones, dubbed pseudopalisading necrosis, which 
illustrate the stressful nature of the tumour microenvironment generated by excessive 
cellular proliferation250–252. These tumours also exhibit elevated levels of 
microvasculogenesis, with the resulting naïve vessels unable to adequately supply the 
tissue with oxygen or nutrients. 
Several different features of GBM tumours hinder the effective treatment of 
patients251. For example, the blood-brain barrier reduces the concentration of drugs, 
especially those based on antibodies, which can be delivered to tumour tissue. 
Furthermore, the highly invasive nature of GBM cells represents a significant 
challenge with regards to surgical resection. Given the delicacy and significance of 
the tissue surrounding the tumour, it is not possible to cut around the tumour, with 
cancerous cells remaining at the margins and spawning re-growth. Indeed, tumours 
that form during GBM relapse generally occur proximal to the site of primary tumour 
removal. GBM stem-like cells are believed to be the source of tumour recurrence as 
they are highly resistant to the current treatments, such as temozolomide and radiation 
(see section 8.5.1)253–256. Additionally, GBM tumours exhibit high degree of 
heterogeneity, not just between different tumours but also in the same tumour251.  
8.4.2 Subtypes and Mutational Landscape 
The current poor patient survival rate of GBM necessitates the development of more 
rational therapeutic approaches. To do this, it is critical to understand the oncogenic 
processes that support glioblastoma growth. With the advent of advanced sequencing 
technology, frequently mutated genes in GBM patients have been identified, leading 
to the classification of GBM into four different molecular subtypes: proneural, neural, 
classical, and mesenchymal250,251. Furthermore, these analyses found that the most 
frequently mutated genes in GBM broadly fall into three pathways: aberrant RTK 
signalling, Tp53 loss of function, and pRb deregulation. By identifying the most 
common transforming aberrations in each subtype, the best means of applying  
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Figure 8.6 Summary of the Main Driving Mutations in Glioblastoma Multiforme 
A select set of pathways are the focus of GBM oncogenic mutations: over-activity of RTK signalling 
(red/orange), loss of function of the Tp53 pathway (green), and deregulation of the pRb pathway 
(blue)250. 
 
Table 8.1 Summary of the Mutations Enriched in Glioblastoma Multiforme Subtypes 
Analyses of genetic data gathered from patient tumours facilitated the definition that four ‘subtypes’ of 
GBM250,251 

























targeted therapies may be clarified (Table 8.1)250,257. However, although these 
classifications may be useful in trying to generate efficient personalised medicines 
and understanding how resistance can develop, it is known that these subtypes are not 
completely distinct and several different subtypes can exist within one patient. 
The efficacy of targeting specific signalling pathways with single-targeting agents has 
so far been poor in GBM257. For example, trials of the EGFR inhibitor erlotinib 
alongside the DNA alkylating agent temozolomide and radiotherapy exhibit only 
minor initial improvements, with no significant influence on progression-free 
survival258,259. Similar results were also seen with the PDGFR inhibitor imatinib260. 
The redundancy and cross talk that is known to exist between these RTK-mediated 
signalling pathways provides an opportunity for resistance to develop. Therefore, it is 
becoming increasingly clear that simultaneously treating with multiple targeting 
agents may be necessary to properly attenuate growth factor signalling or, 
alternatively, an agent that can target the activity of several processes simultaneously 
would be valuable257. 
8.5 Autophagy and Glioblastoma Multiforme 
The rapid growth of GBM tumours outpaces the production of vasculature to deliver 
oxygen and nutrients to the proliferating tumour cells. Such a stressful environment 
requires the upregulation of survival pathways to maintain cell growth. One such 
pathway is autophagy and, indeed, several recent studies are starting to reveal a 
requirement for autophagy in GBM.  
8.5.1 The Role of Autophagy in Glioblastoma Cancer Stem Cells 
One hypothesis that may explain the heterogeneous oncogenic mutations found in 
GBM tumours is the generation of distinct populations of differentiated progeny from 
an oncogenic parental cancer stem cell (CSC) (Figure 8.7). CSCs are characterised by 
self-renewal, slow replication, and evasion of the Hayflick limit by the expression of 
telomerase253,261–264. Additionally, GBM recurrence may be attributable to the ability 
of CSCs to evade DNA damaging agents253,256,265, although alternative reports suggest 
that there may be additional factors at play including the underlying mutational 
landscape255.  
CSCs are frequently observed in association with the hypoxic core of GBM 
tumours266–271. Hypoxia is a condition that upregulates autophagy and there is 
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increasing evidence that autophagy is required to regulate cell ‘stemness’ in a variety 
of different contexts, from normal haematopoietic stem cells to cancer stem cell 
maintenance272–275. Studies that have investigated the role of autophagy in GBM 
stemness have generated interesting results. For example, DRAM1 and p62, which 
are both implicated in autophagy induction, have been found to be important for the 
aggressive invasive qualities of GBM stem cells and their expression levels correlate 




Conversely, CD133-positive GBM stem-like cells correlate with low levels of 
autophagy gene expression when treated with temozolomide, suggesting GBM CSCs 
have low levels of autophagy254. Moreover, Nager et al. revealed that Wnt/β-catenin 
signalling activity, which has been associated with stemness, inhibits autophagy in 
GBM cells276,277. By combining autophagy and Wnt signalling inhibitors the authors 
were able to significantly inhibit cell viability and tumourigenesis. This suggests a 
switch between autophagy and Wnt signalling that may represent the stemness state 
of GBM cells. When regarding non-drug treated cells, however, it seems that 
autophagy generally promotes cancer cell stem properties278. With such conflicting 
reports, it remains to be clarified how autophagy relates to GBM cancer stem cell 
states. 
Figure 8.7 Schematic Model of a Potential Heterogeneous GBM Tumour 
Lineage Derived from a Single Glioblastoma Stem Cell 
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8.5.2 Modelling Glioblastoma Using the RCAS/tv-a System 
The Replication-Competent Avian Sarcoma-leukosis virus LTR splice 
acceptor/Tumor Virus A (RCAS/tv-a) model of GBM been in use for over twenty 
years (Figure 8.8)252,279. This system uses avian virus-based vectors that can be 
propagated in chicken fibroblast cells (‘DF-1’). Either the DF-1 cells or viral particles 
produced can be directly introduced into mouse brains. The somatic cell gene transfer 
system can specifically infect brain cells expressing the avian viral receptor tv-a. This 
receptor is expressed under the control of either Nestin promoter (ntv-a) in glial  
 
 
Figure 8.8 The RCAS/tv-a in vitro and in vivo Model Workflows 
The RCAS vector harbouring oncogenic drivers and/or autophagy gene shRNA can be introduced into 
either mouse glial cells (XFM) or mice via the transgenic expression of the tv-a viral receptor under the 
control of a glial-specific promoter. DF-1 chicken fibroblast cells produce virus, and either this virus or 
the DF-1 cells can be introduced into the mouse brain to transform glial cells and induce GBM. 
progenitors or the Gfap promoter in astrocyte progenitors (gtv-a) 279,280. Chicken 
fibroblast cells produce high viral titres and thereby provide efficient vector delivery 
to target cells, following which they are then cleared from the mouse brain. RCAS 
viral vectors are extremely adaptable, making it possible to manipulate many of the 
genes that are commonly perturbed in glioblastoma. Vectors can be modified to 
concurrently express shRNA against genes of interest, (e.g. Atgs, Nf-1, or Tp53), and 
gene overexpression (e.g. KRas, Pdgf, or Cre recombinase)280–283. Studies utilising 
this system have reported a close resemblance to patient tumour histology284. By 
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inducing tumour formation in situ in the mouse brain the RCAS model is able to assay 
the influence of a particular process, such as autophagy, on tumourigenesis in the 
context of a fully functioning immune system. 
Furthermore, this system can also be used to model GBM in vitro. Glial cells 
expressing the tv-a receptor are selected by puromycin from a mixed population of 
brain cells extracted from untreated mice252. These cells, called XFM/tv-a, can then be 
infected with viruses produced in DF-1 cells. Therefore, it is possible to carry out 
complementary studies in mice and cells using the RCAS/tv-a system. 
8.5.3 Investigating Autophagy Inhibition as a GBM Treatment 
Although autophagy has been identified as an attractive potential therapeutic target in 
glioblastoma, challenges remain regarding how to best study the impact of autophagy 
inhibition on GBM experimentally. Some of the approaches that have been employed 
to tackle this question are outlined below. 
8.5.3.1 Genetically Engineered Mouse Models of Autophagy Inhibition 
The genetic ablation of autophagy players is currently the only specific method to 
inhibit the pathway due to the non-specificity of inhibitors such as lysosome 
disrupting agents. Therefore, many researchers have chosen to prevent the expression 
of proteins by short-hairpin or small interfering RNA silencing, Cre-Lox gene 
deletion, or CRISPR/Cas9 gene modification.  
The loss of autophagy gene expression in the whole-body of the mouse is preferably 
done by inducible means as autophagy is required for the survival of neonates4. 
Alternatively, by using tissue-specific promoters or xenografting of autophagy-
deficient cell lines it is possible to achieve tumour-specific autophagy targeting, 
whilst retaining autophagy in the remainder of the animal and thereby maintaining its 
health. For example, some recent mouse xenograft studies have shown that autophagy 
promotes the growth of gliomas, with a particular focus on the employment of 
autophagy as a stress-response mechanism during hypoxia and therapeutic 
treatments40,270,285. However, a whole-body inhibition of autophagy is likely to be a 
more accurate representation of the application of a potential therapeutic that would 
be systemically introduced into patients. To make a whole-body Atg5 knockout 
mouse viable, the Mizushima group expressed Atg5 specifically in neurons286. This 
rescued neurological functions such as neonatal suckling and therefore enabled 
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studies on the function of Atg5 in adult mice. However, this mouse is clearly not 
appropriate for studies in the brain, such as GBM modelling. 
8.5.3.2 Chemical Inhibition of Autophagy in GBM 
Although genetically engineered models offer a clean means of inhibiting autophagy, 
it is likely that a chemical inhibitor will be utilised in the clinic. With this in mind, 
several GBM studies have employed chemical inhibitors of autophagic flux that have 
yielded promising results. These are explored below. 
8.5.3.2.1 Use of Lysosomal Disrupting Agents in GBM 
Bafilomycin A1 and hydroxychloroquine (HCQ), both of which prevent the 
acidification of compartments such as autolysosomes, lysosomes, and endocytic 
vesicles, are the most common inhibitors used to inhibit autophagic flux in vitro. Of 
these, HCQ has been approved for human use and is routinely used as an anti-malarial 
drug. Clinical trials are currently on-going with the hope of re-purposing it to inhibit 
autophagy in cancer225,287. With regards to GBM, a phase I/II clinical trial of HCQ 
had mixed results288. Although LC3-II levels and autolysosomal numbers were 
increased in HCQ-treated patient blood cells, suggestive of successful lysosomal 
inhibition, the consistent and significant inhibition of autophagy was not achievable at 
the tolerated doses of the drug. Additionally, side-effects were reported in response to 
this drug in combination with other cytotoxic agents, including myelosuppression, 
and the pharmacokinetic variability lead the authors to suggest HCQ should not yet be 
utilised outside the clinical trial setting. These results suggest that a more specific 
autophagy inhibitor that could be specifically targeted to tumour tissue is needed to 
minimise toxicity.  
Furthermore, we must take into consideration that these agents are far from specific to 
the autophagy pathway; they also inhibit of the acidification of the endolysosomal 
system. Inhibition of the endocytic pathway perturbs homeostasis and cellular 
function in both healthy and transformed cells. An example of one of the many 
processes that would be disrupted by this would be the detachment of ligands from 
receptor complexes (e.g. RTKs) that is required for the termination of their 
signalling129. Without this, the co-ordination of intracellular activities would be 
irresponsive to the extracellular conditions, whether that be adhesion or nutrient 
availability. Indeed, in contrast to studies that describe chloroquine synergising with 
RTK inhibitors, HCQ has also been seen to prolong endosomal signalling from RTKs 
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such as the insulin receptor289. Furthermore, reports are emerging that suggest that 
any potential efficacy of HCQ is in fact not attributable to autophagy inhibition290,291. 
Therefore, although several clinical trials are underway utilising HCQ in combination 
with traditional therapeutics292, it is likely be beneficial to pursue other, more specific 
autophagy inhibitors.  
8.5.3.2.2 Targeting Autophagy-Regulating Kinases 
Kinase domains are generally considered appealing targets against which to develop 
inhibitors. The only kinase players that present a good opportunity to inhibit the 
autophagy pathway upstream are ULK1 and PIK3C3. To this end, inhibitors of ULK1 
have recently been developed293. Unfortunately, these inhibitors also cross-react with 
other kinases, such as TBK1 and IKKϵ, making results more difficult to interpret and 
raising the possibility for side effects.  
PIK3C3 inhibitors have also been developed, such as a highly specific compound 
called SAR405, which does indeed ablate LC3 lipidation294. This represents a 
significant advance from 3-MA, which also inhibits PIK3C1 activity295. However, as 
discussed above, PIK3C3 functions not only in autophagy but also in the endosomal 
pathway. Disruption of endosomal trafficking is likely to disrupt not just tumour cells 
but also normal cells and therefore side effects may be probable for patients. 
8.5.3.2.3 Autophagy Inhibition as a Combination Therapy for GBM 
Autophagy is frequently elevated following current GBM treatments. For example, 
treatment with the vascular endothelial growth factor (VEGF)-neutralizing antibody 
bevacizumab resulted in the upregulation of autophagy270. Here autophagy was seen 
to be important in tumour resistance to bevacizumab, with the knockdown of ATG7 
reducing tumour burden in mouse xenografts in combination with this treatment. 
Additionally, autophagy is induced by both of the dual PI3K-mTOR inhibitors PI-103 
or NVP-BEZ235 to promote resistance in xenografted cells296.  
Furthermore, upregulated autophagy correlates with GBM cell survival following 
temozolomide treatment, the most commonly used chemotherapy in GBM297. 
Mechanistically, high temozolomide doses have been seen to induce the autophagic 
targeting of aldehyde dehydrogenase 1A3 (ALDH1A3), an enzyme important in 
cancer cell ‘stemness’ and resistance to chemotherapies298,299.  
In addition to induction by chemotherapies, autophagy was also significantly induced 
by γ-radiation therapy in CD133+ GBM stem-like cells, which was required for their 
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survival following exposure to this stress300. This was corroborated by a study by 
Huang et al., who showed that expression of the serine/threonine kinase MST4 is 
upregulated in GBM cells following irradiation, which mediates the phosphorylation 
and activation of ATG4B thereby promoting LC3 lipidation40. Remarkably, using a 
specific inhibitor of ATG4B that was well tolerated in animals, NSC185058, the 
authors were able to demonstrate that this mechanism was important for in vivo 
tumourigenicity following exposure to radiation. This may well be the first step to the 
use of an autophagy-specific inhibitor to treat GBM. Overwhelmingly, these studies 
find autophagy to be a resistance mechanism against a wide variety of GBM treatment 
strategies, thereby representing exciting opportunity for advancing therapeutic 
efficacy.  
 
There remains a lot to be resolved regarding autophagy inhibition as a GBM 
treatment. Firstly, HCQ may not be able to reach sufficient levels over the BBB to 
inhibit the lysosome in GBM tumours288. Moreover, although studies using the 
available autophagy inhibitors, including HCQ and SAR405, have suggested 
autophagy inhibition may be an efficacious cancer therapy, these come with caveats, 
such as lack of target or pathway specificity. In order to identify further ‘druggable’ 
targets that may be more specific to the autophagy pathway, it is necessary to better 
understand the regulation of the molecular machinery of autophagy. Furthermore, 
testing the impact of autophagy loss in an immune competent background is key to 
studying autophagy in GBM, particularly given that autophagy, senescence, 
immunity, and tumourigenicity are interconnected. Additionally, the reliance of 
different GBM molecular subtypes on autophagy has not been explored, although this 
is likely to produce significant variation in the efficacy of autophagy inhibition201. 
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9 Aims and Objectives 
As described above, interesting and unanticipated roles for autophagy in the cell are 
beginning to emerge that influence the development of pathologies such as cancer. In 
glioblastoma multiforme (GBM) there is strong suggestion that autophagy may 
promote properties that contribute to the aggressive phenotype that characterises these 
tumours. However, much of the research into the impact of autophagic flux on 
tumourigenesis in various models has relied on xenografts in immunocompromised 
animals and appears to produce highly context-dependent results. There is, therefore, 
a need for a study of autophagy in tumour formation in immunocompetent mice, 
particularly with regards to GBM.  
The primary question at the commencement of this study therefore became:  
‘Is autophagy able to drive pro-growth processes in GBM cells?’ 
To address this question, the following aims were proposed that were then challenged 
with a series of different experimental strategies. 
 
Autophagy appears to play a context-dependent role in cancer. Is it required for 
gliomagenesis in an RCAS/tv-a mouse model? If so, what processes does it 
regulate? (Chapter 11) 
As described above, there is currently a great deal of conflicting evidence regarding 
the influence of autophagy in cancer, which can be largely attributed to context-
dependency. This extends to GBM, where it is unclear what impact autophagy has on 
tumour generation or maintenance, particularly in a host with a functional immune 
system. In an attempt to investigate this, constitutively active KRasG12D was used to 
drive the formation of tumours in the RCAS/tv-a mouse model alongside the 
concurrent knockdown of different autophagy players. To carry out a detailed 
molecular investigation of the phenotype, the oncogenic properties of transformed 
XFM/tv-a glial cells were assayed in vitro, using conditions akin to those experienced 
during GBM tumourigenesis.  
 
Do the GBM subtypes experience differential reliance on autophagy for 
oncogenic transformation? (Chapter 12) 
Disrupting autophagy in cells with different oncogenic mutations has been seen to 
cause varying outcomes in other cancer types, but how autophagy loss impacts 
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different glioblastoma subtypes is not known. To address this, here I used a set of cell 
lines derived from common parental XFM/tv-a cells and transformed them with 
different oncogenic perturbations. Autophagy was then inhibited and their capability 
for oncogenic anchorage-independent growth was assayed. In this way it was possible 
to directly compare the requirement for autophagy in models of different GBM 
subtypes. 
 
Can autophagy influence the activity of receptor tyrosine kinase (RTK) 
signalling in glioblastoma? (Chapter 13) 
Reports are emerging that autophagy proteins and autophagy-related endomembranes 
can have roles outside their canonical participation in autophagosome biogenesis, 
such as in the mediation of RTK signalling. However, the mechanistic details of this 
interplay are currently unclear. As aberrant RTK activity and downstream signalling 
is a key feature in GBM and is observed in the vast majority of tumours, I was 
interested to understand whether autophagy may regulate such signalling. To test this, 
transformed XFM/tv-a glial cells were stimulated with ligands for different RTKs and 
the signalling outputs were measured. I then set out to characterise the impact of 
autophagy on RTK signalling in this context. 
 
How do autophagy proteins regulate RTK signalling? (Chapter 14) 
Recent research has elucidated extensive connections between autophagy proteins, the 
endocytic pathway, and RTK signalling. Although studies have been able to show 
how autophagosome formation is facilitated by endosomes, little is known regarding 
how the presence of autophagy proteins in endosomal compartments impacts the 
homeostasis of the endocytic system and its function in regulating RTK signalling. In 
the XFM/tv-a glial cell model, the impact of autophagy loss on endosomal function 
was queried by its ability to properly traffic RTKs. Detailed molecular analyses 
ensued and revealed an intriguing novel role for autophagy. 
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10 Materials and Methods 
10.1 Cell Culture 
All cells were grown at 37°C with 5% CO2, unless otherwise stated. 
XFM/tv-a glial cells280, DF-1 chicken fibroblasts (ATCC, CRL-12203), mouse 
embryonic fibroblasts (MEFs), and human embryonic kidney 293T (HEK293T) cells 
were cultured with Dulbecco’s modified Eagle’s media (DMEM) (Gibco) 
supplemented with 100 units/ml penicillin (Gibco) and 100 µg/ml streptomycin 
(Gibco), 2 mM L-glutamine (Gibco), and, unless otherwise specified, 10% fetal 
bovine serum (FBS) (Gibco).  Transfection of DF-1 cells was achieved by culturing in 
Opti-MEM (Gibco) and application of DNA suspended in Lipofectamine 2000 (Life 
Technologies). XFM/tv-a cells were infected using 0.4 µm-filtered DF-1 virus-
containing media, with the addition of 1 µg/ml polybrene (Sigma Aldrich).  
Mouse neural stem cells (ANS4 and IENS) were kindly provided by Dr Steve Pollard 
(MRC Centre for Regenerative Medicine, University of Edinburgh) and have been 
described previously301–304. Cells were cultured with DMEM/Nutrient Mixture F-12 
Ham (Sigma) supplemented with 1.45 g/L glucose (Sigma), 1% MEM non-essential 
amino acids (Gibco), 0.012% bovine serum albumin (Gibco), 100 µM beta-
mercaptoethanol (Gibco), 0.5% B-27 supplement (Gibco), and 0.5% N-2 supplement 
(Gibco), with 10 ng/ml epidermal growth factor (EGF) and fibroblast growth factor 
(both Peprotech) and 1 µg/ml laminin (Sigma Aldrich) added to media immediately 
prior to plating cells. ANS4 and IENS cells were twice transfected with CRISPR/Cas9 
vectors using the Amaxa Nucleofector kit (Lonza). 
10.2 Vectors and Cloning 
10.2.1 Transient gRNA Cloning Strategy 
To target genes in ANS and IENS stem cells and MEF cells, transient non-selectable 
expression vectors for Cas9 and gRNAs were used (Table 10.1).  
gRNAs were designed on http://crispr.mit.edu then inserted into the oligonucleotide 
sequences in Table 10.1 below. 
For 50µl PCR: 0.5 µl Phusion polymerase and 10 µl HF Phusion Reaction Buffer 
(both New England Biolabs (NEB)), 2.5 mM dNTPs (Invitrogen), 2 µM forward 
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oligonucleotide and 2 µM reverse oligonucleotide. The resulting product was then gel 
purified. 
PCR Cycles:  1X 98°C 30 sec 
  30X 98°C 10 sec 
   55°C 30 sec 
   72°C 20 sec 
  1X 72°C 20 sec 
For 50 µl Digest: 2 µg vector, 2 µl Af1II, and 5 µl CutSmart buffer (both NEB). 
For 4 µl Ligation: 4 ng PCR product, 30 ng linearised vector, 2 µl Gibson’s Assembly 
Ligation Mix (Invitrogen). Incubated for 1 hr at 50°C. 
Following transformation into DH5α cells, single colonies were selected from 
kanamycin-selection plates. These were tested for the presence of an insert using the 
‘transient gRNA sequencing primer’ in Table 10.1. 
10.2.2 RCAS-sgRNA Cloning Strategy 
As described in introduction section 8.5.2, the RCAS vector can be used to generate 
viruses that efficiently infect XFM/tv-a cells to overexpress or knockdown proteins of 
interest. To develop this system further and generate CRISPR/Cas9-mediated 
knockout in XFM/tv-a cells, sgRNAs were cloned into the RCAS vector. These were 
then expressed alongside Cas9 delivered by lentivirus, which was selectable by 
blastocyodine (Sigma). The cloning strategy for this vector is described in further 
detail in results section 12.3.3 and briefly outlined below along with the sources of the 
reagents. 
For 50 µl PCR: 0.5 µl Phusion polymerase and 10 µl HF Phusion Reaction Buffer 
(both New England Biolabs), 2.5 mM dNTPs (Invitrogen), 500 ng gRNA vector, 1.25 
µM forward oligonucleotide and 1.25 µM reverse oligonucleotide to amplify gRNA 
sequence + U6 promoter + NotI digestion sites.  
PCR Cycles: 1X 98°C 30 sec 
  30X 98°C 10 sec 
   55°C 45 sec 
   72°C 45 sec 
  1X 72°C 10 min 
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For 50 µl Vector NotI Digest: 3 µg RCAS empty vector, 3 µl NotI (NEB), 5 µl Buffer 
H. Followed by 5 min room temperature incubation with 2 µl calf alkaline 
phosphatase (NEB). 
For 30 µl PCR Insert Digest: 400 ng purified PCR product, 0.5 µl NotI, 3 µl Buffer H. 
For 10 µl Ligation: 90 ng digested PCR product, 30 ng digested vector, 0.5 µl T4 
ligase and 1 µl T4 ligase buffer (both Promega). Incubated for 2 hr at room 
temperature. 
Following transformation into DH5α cells, single colonies were selected from 
ampicillin-selection plates. These were tested for the presence of a correct insert 
firstly by KpnI digest (Promega) to determine correct orientation. As both the RCAS-
Y vector and the U6 promoter sequence harbour one KpnI restriction site each, an 
excised product can only be generated from vectors where the PCR product was 
successfully inserted. The KpnI site lies upstream of the NotI cloning site in the 
RCAS-Y vector and at the start of the U6 promoter sequence. Therefore, a smaller 
digest product can distinguish between RCAS-Y vectors with a properly orientated 
gRNA insertion (6,035 bp+385 bp) from those with reversed insert (6,000 bp+420 bp). 
Secondly by sequencing with the ‘RCAS-Y 5’ sequencing primer’ in Table 10.1 to 
ensure sequence fidelity was ensured. 
10.2.3 Vectors 
Vectors and sequencing primers used throughout this manuscript are summarised 
below in Table 10.1. 
Table 10.1 Information on Vector Sequences, Derivations, and Cell Culture Usage 













RCAS-shAtg3 shRNA target: 
GTACATCACTTA
CGACAAA 
RCAS-shAtg7 shRNA target: 
CAGTTCAGAGCT
AAATAAT 
RCAS-shAtg13 shRNA target:  
GAGAAGAATGTC
CGAGAAT 
RCAS-shUlk1 shRNA target:  
GAGCAAGAGCA
CACGGAAA 
RCAS-shNf-1 #1 Cloned by PCR 
 
shRNA target:  
CAAGGAGTGTCT
GATCAAC 







which was a kind 
gift from Eric 
Holland282–284 












RCAS-sgAtg3 #1 Cloned by PCR 




RCAS-sgAtg3 #3 Cloned by PCR 





RCAS-sgAtg7 #2 Cloned by PCR 




RCAS-sgAtg7 #3 Cloned by PCR 




RCAS-sgAtg16l1 #1 Cloned by PCR 




RCAS-sgAtg16l1 #2 Cloned by PCR 




RCAS-sgAtg16l1 #3 Cloned by PCR 




RCAS-PDGFB Kind gift from Eric 
Holland 
- 








sgAtg3 #1 Cloned by PCR 
sgRNA targets 
as above KAN 
sgAtg3 #3 Cloned by PCR 
sgAtg7 #2 Cloned by PCR 
sgAtg7 #3 Cloned by PCR 
Addgene #75228 
sgAtg16l #1 Cloned by PCR 
sgAtg16l #2 Cloned by PCR 
sgAtg16l #3 Cloned by PCR 
Transient Cas9 Addgene #41815 - AMP/Puro 
Lentiviral Cas9 Addgene #52962 - AMP/Blast 
pBabe 
FLAG-S-ATG16L1 Cloned by PCR - AMP/Puro 
GFP-ATG16L1 Cloned by PCR - AMP/Puro 
GFP-LC3 Cloned by PCR - AMP/Puro 
mCherry-Rab5 - - AMP/Puro 
mCherry-Rab7 - - AMP/Puro 
mCherry empty - - AMP/Puro 
mCherry-Rab4 Addgene #55125 - KAN/Neo 
mCherry-Rab11 Addgene #55124 - KAN/Neo 
pRetro GFP-LAMP1 - - AMP/Puro 
pEGFP 
C2 
GFP-CD63 Addgene #62964 - KAN/Neo 
MSCV EGFRvIII Addgene #20737 - AMP 







































10.3 Cell Treatments 
10.3.1 Low Serum 
XFM/tv-a cells were seeded under normal culture conditions with 10% FBS-
supplemented DMEM 24 hr prior to changing to DMEM with 0.1% FBS for the 
indicated periods of time. 
10.3.2 Hypoxia 
Cells incubated for specified time prior to lysis on ice in Whitley H35 Hypoxystation 
set to 37°C, with 0.5% O2. 
10.3.3 Growth Factor Stimulation 
Following 4 hr of serum starvation, the following factors were added for the durations 
specified at the following concentrations (unless otherwise stated): 20 ng/ml EGF 
(Peprotech #100-18b), 20 ng/ml FGF (Peprotech #100-18b), 10 ng/ml HGF (R&D 
Systems #2207-HG-025), and 10 ng/ml insulin (Sigma #I9278).  
10.3.4 Soft Agar 
10,000 cells were suspended in DMEM containing 0.4% agar (Sigma Aldrich) and 
plated on DMEM containing 0.8% agar in 6-well plates and grown for 3 weeks, 
replenished weekly with 0.4% agar DMEM. To stain colonies, 0.02% 
iodonitrotetrazolium (Sigma Aldrich) in PBS was applied overnight. Images of plates 
taken using Epson Perfection V750 Pro scanner and colonies quantified using ImageJ. 
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10.3.5 Culture on Low-Adherence Alvetex Scaffolds 
5,000 cells were seeded per Alvetex 12-well insert (AVP005-12) that were then filled 
with each cell type’s respective medium. Media was changed every 2-3 days for 14 
days, before staining with 0.02% iodonitrotetrazolium (Sigma Aldrich) in PBS 
overnight. Images were then taken using Leica DM IL LED microscope using the 
Qimaging Retiga EXi Fast1394 Camera and quantified using ImageJ.  
10.3.6 Acute Cell Suspension Assay 
90% confluent 10 cm diameter plates of cultured cells were trypsinised then spun 
down. Cells were then re-suspended in media without FBS (XFM/tv-a) or without 
growth factors (IENS) and seeded onto plates without tissue culture treatment. Cells 
were incubated at 37°C for the indicated number of hours before harvesting cells for 
Western blot or addition of propidium iodide (images taken using Leica DM IL LED 
microscope using the Qimaging Retiga EXi Fast1394 Camera then quantified using 
ImageJ).  
10.3.7 Inhibitors 
The following inhibitors were used at the indicated final concentration: 20 nM 
bafilomycin (Sigma), 25 µM erlotinib (LKT labs, E6846), 10 µM PIK3C3 inhibitor 
(kind gift from Ian Ganley, PPU, University of Dundee), 10 µg/ml 3-MA (Sigma), 
100 µM monensin, and 30 µM Dynasore (Sigma).  
10.3.8 Autophagic Flux Assay 
Autophagic function was measured by culturing cells in Hank’s buffered salt solution 
(Gibco) for 2 hr with 20 µM bafilomycin (Sigma Aldrich). 
10.4 Western Blotting and Antibodies 
Cells were washed twice in ice cold PBS before lysis in RIPA buffer, as previously305, 
with protease and phosphatase inhibitors (both Fisher Scientific: 1287-1640 and 
1284-1650, respectively). Lysates were run on 8, 10, or 15% acrylamide gels then 
transferred onto nitrocellulose membranes. Membranes were blocked with 5% non-fat 
milk before probing with primary antibodies at room temperature for 2-4 hours or at 
4°C overnight. The antibodies used throughout this manuscript for Western blotting 
are summarised in Table 10.2.  
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Table 10.2 Antibodies and beads used for Western blotting, 
immunofluorescence/immunohistochemistry (IF/IHC)), and immunoprecipitation (IP) 








β-Actin Mouse Sigma A5316 AC-74 1:3000 - - 
Akt Rabbit CST 9272 - 1:1000 - - 
Akt 
p- Ser473 Rabbit CST 4060 - 1:3000 - - 
AP-2 Mouse Thermo Fisher MA1-064 AP6 1:500 - - 
Atg3 Mouse MBL M133-3 3E8 1:3000 - - 
Atg7 Rabbit Sigma A2856 - 1:3000 - - 
Atg13 Rabbit Sigma SAB4200100 - 1:2000 - - 
Atg14l1 Rabbit MBL PD026 - 1:1000 - - 
Atg16l1 Rabbit MBL PM040 - 1:3000 1:200 2 µl 
Atg16l1 Mouse MBL M150-3 1F12 1:2000 - 1 µl 
Beclin-1 Rabbit MBL PD017 - 1:2000 - 2 µl 
BrdU Mouse BD Biosci 555627 3D4 - 1:200 - 
Caspase-3 Rabbit CST 9665 - 1:1000 - - 
EEA1 Rabbit CST 3288 C45B10 1:2000 1:200 - 
EEA1 Mouse BD Biosci 410456 - - 1:200 - 
EGFR Rabbit Santa Cruz sc-03 - 1:3000 1:500 2 µl 
EGFR Mouse Millipore 04-290 13G8 1:2000 - 2.5 µl 
EGFR  
p-Tyr1068 Rabbit CST 2234 - 1:500 - - 




Rabbit CST 4370 D13.14.4E 1:3000 - - 
GFP Rabbit CST 2956 D5.1 1:2000 - - 
HIF-1α Mouse R&D Systems MAB1536 241809 1:500 - - 
IL-1β Mouse R&D Systems AF-301-NA - 1:500 - - 
IL-6 Mouse R&D Systems BAF-406 - 1:500 - - 
β1-Integrin Rabbit CST 4706 - 1:1000 - - 
Ki67 Rabbit Vector Labs VP-K451 - - 1:200 - 
KRasG12D Rabbit CST 14429 - 1:1000 - - 
LC3B Rabbit Sigma L7543 - 1:3000 - - 
Nestin Mouse BD Biosci 556309 RAT401 - 1:200 - 
Nf-1 Rabbit Bethyl Labs A300-140A - 1:1000 - - 
p27 Rabbit CST 2552 - 1:1000 - - 
PCAF Mouse Santa Cruz E-08 - 1:1000 - - 
PIK3C3 Rabbit CST 4263 D9A5 1:3000 - 2 µl 
Rab4 Rabbit CST 2167 - 1:2000 1:100 - 
Rab5 Rabbit CST 3547 C8B1 1:1000 1:200 - 
Rab5-GTP Mouse New East Biosciences 26911 - - - 1 µl 
Rab7 Rabbit CST 9367 D95F2 1:1000 1:200 - 
Rab11 Rabbit CST 5589 D4F5 1:1000 1:200 - 
Rab11-GTP Mouse New East Biosciences 26919 - - - 1 µl 
Ras Mouse Calbiochem OP40 RAS10 1:1000 - - 
RasG12D Rabbit CST 14429 D8H7 1:3000 - - 
pRb/p105 Mouse BD Biosci 554136 G3-245 1:1000 - - 
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Rubicon Rabbit MBL PD027 - 1:1000 - - 
S6 Rabbit CST 2217 - 1:3000 - - 
S6 
p-Ser235/236 Rabbit CST 4858 - 1:3000 - - 
TBK1  
p-Ser172 Rabbit CST 5483 D52C2 - 1:200  
Tp53 Mouse CST 2524 1C12 1:1000 - - 
α-Tubulin Rabbit CST 2144 - 1:3000 - - 
ϒ-Tubulin Mouse Sigma T6557 GTU-88 1:2000 - - 
ULK1 Rabbit Sigma A7481 - 1:2000 - - 
UVRAG Mouse MBL M160-3B Clone 1H4 1:2000 - - 
FLAG Tag Mouse Sigma F1804 M2 - 1:200 - 
HA Tag Mouse Thermo Scientific 26183-HRP - 1:1000 - - 
S Tag Rabbit Bethyl Labs A190-135A - - 1:200 1 µl 
Normal 




Secondary) Goat CST 7074 - 1:5000 - - 
Mouse (HRP 

























- GE Healthcare 17-0618-01 - - - 7.5 µl 
GFP-Trap 






- GE Healthcare 17-5113-01 - - - 7.5 µl 
10.5 Reverse Phase Protein Array 
Protein analysis by RPPA was carried out as previously described306. Cells were 
either untreated (10% FBS) or starved of serum for 4hr then stimulated with 20 ng/ml 
EGF or 1% FBS for the indicated length of time. Cells were then lysed with MD 
Anderson lysis buffer (1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM sodium 
chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 100 mM sodium fluoride, 10 
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mM sodium pyrophosphate, 1 mM sodium vanadate, 10% glycerol, supplemented 
with Complete ULTRA protease inhibitor and PhosSTOP phosphatase inhibitor 
cocktails). Following normalisation of protein concentration using the Bradford assay, 
samples were dotted on nitrocellulose-coated slides (Grace Bio-Labs) in serial 
dilution using Aushon Biosystems 2470 array platform. Slides were probed with an 
array of different validated antibodies (Table 10.3) that were detected using anti-
rabbit and –mouse DyLight800-conjugated secondary antibody (New England 
BioLabs) and read by the InnoScan 710-IR scanner (Innopsys). Relative fluorescence 
was determined using Mapix software (Innopsys). Values presented represent the 
mean of technical triplicates ± SEM. 
Table 10.3: Antibodies Used In Reverse Phase Protein Array Assay 
Epitope Company Catalogue Number Species 
4E-BP1 P Ser65 CST 9451 Rabbit 
4E-BP1 P Thr37,Thr46 CST 2855 Rabbit 
Akt CST 9272 Rabbit 
Akt P Ser473 CST 4060 Rabbit 
Akt P Ser473 CST 9271 Rabbit 
Akt P Thr308 CST 2965 Rabbit 
AMPK alpha CST 2532 Rabbit 
AMPK alpha P Thr172 CST 2535 Rabbit 
ATM Merck (Calbiochem) PC116 Rabbit 
ATM/ATR Substrate P Ser/Thr CST 2851 Rabbit 
Aurora A/B/C P Thr288/Thr232/Thr198 CST 2914 Rabbit 
Bad P Ser112 CST 9291 Rabbit 
Bad P Ser136 CST 9295 Rabbit 
Bak Epitomics 1542-1 Rabbit 
Bax Epitomics 1063 Rabbit 
Bcl-2 Epitomics 1017-1 Rabbit 
Bcl-x Epitomics 1018 Rabbit 
beta-actin CST 4970 Rabbit 
beta-Catenin CST 9562 Rabbit 
beta-Catenin P Ser33,Ser37,Thr41 CST 9561 Rabbit 
beta-Catenin P Thr41,Ser45 CST 9565 Rabbit 
beta-Tubulin Abcam ab6046 Rabbit 
Bid Epitomics 1008 Rabbit 
Bim Epitomics 1036 Rabbit 
Bim P Ser69 CST 4585 Rabbit 
BRCA1 CST 9010 Rabbit 
Calmodulin Calbiochem - - 
Calpain2 CST 2539 Rabbit 
Calpastatin CST 4146 Rabbit 
CamKII alpha (22B1) P  Thr286 Abcam ab2724 MouseIgG1 
CamKII P Thr286 CST 3361 Rabbit 
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Caspase 3 CST 9662 Rabbit 
Caspase 3 cleaved CST 9664 Rabbit 
cdc25A CST 3652 Rabbit 
cdc25c P Ser216 CST 4901 Rabbit 
CDK1 (p34cdc2)  P Tyr15 CST 9111 Rabbit 
CDK2 Epitomics 1134-1 Rabbit 
Chk1 P Ser345 CST 2348 Rabbit 
Chk2 P Thr68 CST 2661 Rabbit 
c-Jun N-term Epitomics 1254-1 Rabbit 
c-Jun P Ser73 CST 9164 Rabbit 
c-Myc CST 5605 Rabbit 
c-Myc P Thr58,Ser62 Epitomics 1203-1 Rabbit 
CREB CST 9197 Rabbit 
CREB P Ser133 Millipore (Upstate) 06-519 Rabbit 
CrkL CST 3182 MouseIgG1 
CrkL P Tyr207 CST 3181 Rabbit 
Cyclin D1 CST 2926 MouseIgG2a 
Cyclin D1 P Thr286 CST 3300 Rabbit 
E-Cadherin CST 3195 Rabbit 
eEF2 CST 2332 Rabbit 
EGFR P Tyr1068 Invitrogen (Biosource) 44-788G Rabbit 
EGFR P Tyr1173 CST 4407 Rabbit 
ErbB-1/EGFR CST 2232 Rabbit 
ErbB-2/Her2/EGFR Dako A0485 Rabbit 
ErbB-2/Her2/EGFR P Tyr1248/Tyr1173 CST 2244 Rabbit 
ErbB-3/Her3/EGFR CST 4754 Rabbit 
ErbB-3/Her3/EGFR P Tyr1289 CST 4791 Rabbit 
FAK1 CST 3285 Rabbit 
FAK1 P Y397 CST 3283 Rabbit 
FLT3 P Tyr591 P Tyr591 CST 3461 Rabbit 
FRA1 (R20) Santa Cruz sc-605 Rabbit 
GAPDH Abcam ab9484 MouseIgG2b 
GFAP Abcam ab7260 Rabbit 
GSK 3 B CST 9315 Rabbit 
GSK-3-alpha/beta P Ser21/Ser9 CST 9331 Rabbit 
GSK-3-beta CST 9315 Rabbit 
GSK-3-beta P Ser9 CST 9336 Rabbit 
Hexokinase CST 2867 Rabbit 
Histone H2A.X P Ser139 Millipore (Upstate) 05-636 MouseIgG1 
HSP27 (HSPB1) CST 2402 MouseIgG1 
HSP27 (HSPB1) P Ser78 CST 2405 Rabbit 
IGF-1R beta P Tyr1162,Tyr1163 Invitrogen (Biosource) 44-804G Rabbit 
IkB-alpha CST 4812 Rabbit 
IkB-alpha P Ser32 CST 2859 Rabbit 
IKK alpha/beta P Ser176/Ser177 CST 2078 Rabbit 
IRS-1 CST 2382 Rabbit 
IRS-1 P S636/639 CST 2388 Rabbit 
JAK1 CST 3332 Rabbit 
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JAK1 P Tyr1022,Thr1023 Invitrogen (Biosource) 44-422G Rabbit 
Ki-67 (Annexin II, p36) Beckton Dickinson 610968 MouseIgG1 
LKB1 CST 3047 Rabbit 
MAPKAPK-2 Epitomics 1497-1 Rabbit 
MAPKAPK-2 P Thr334 CST 3041 Rabbit 
M-CSF P Tyr723 CST 3155 Rabbit 
MEK1/2 CST 9122 Rabbit 
MEK1/2 P Ser217/221 CST 9154 Rabbit 
Met CST 4560 Rabbit 
Met P Signalway 11238 Rabbit 
Met P Tyr1234 Signalway 11227-1 Rabbit 
MNK1 (MKNK) P Thr197,Thr202 CST 2111 Rabbit 
MSK1 P Ser376 CST 9591 Rabbit 
mTOR CST 2972 Rabbit 
mTOR P Ser2448 CST 2971 Rabbit 
mTOR P Ser2448 CST 2971 Rabbit 
mTOR P Ser2481 Millipore (Upstate) 09-343SP Rabbit 
NFkB p105/p50 GeneTex GTX110585 Rabbit 
NFkB p65 Ser536 CST 3033 Rabbit 
P Myosin light chain CST 3761 Rabbit 
p21 CIP/WAF1 CST 2946 MouseIgG2a 
p21 CIP/WAF1 p Thr145 Santa Cruz 20220-R Rabbit 
p38 MAPK CST 9212 Rabbit 
p38 MAPK PThr180,Tyr182 CST 9211 Rabbit 
p44/42 MAPK (ERK1/2) CST 9102 Rabbit 
p44/42 MAPK (ERK1/2) P 
Thr202/Thr185,Tyr204/Tyr187 CST 4370 Rabbit 
p53 CST 9282 Rabbit 
p53 P Ser15 CST 9284 Rabbit 
p70 S6 Kinase CST 9202 Rabbit 
p70 S6 Kinase P Thr389 Epitomics 1175-1 Rabbit 
p70 S6 Kinase P Thr421,Ser424 CST 9204 Rabbit 
p90 S6 kinase (Rsk1-3) Santa Cruz sc-231 Rabbit 
p90 S6 kinase (Rsk1-3) P Thr359,Ser363 CST 9344 Rabbit 
PABP1 CST 4992 Rabbit 
PARP CST 9542 Rabbit 
PARP cleaved Asp214 CST 9541 Rabbit 
PDGFR  P Tyr751 CST 4549 Rabbit 
PDGFR P Tyr1021 CST 2227 Rabbit 
PDK-1 CST 3062 Rabbit 
PDK-1 P Ser241 CST 3061 Rabbit 
PI3 Kinase p110-alpha CST 4249 Rabbit 
PKA Abcam ab26322 Rabbit 
PKA RII P Ser96 Epitomics 1151-1 Rabbit 
PKC (pan) P Ser660 (beta-2) CST 9371 Rabbit 
PKC substrate P (R/K)X(S*)(Hyd)(R/k) CST 2261 Rabbit 
PKC-alpha Beckton Dickinson 610108 MouseIgG2b 
PKC-alpha  P Thr638 Abcam ab32502 Rabbit 
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PKC-gamma P Thr514 GeneTex GTX25778 Rabbit 
PKC-zeta CST 9372 Rabbit 
PKC-zeta/lambda P Thr410/403 CST 9378 Rabbit 
PKM2  XP(R) CST 4053 Rabbit 
PLC-gamma1 CST 2822 Rabbit 
PLC-gamma1 P Tyr783 CST 2821 Rabbit 
Prohibitin Santa Cruz sc-28259 Rabbit 
PTEN CST 9552 Rabbit 
PTEN P Ser380,Thr382,Thr383 CST 9554 Rabbit 
Puma CST 4976 Rabbit 
Raf P Ser259 CST 9421 Rabbit 
Raf P Ser338 CST 9427 Rabbit 
Raf1 (C-12) Santa Cruz sc-133 Rabbit 
Rap1 CST 4938 Rabbit 
Ras Beckton Dickinson 8100001 Mouse 
Rb Epitomics 2655-1 Rabbit 
Rb P  Ser807,Ser811 CST 9308 Rabbit 
Rb P Ser780 CST 9307 Rabbit 
Rsk2 Pser 227 CST 3556 Rabbit 
S6 Ribosomal Protein CST 2217 Rabbit 
S6 Ribosomal Protein CST 2217 Rabbit 
S6 Ribosomal Protein CST 2211 Rabbit 
S6 Ribosomal protein P Ser235,Ser236 CST 2211 Rabbit 
S6 Ribosomal protein p Ser240,Ser244 CST 2215 Rabbit 
SAPK/JNK CST 9258 Rabbit 
SAPK/JNK P CST 4668  
SAPK/JNK P Thr182,Tyr185 CST 4668 Rabbit 
SAPK/JNK P Thr183,Tyr185 CST 9251 Rabbit 
SHP2 P Tyr542 CST 3751 Rabbit 
SirT1 (IF3) CST 8469 Mouse 
Smad1/5 P Ser463/Ser465 CST 9516 Rabbit 
Smad2 P Ser465,Ser467 CST 3108 Rabbit 
Smad2/3 P Ser465/Ser423,Ser467/Ser425 CST 9510 Rabbit 
Smad3 P Ser423,Ser425 CST 9520 Rabbit 
SQSTM1 CST 8205 Rabbit 
Src CST 2109 Rabbit 
Src (family) P Tyr416 CST 2101 Rabbit 
Stat1 CST 9176 MouseIgG1 
Stat1 P Ser727 Invitrogen (Biosource) 44-382G Rabbit 
Stat1 P Tyr701 CST 9171 Rabbit 
Stat3 CST 9132 Rabbit 
Stat3 P Tyr705 CST 9131 Rabbit 
Stat3 P Tyr705 CST 9138 MouseIgG1 
Stat5 Invitrogen (Biosource) 44-368G Rabbit 
Stat5 CST 9351 Rabbit 
Stat6 CST 9362 Rabbit 
Stat6 P Tyr641 CST 9361 Rabbit 
Survivin CST 2808 Rabbit 
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Tau Epitomics 2368-1 Rabbit 
Tau P Ser396 Epitomics 1178-1 Rabbit 
Tsc-2 (Tuberin) CST 3612 Rabbit 
Tsc-2 (Tuberin) P Thr1462 CST 3617 Rabbit 
Tuberin  P S1387 CST 5584 Rabbit 
Tyk2 P Tyr1054,Tyr1055 CST 9321 Rabbit 
Ubiquitin (P4D1) CST 3936 MouseIgG1 
VEGFR P Tyr1059 CST 3817 Rabbit 
VEGFR P Tyr1175 CST 3770 Rabbit 
VEGFR P Tyr951 CST 4991 Rabbit 
VEGFRP  Tyr1175 CST 2478 Rabbit 
XIAP CST 2045 Rabbit 
YB1 CST 4202 Rabbit 
Zap70 CST 2705 Rabbit 
cdc2 CST 9112 Rabbit 
BCL2 P CST 2827 Rabbit 
FOX01 P CST 9461 Rabbit 
HDAC 4/5/7  P CST 3443 Rabbit 
EZRIN P CST 3149 Rabbit 
FAK P Y397 Invitrogen (Biosource) 44624G Rabbit 
Stat 5 CST 9363 Rabbit 
TBK1/NAK CST 3504 Rabbit 
P44/P42 CST 4696 Rabbit 
PLK1 CST 3472 Rabbit 
 
10.6 Immunohistochemistry 
Mouse brains harvested from animals were fixed in 10% formalin for 24–72 h and 
then transferred to 70% ethanol. Samples were then paraffin-embedded, sectioned and 
stained with H&E by Histoserv Inc., Maryland. Similarly, MEFs derived from 
wildtype or atg7 knockout cells were pelleted and processed for paraffin embedding. 
For immunocytochemistry staining, paraffin-embedded sections were treated with 
xylene twice for 10 min each before being sequentially hydrated in decreasing 
concentrations of ethanol. Epitope retrieval was performed by incubating slides in 10 
mM sodium citrate buffer, pH 6 for 15 min at 95°C then allowed to cool for 20–45 
min. Subsequently, slides were blocked with TBST (150 mM NaCl and 10 mM Tris 
pH 7.5, 0.1% Tween 20 [Sigma, P5927] + 5% BSA [Thermo Fisher Scientific, 
BP1605-100]) for 45 min, and incubated with primary antibodies overnight at 4°C. 
Subsequently, slides were incubated with Alexa-conjugated secondary antibodies and 
images acquired using a Nikon Eclipse Ti-U Confocal Microscope. 
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10.7 Beta-Galactosidase Assay for Senescence 
Cellular senescence was measured using an SA-GLB1 assay221. Briefly, cells were 
fixed with 0.5% glutaraldehyde then incubated with X-gal staining solution, pH 6.0 (1 
mM MgCl2 phosphate-buffered saline [Fisher BioReagents, BP399], X-gal [Thermo 
Fisher Scientific, R0941], 0.12 mM K3Fe[CN]6 [Sigma, 60299], 0.12 mM 
K4Fe[CN]6 [Sigma, 60279]) overnight at 37°C. Images of cells were taken using a 
Nikon Digital Sight DS-L3. 
10.8 BrdU Proliferation Assay 
For the BrdU incorporation assay, cells were pulsed with 50 µM BrdU (Sigma, 
B5002) for 18 h followed by fixation with 3.7% paraformaldehyde and 
permeabilization with 0.2% Triton-X100. Cells were blocked with 0.2% gelatin-fish 
(Sigma, G7765) in 5% BSA-phosphate-buffered saline and incubated with anti-BrdU 
primary antibody, 0.5 U/L DNase (Sigma, D4527), and 1 mM MgCl2 in blocking 
solution. Subsequently, slides were incubated with Alexa-conjugated antibodies and 1 
µg/ml DAPI; images were acquired using ImageXpress and analyzed using 
MetaXpress software. 
10.9 Cell Fractionation 
The fractionation buffer base was made of 150 mM NaCl (Sigma), 25 mM HEPES 
pH 7.5 (ThermoFisher), 1 mM β-mercaptoethanol (Sigma), 0.2 mM CaCl2 (Sigma), 
0.5 mM MgCl2 (ThermoFisher) +1:100 phosphatase and protease inhibitors (both 
Fisher Scientific: 1287-1640 and 1284-1650, respectively). This was supplemented 
with 1 µg/ml digitonin (Sigma, D141) for 30 min at 4°C before spinning 1 min 13,000 
rpm to obtain the ‘cytosolic fraction’. The resulting pellet was washed three times 
with the fractionation buffer then 0.5% NP-40 (Source Bioscience, ABE5465) was 
added, the pellet was vortexed, then the lysate was spun 1 min 13,000 rpm leaving the 
‘membrane fraction’ in the supernatant. The pellet was again washed then the 
‘nuclear fraction’ was re-suspended in 1X SDS loading buffer. 
10.10 Immunoprecipitation 
Detergent-free buffer: 150 mM NaCl (Sigma), 25 mM HEPES pH 7.5 (Fisher), 1 mM 
β-mercaptoethanol (Sigma), 0.2 mM CaCl2 (Sigma), 0.5 mM MgCl2 (Fisher) +1:100 
phosphatase and protease inhibitors (both Fisher Scientific: 1287-1640 and 1284-
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1650, respectively). To this buffer was added either 1 µg/µl digitonin (for 
fractionation: Sigma, D141), 0.5% NP-40 (for fractionation: Source Bioscience, 
ABE5465), or 0.8% CHAPS (for Beclin-1 and PIK3C3 IPs: Sigma). IPs were also 
supplemented with Mg132 (Sigma). 
Rab-GTP IP buffer: 25 mM Tris pH 7.5, 30 mM MgCl2, 150 mM NaCl, 1% NP-40 
+1:100 phosphatase and protease inhibitors (both Fisher Scientific: 1287-1640 and 
1284-1650, respectively) and Mg132 (Sigma). 
10.11 Cell Surface Biotinylation Endocytosis/Recycling Assay 
Cells were seeded 1 day in advance. Then, to accumulate receptors on the plasma 
membrane, cells were starved of serum for 4 hr. After washing twice with ice-cold 
PBS, cells were incubated with 0.2 mg/ml biotin (EZ-Link sulfo-NHS-SS-biotin 
Pierce, ThermoFisher) 30 min 4°C. Excess biotin was washed off with PBS then 
quenched with 20 mM glycine (Alfa Aesar, J61855) in PBS 15 min 4°C. Endocytosis 
was induced with serum-free media supplemented with 2 ng/ml EGF 15 min 37°C. 
Plates were then returned to ice and washed with ice-cold PBS. To remove un-
endocytosed biotin, cells were incubated with stripping buffer (37.5 mM NaOH 
(Sigma), 37.5 mM NaCl (Fisher), 25 mM L-glutathione (Sigma), 25 mM MesNA 
(Sigma), 0.5% BSA (Fisher)) 30 min 4°C, washed, then quenched with 20 mM 
iodoacetamide (Sigma) in PBS 20 min 4°C. To allow recycling, cells were returned to 
37°C with EGF media for a further 15 min. The stripping procedure was then 
repeated. Thus, both endocytosis and recycling rates can be measured according to the 
quantity of protein (e.g. EGFR) that is biotinylated, as measured by pulling down 
overnight 4°C with streptavidin-sepharose beads following cell lysis with RIPA. 
Beads were then washed three times with RIPA and 300 mM NaCl RIPA, followed 
by 2 washes with PBS, then resuspended in 2X SDS loading buffer and subjected to 
Western blotting. 
10.12 in vitro EGFR Kinase Assay 
Cells were serum-starved for 4 hr before they were lysed in kinase assay buffer (1% 
NP-40 (Source Bioscience, ABE5465, 20 mM HEPES pH 7.5 (Fisher), 150 mM NaCl 
(Fisher), 10 mM MgCl2(Fisher), 1 mM EDTA (Sigma), 1 mM DTT (Sigma), 1:50 
phosphatase inhibitors, 1:100 protease inhibitors) and spun 13,000 rpm 1 min. In a 
total reaction volume of 60 µl, 4.2 µl of phosphocreatine (Sigma), 1 mM ATP 
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(Sigma) and 50 ng EGF were added on ice, before incubation at 30°C for 15 min 
before the addition of 4X SDS loading buffer and incubation at 95°C. 
10.13 Microscopy Analyses 
10.13.1  Cell Culture Imaging 
Images of cells in culture were taken on a Leica DM IL LED microscope using the 
Qimaging Retiga EXi Fast1394 Camera.  
10.13.2  Fixed Sample Preparation 
Cells were plated on glass coverslips in a 6-well plate 24 hr prior to experiment, then 
were treated as indicated for each experiment. Cells were washed twice with ice-cold 
PBS then fixed with PFA (3.7% PFA (Sigma) 200 mM HEPES pH 7.4 
(ThermoFisher) in PBS (ThermoFisher)) 10 min on ice and 20 min RT. Either 0.1% 
Triton X-100 (Sigma, T9284) 5 min or, in the case of Atg16l1 staining, methanol 
(ThermoFisher) 3 min were used to permeabilise cells. 1% BSA in PBS was used to 
block for 15 min. Coverslips were then incubated with 1:200 primary antibodies 
(Table 10.2) in blocking buffer either 4°C overnight or 37°C 3 hr. Following washing, 
cells were incubated 1 hr RT with 1:500 dilution of appropriate secondary antibody 
conjugated to Alexa fluorophores (Table 10.2). Finally, nuclei were stained with 1 
µg/µl DAPI (Sigma) 5 min RT then coverslips were mounted with Prolong Gold Anti-
fade (Invitrogen).  
10.13.3  Confocal Microscopy Analysis 
Leica SP5 confocal microscope was used for fixed samples. The 488 nm and 594 nm 
laser lines were used as well as the UV line for DAPI. 63X objective was used for the 
majority of experiments, except for Alexa555-Transferrin recycling analyses. For the 
majority of experiments, Pearson’s correlation coefficient was obtained using the 
unbiased ImageJ Coloc2 plugin. However, to calculate the Pearson’s correlation 
coefficient for 555-EGF colocalisation with EEA1, Rab5, and Rab7 it was necessary 
to use Imaris Coloc software was used to identify EGF vesicles due to their low 
fluorescence intensity that was incompatible with the use of Coloc2. 
Where co-localisation is given as a percentage of total vesicles that are co-localised, 
vesicle quantification was undertaken manually. 
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10.13.4  Perinuclear EGFR Quantification 
Using ImageJ software, circles were drawn around the nucleus with diameter 30 µm. 
The quantity of EGFR inside these parameters was measured and classed as 
‘perinuclear’. 
10.13.5  Transferrin Recycling Analysis 
Following 4 hr serum starvation, serum-free media with 20 ng/ml Alexa555-
Transferrin (Tfn) (Invitrogen T35352) was applied for 15 min. Cells were then either 
fixed with 3.7% PFA or chased with serum- and Tfn-free media for 5 or 15 min 
before fixation to allow recycling of the Tfn receptor and expulsion of fluorescent 
Tfn. The Tfn levels in cells following these treatments were imaged by confocal 
microscopy at 20X magnification and quantified using ImageJ.  
10.13.6  EGF Uptake Quantification 
20 ng/ml Alexa555-EGF was applied to cells plated in a 12-well plate for the 
specified length of time following 4 hr serum starvation. Cells were then fixed using 
3.7% PFA and stained for DAPI. Fluorescence readings were taken using the 
ImageXpress plate reader and analysed using ImageJ software. 
10.13.7  Live Cell Imaging and Analysis 
Cells were plated on glass-bottom plates (World Precision Instruments, FluoroDish 
FD35-100) and starved of serum for four hours before the addition of Alexa555-EGF. 
Live cell imaging was performed using the Andor Dragonfly spinning disc confocal 
microscope. Images were captured using 63X objective lens and the 488 and 594 nm 
laser lines. Vesicle speed, direction, and duration were analysed using Imaris Cell and 
Tracking software. 
10.13.8  Super-Resolution Microscopy and Analysis 
Samples were prepared on Zeiess High-Performance coverslips (thickness no. 1.5, 
18x18 mm) and incubated with antibodies as described above. The Nikon NSIM 
structured-illumination microscope was used to capture images with a 100X objective 
and the 488, 594, 647, and UV laser lines. Images were then reconstructed using the 
NIS Elements software. 
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10.13.9  PI(3)P Probe Levels and Detection 
The FYVE-Alexa488 probe used to detect PI(3)P was kindly donated by Ian Ganley 
(PPU, University of Dundee) and cells were stained for PI(3)P as previously 
described1. Briefly, cells plated on coverslips were treated with serum starvation for 4 
hr before 15 min EGF stimulation (2 ng/ml). Cells were washed with PBS and placed 
in glutamate buffer (25 mM HEPES pH 7.4, 25 mM KCl, 2.5 mM MgAc, 5 mM 
EGTA, 150 mM potassium glutamate). Coverslips were then briefly submerged in 
liquid nitrogen, brought back to room temperature then returned to glutamate buffer. 
Following washing with glutamate, cells were then fixed with PFA (3.7% PFA, 200 
mM HEPES pH 7.4) for 30 min. PFA was quenched using two washes and 10 min 
incubation in DMEM with 10 mM HEPES pH 7.4. After blocking in 1% BSA in PBS, 
cells were incubated with 1:200 primary antibody against EEA1 3 hr 37°C. Then they 
were incubated with 1:300 FYVE-Alexa488 and 1:500 anti-mouse-Alexa594 for 1 hr 
RT. Cells were then washed, stained with 1 µg/µl DAPI (Sigma) 5 min RT, then 
mounted with Prolong Gold Anti-fade (Invitrogen). 
10.13.10 Electron Microscopy Analysis 
Cells were starved for 4 hr before they were trypsinised and pelleted. Cells were then 
washed twice with PBS and fixed with glutaraldehyde. Sections were then cut using a 
diamond knife by the University of Edinburgh electron microscopy facility. 
10.13.11  Serum Starvation Cell Death Assay Analysis 
To induce cell death, cells plated in a 12-well plate were starved of serum for 24 hr in 
the presence or absence of 20 ng/ml EGF or 10 ng/ml HGF. 1 µg/ml of propidium 
iodide dye (Caymen Chemical Company, #10008351) was added to cells and 
measured using the Tecan Spark20M plate reader.  Cells were then fixed with 3.7% 
PFA and stained for DAPI, which was also measured using the Tecan reader. The 
ratio of propidium iodide/DAPI relative fluorescence signals was then calculated and 
made relative to RCAS-Y control cells. Representative images were taken on a Leica 
DM IL LED microscope using Qimaging Retiga EXi Fast1394. 
10.13.12  Statistical Analyses 
Experiments were repeated a minimum of three times and represented in all cases as 
mean ± S.E.M. Statistical significance was calculated using two-tailed unpaired t-tests 
with *<0.05, ** <0.01, ***<0.005. 
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11 Autophagy is Required for KRASG12D-driven 
Glioblastoma 
11.1 Introduction 
11.1.1 Modelling GBM Using Constitutively Active KRasG12D 
The overwhelming plethora of mutations exhibited in glioblastoma multiforme 
(GBM) makes it challenging to choose an accurate model system in which to best test 
the relevance of select cellular processes in gliomagenesis. Lying at the heart of the 
aberrant mutational landscape, however, is the proto-oncogene and key signalling 
integrator, Ras (Figure 11.1). Therefore, Ras is a good candidate to manipulate in a 
model of GBM.  
 Furthermore, Ras is seen to have high activation in all glioblastoma lines that have 
been tested and previous models utilising KRas as a driving mutation have developed 
features which closely represent the human disease281,307,308. It must be considered, 
however, that although the upstream regulators and downstream targets of Ras are 
frequently seen to be mutated in GBM, mutations in Ras itself are rarely seen251. 
Consequently, although elegant in its simplicity, a model using Ras as its one driving 
mutation can be considered as a preliminary basis for future studies. Nonetheless, 
given the considerable inter-patient mutational variations and that the aetiology of 
Figure 11.1 A simplified cartoon depicting the major pathways mutated in GBM 
Signalling from receptor tyrosine kinases (EGFR, HER2, c-MET, PDGFRA) through PI3K-AKT and 
MAPK cascades is found in 88% of GBM tumours. These can feed into the regulation of DNA damage 
and cell-cycle mediators, such as p53 and p16, which are themselves frequently found to be mutated in 
GBM. At the centre of many of these signalling and regulatory networks is Ras (highlighted box). 
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GBM is still unknown, generating a completely accurate representation of GBM is 
impossible, even if a vast array of genes were to be perturbed in a single model.  
To introduce this oncogene in vivo and in vitro the RCAS/tv-a system was employed 
(see introduction section 8.5.2)252,279,281. Briefly, the RCAS vector can contain both 
overexpression of a target protein (e.g.KRasG12D) and shRNA against the target of 
choice (e.g. Atg7). This vector is then transfected into DF-1 chicken fibroblast cells, 
which produce ‘RCAS viruses’. The viruses or virus-producing cells are then used to 
infect either the cultured XFM/tv-a glial cell line or N/TVA;cdkn2a/ink4a-arf-/-;Ptenfl/fl 
mouse pups. This mouse line expresses the avian virus receptor ‘tv-a’ under the 
control of the Nestin promoter and has deletion of the Ink4a/Arf-/- locus. Therefore, 
whilst cultured cells have constitutive expression of tv-a, in vivo this receptor is only 
expressed in neural progenitor cells309. Following the infection of these cells with 
RCAS viruses, mice undergo a period of latency before gliomagenesis occurs.  
My supervisor, Dr Noor Gammoh, performed all experiments involving the direct 
handling mice and the harvesting and sectioning of tumours as well as some of the 
immunocytochemistry.  
11.1.2 Autophagy and Ras-induced Tumourigenesis 
What hypothesis might we draw regarding the role of autophagy in this KRasG12D-
driven model of gliomagenesis? In previous studies, the loss of autophagy in Ras-
driven cancer has produced varying results. The function of autophagy in cultured 
cells expressing oncogenic Ras has been conflictingly described as either pro-cell 
death192 and pro-senescence191,310, or pro-malignant195 and anti-senescence194,223. 
However, upon mining the literature one finds that studies from mouse tumour 
models point to a more conclusive result: Ras-driven cancers seem to rely on 
autophagy for malignant transformation196–200. With these studies in mind, how a 
KRasG12D gliomagenesis mouse model might respond to the loss of autophagy was 
unknown, but it was possible to hypothesise that tumourigenic growth may inhibited. 
11.1.3 The Function of Autophagy In Low Nutrient and Hypoxic Conditions 
Autophagic flux occurs constitutively at basal levels in cells then can be amplified 
further by certain stress stimuli311. Conditions like hypoxia and low nutrients that 
induce autophagy are often found in rapidly growing tumours where the generation of 
vasculature lags behind cellular proliferation and occurs in an erratic and disorganised 
fashion178.  The function of autophagy under such conditions has traditionally been 
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considered to produce additional metabolites and nutrients for the cell to survive. 
However, others have argued that these stressors can initiate autophagy to such an 
extent that the eventually the cell actually degrades itself, thereby causing so-called 
‘autophagic cell death’, although this concept remains controversial in the field312–314. 
Alternatively, under such conditions autophagy has been seen to mediate a diverse 
array of other cellular processes, such as mitophagy to prevent the errant production 
of reactive oxygen species, ‘ER-phagy’ to maintain the function and integrity of the 
endoplasmic reticulum, or the regulation of cytokine secretion69,70,315,316. The cellular 
outcome of autophagy loss during conditions of low nutrients or oxygen therefore 
appears to be varied. This can be additionally confounded in the context of cancer 
where oncogenic mutations can perturb normal pathways and generate additional 
metabolic demand. Therefore, the role of autophagy in regulating vascular-deficient 
tumourigenic growth can be complex.  
11.1.4 Senescence: What Is It and How Does It Relate to Autophagy? 
Senescence is a state of irreversible cellular proliferation arrest that can be induced 
when a cell is exposed to certain stressors, such as DNA damage, oncogene 
activation, or replicative exhaustion202,317–319. This phenotype can be defined 
experimentally by a set of molecular and cellular hallmarks including increased cell-
cycle arrest markers, such as p21, p27, Tp53, and Rb, a non-responsiveness to growth 
factors, positive staining for β-galactosidase, or expression of pro-inflammatory 
senescence-associated secretory phenotype (SASP) factors216. 
Apparently opposing functions have been proposed for autophagy in the 
establishment and maintenance of senescence. On the one hand, autophagy is seen to 
be activated upon the induction of oncogene-induced senescence (OIS), with some 
reports suggesting that autophagy actually facilitates this switch310,320. Autophagy 
proteins have also been implicated in the generation of the SASP, which can act to 
promote senescence in both an autocrine and paracrine manner223,316. Furthermore, 
autophagy has been shown to degrade the nuclear lamina, a phenomenon found in 
several types of senescence191. Additionally, in mouse cancer models the loss of 
autophagy is associated with DNA damage and senescence, resulting in either a lack 
of tumourigenesis or failed progression from neoplastic to malignant 
phenotype196,201,321. However, conflicting evidence shows that autophagy proteins can 
protect cells against senescence and maintain them in a proliferation-competent 
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state192,223,322. Given these disparities in reports, I was interested to understand 




Research question: Is autophagy important in regulating KRasG12D-driven 
gliomagenesis in vivo and, if so, why? 
To address this question, two objectives must be undertaken: 
1. Test the impact of autophagy on KRasG12D-driven glioblastoma in vivo 
2. Measure the activity of key pro- and anti-proliferative regulators in autophagy-
competent and -deficient KRasG12D-transformed XFM/tv-a cell lines when 
exposed to tumour-like conditions in vitro 
 
 
11.3 KRasG12D-Driven Gliomagenesis Relies on the Expression of Key 
Autophagy Players 
To investigate the role of autophagy in KRas-driven gliomagenesis, 
N/TVA;cdkn2a/ink4a-arf-/- mice were generated by Dr Gammoh with KRasG12D 
expression and shRNA against either LacZi or the autophagy players Atg7, Atg13, and 
Ulk1. Animals injected with control shLacZi had a short latency period (4-6 weeks) 
before the onset of symptoms suggestive of GBM formation (macrocephaly, lethargy, 
dehydration, weight loss, or poor grooming) and the culling of the animals. However, 
when autophagy genes were concurrently lost there was a striking reduction in 
gliomagenesis (Figure 11.2A). shRNA against Ulk1 and Atg13 resulted in the 
complete loss of tumourigenesis and only a small number of KRasG12D:shAtg7 mice 
developed GBM. As Ulk1 and Atg13 are upstream signalling regulators of autophagy 
initiation and Atg7 acts in the final stages of autophagosome biogenesis, we can 
conclude that it is the process of autophagy rather than individual players that is 
important in the formation of these tumours. However, these results raise the question 
of why tumours were able to form when Atg7 is knocked-down but not when Ulk1 or 
Atg13 were lost? And were the resulting gliomas any different to their control 
counterparts?  
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Dr Gammoh assessed the efficiency of the virus-producing DF-1 cells used during 
this experiment and confirmed all shRNAs were equally able to reduce expression 
levels of their target autophagy genes in vitro, thereby discounting the possibility of 
poor shRNA targeting by KRasG12D:shAtg7 RCAS vectors (Figure 11.2B). It has 
previously been shown that autophagy-deficient tumours are unable to progress to a 
malignant phenotype (for example, Karsli-Uzunbas et al.198). Therefore, Dr Gammoh 
undertook haematoxylin and eosin staining of the tumours formed in 
KRasG12D:shLacZi and KRasG12D:shAtg7 mice, which revealed an apparently similarly 
high grade of aggressive GBM in both cases (Figure 11.2C). Both control and 
knockdown tumours exhibited high cellularity and the formation of micro-vasculature 
characteristic of high-grade gliomas250. To confirm the active growth and 
tumourigenic status molecularly, I performed immunohistological staining of the stem 
cell and GBM cell marker Nestin and the proliferation marker Ki67. Both of these 
proteins were exhibited to a similar degree in KRasG12D:shLacZi and KRasG12D:shAtg7 
mouse tumours (Figure 11.2D). These results suggest that the tumours from these 
mice were of a similar grade and both were still actively growing at the time their 
hosts were sacrificed. 
Finally, Dr Gammoh tested the expression of Atg7 in the GBM mass itself by 
immunohistological staining, which revealed that KRasG12D:shLacZi and 
KRasG12D:shAtg7 tumours were expressing the Atg7 protein to similar levels, or, 
indeed, elevated levels in tumours where Atg7 was supposed to be knocked-down 
(Figure 11.2E). The Atg7 antibody was then applied using a similar protocol to Atg7-
/- mouse embryonic fibroblasts (MEFs), which were negative for staining by this 
antibody thereby confirming its specificity (Figure 11.2F). KRasG12D:shAtg7 tumours 
must therefore have adapted in some way to counteract the shRNA, such as 
acquisition of mutations in the targeted region of Atg7 or silencing of the shRNA or 
its processing machinery. Consequently, all KRasG12D-driven GBM tumours formed 
in the course of this experiment were actually autophagy-competent. I was then 








Figure 11.2 Expression of key autophagy players is required for KRasG12D-driven gliomagenesis 
A: Kaplan Meier curve of tumour-free survival in N/TVA;cdkn2a/ink4a-arf-/-;KRasG12D mice with or 
without shRNA against different autophagy players, B: Western blot confirms that autophagy protein 
expression is suppressed efficiently by RCAS KRasG12D:shAtg7, Atg13, and Ulk1 in XFM/tv-a glial 
cells, C: Haematoxylin and eosin staining in untreated and KRasG12D-induced GBM tumours, revealing 
similar histological features in shLacZi and shAtg7 tumours, D, E: Immunocytochemical staining 
against Nestin, Ki67, and Atg7 in sections taken from normal brain tissue or tumour regions from 
KRasG12D:shLacZi or KRasG12D:shAtg7 animals, F: Immunofluorescence against Atg7 in wild-type or 
Atg7 knockout mouse embryonic fibroblasts (MEFs). Each experiment was performed at least 3 times. 
A-C, E, F: Data generated by Dr Gammoh, D: Data generated by the author. 
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11.4 Molecular Characterisation of XFM/tv-a KRasG12D Cells 
Exposed to Hypoxic and Low Nutrient Stress  
11.4.1 Pro-Growth Signalling Activity Under Tumour-Like Stress Conditions 
Requires Autophagy 
To investigate how autophagy might play a role in malignant transformation and 
gliomagenesis in this mouse model, cells were assayed with conditions akin to those 
cancer cells are exposed to during the rapid proliferation that generates tumours. 
Deficient and disorganised vasculature is a well-established hallmark of cancer that 
results in areas of poor nutrient supply and low oxygen tension250. To mimic these 
conditions, cells were grown either in media with low serum content (1% foetal 
bovine serum (FBS)) or in a cell culture chamber where oxygen levels were reduced 
to 0.5%. The mechanisms that sense oxygen and nutrient availability are intimately 
linked with the activities of PI3K/Akt, mTOR, and MAPK pro-growth signalling 
pathways that promote cell proliferation and survival (represented in a simplified 
format in Figure 11.1)323–327. Therefore, the activities of these pathways were tested to 
assess the impact of autophagy on cells exposed to low oxygen and serum. 
Cells were exposed to hypoxia (0.5% oxygen) for seventy-two hours, following which 
they were lysed for Western blotting analysis. In agreement with previous reports, 
hypoxia dramatically increased autophagic flux in autophagy-competent cells, as 
shown by an increase in the LC3-II:LC3-I ratio (Figure 11.3A)328–330. Additionally, 
blotting revealed a novel role for autophagy in promoting the activities of the key pro-
growth signalling proteins Akt and ERK during hypoxia. Whilst comparable under 
untreated conditions, phosphorylation levels were significantly reduced in autophagy-
deficient cells relative to shLacZi controls when grown in hypoxia. Several papers 
have suggested that HIF-1α lies downstream of PI3K/Akt and ERK signalling 
cascades324,327,331 and, interestingly, HIF-1α expression was significantly lower in 
Atg7 knockdown cells (Figure 11.3A). Therefore, autophagy appears to facilitate the 
activities of Akt and ERK under hypoxia, which then induce the expression of HIF-
1α. HIF-1α expression is then known to initiate a variety of cellular adaptations that 
can stimulate cell survival and proliferation and promote tumourigenesis in hypoxic 
conditions332. However, on the cellular level, the morphology and growth of shLacZi 
and shAtg7 cells was similar and cell death did not appear to be induced in hypoxia 
(Figure 11.3B). Together, these data show that autophagy is required for hypoxia-
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induced signalling but observation of cell morphology and confluency suggests it may 
be dispensable for proliferation and survival in hypoxia. 
 
Figure 11.3 Autophagy promotes hypoxia-induced cell signalling through Akt and MAPK 
pathways 
A: Western blotting analysis of key pro-growth signalling pathway activities and levels of HIF-1α of 
XFM/tv-a cells transformed with KRasG12D cultured in normoxia (21% oxygen) or hypoxia (0.5% 
oxygen) for 72 hr, B: Images of KRasG12D-transformed cells grown in hypoxia for 72 hr, showing that 
cells exhibit a similar morphology when autophagy-deficient. Experiment was repeated 3 times. 
Poorly-vascularised tumours not only have reduced oxygen availability, they also 
have a restricted supply of nutrients. When the vast majority of differentiated cell 
types are grown in vitro serum is the principle source for nutrients, so by restricting 
serum we can mimic the conditions found in a tumour with characteristically 
insufficient vasculature. Here, KRasG12D-transformed XFM/tv-a cells were grown in 
DMEM with a low percentage of serum (0.1% FBS) for four or eight hours, or left 
untreated (10% FBS). As has been seen in a variety of cell types previously, LC3 
lipidation was induced following serum starvation333 (Figure 11.4). 
Furthermore, whilst autophagy-competent cells were able to prevent significant loss 
of Akt and S6 activity following serum restriction, cells with Atg7 knockdown 
experienced a dramatic reduction in the phosphorylation of these key pro-growth 
signalling proteins (Figure 11.4). During these short treatment time-points there was 
no change in cell morphology in either cell type (data not shown). However, with the 
reduction in these signalling pathways being so striking, a prolonged serum starvation 
was undertaken in which to test the eventual outcome of this treatment on cells. Equal 
numbers of KRasG12D:shLacZi and KRasG12D:shAtg7 cells were plated then grown in 
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low serum (1% FBS) for fourteen days, at which time there appeared to be similar 
numbers of each cell type. However, the enlarged and flattened morphology exhibited 
by Atg7 knockdown cells highly resembled that of senescent cells (Figure 11.5). 
Senescent cells are insensitive to mitogens and growth factors so to test whether these 
cells had undergone irreversible growth arrest, full growth media (10% FBS DMEM) 
was re-applied to cells for one week. At that time it was apparent that whilst a sub-
population of control cells were able to re-expand following a period of serum 
depletion, autophagy-deficient cells were unable to do so (Figure 11.5). 
 
Figure 11.4 Autophagy promotes cell signalling under conditions of restricted nutrients 
XFM/tv-a cells expressing either KRasG12D:shLacZi or KRasG12D:shAtg7 were grown in low serum 
for 0, 4, or 8 hr before lysis and analysis by Western blotting. Experiment repeated at least 3 times. 
Figure 11.5 Autophagy is required to maintain the proliferation potential of KRasG12D-
transformed cells exposed to prolonged serum starvation  
KRasG12D:shLacZi and KRasG12D:shAtg7 XFM/tv-a cells were grown in 0.1% FBS for 14 days then 
medium was changed to 10% FBS for 7 days. Each medium was changed every 2-3 days. Cell images 
taken at the end of the re-feeding experiment at 4X (left) and 10X (right) magnification. Experiment 
was performed at least 3 times. 
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Therefore, autophagy is required to sustain the proliferative capacity of KRasG12D-
transformed cells during prolonged nutrient deprivation, potentially by maintaining 
the activity of key pro-growth signalling pathways. 
11.4.2 Investigation of the Senescent Phenotype Established In KRasG12D:shAtg7 
Cells Following Prolonged Serum Starvation 
Figure 11.5 shows that after 14 days of culture in low serum conditions, KRasG12D-
transformed cells lacking Atg7 expression enter an irreversible growth arrest. 
However, several hallmarks must be confirmed before a cell can truly be deemed 
senescent (see section 8.3.2.2). The following studies were therefore carried out in 
order to clarify whether this halt in cell cycle was actually senescence and to 
determine how this senescence was established. 
The most widely used marker of senescence is the up-regulation of senescence-
associated (SA) β-galactosidase, which is caused by an expanded perinuclear 
lysosomal compartment217. Staining for this enzyme involves its reaction with X-gal 
and potassium ferricyanide that generates a characteristic electric blue product. Here, 
the culture of cells with low serum for seven days induced staining for SA β-
galactosidase in a subset of KRasG12D-expressing XFM/tv-a control cells (29%) 
(Figure 11.6A, B). However, the number of SA β-galactosidase-positive cells was 
almost double that amount when Atg7 expression was lost (54%). Upon growing for a 
further seven days, SA β-galactosidase staining was increased further for both cell 
types (65% and 78%, respectively), with Atg7-deficient cells again exhibiting 
significantly higher numbers than controls.  
To assess the influence of serum depletion of the rate of cell division, BrdU 
incorporation was measured. When the synthetic nucleoside BrdU is incubated with 
cells overnight it becomes incorporated into any newly synthesised DNA. Subsequent 
immunofluorescence against BrdU then reveals which cells have passed through S-
phase in that period. As senescent cells do not go through the cell cycle they do not 
integrate BrdU and are therefore negative for the stain. Following seven days growth 
in low serum conditions 37% of control cells were positive for BrdU (Figure 11.6C). 
Under normal growth conditions, KRasG12D-transformed XFM/tv-a glial cells divide 
approximately once every 16 hours, therefore these nutrient restricted conditions 
appeared to have a deleterious impact on normal cell division. However, when 
autophagy was prevented by Atg7 loss there was a further reduction in cell division, 
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with only 25% of cells labelled with BrdU. After fourteen days growth in 0.1% FBS 
shLacZi and shAtg7 cells experienced similar cell cycle repression (both ~10% BrdU-
positive). In combination with SA β-galactosidase and starvation/re-feed data, this 
Figure 11.6 Prolonged serum starvation requires autophagy to maintain quiescence and prevent 
senescence in KRasG12D-transformed cells 
A-F: Assays performed in XFM/tv-a KRasG12D cells. A, B: Senescence-associated (SA) β-galactosidase 
activity is significantly higher in Atg7-deficient cells following 7 and 14 days cultured in 0.1% FBS, A: 
Percentage of cells stained positive for SA β-galactosidase, B: Representative images of SA β-galactosidase 
staining, C: Percentage of actively dividing cells, as measured by BrdU incorporation, is reduced in shAtg7 
cells relative to shLacZi following 7 days cultured in 0.1% FBS, but both are similarly reduced by 14 days of 
treatment, D: Western blotting demonstrating the efficacy of the RCAS vector is maintained during 
establishment of senescence, E: Western blotting showing the upregulated expression of certain senescence 
markers in Atg7 knockdown cells after growth in 0.1% FBS for 0, 3, 7, or 14 days (Rb family members: 
Rb/p105, p130, and p107), F: Expression of senescence-associated secretory phenotype markers in 
autophagy-deficient cells after culture in 0.1% FBS for 0, 7, or 14 days. n=3, error bars represent SEM, * 
p<0.05, ** p<0.01, *** p<0.001. 
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suggests that whilst shAtg7 cells become senescent, some shLacZi cells are able to 
adopt a non-dividing yet proliferation-competent quiescent state.  
During the experiments in mice, cells infected with KRasG12D:shAtg7 eventually 
evolved a response to overcome Atg7 shRNA targeting and thereby facilitate Atg7 
expression, autophagy, and tumour formation. To investigate whether such selection 
pressure was exhibited under these conditions, following fourteen days of growth in 
low serum the expression of KRasG12D and Atg7 were examined as well as LC3 to 
measure autophagic flux. As expected, nutrient deprivation-induced stress increased 
the ratio of LC3-II:LC3-I in control cells, suggesting increased autophagic activity 
(Figure 11.6D, E).  Furthermore, Atg7 expression was upregulated by serum depletion 
in control cells. Although there was no evident re-expression of Atg7 in shAtg7 cells 
over this period, there was a detectable amount of LC3-II, implying that at least some 
cells were expressing Atg7 (Figure 11.6D, E). Interestingly, both autophagy-
competent and -deficient cells also exhibited increased stabilisation of KRasG12D when 
serum was restricted for two weeks (Figure 11.6D). Therefore, autophagy was 
upregulated and KRasG12D was stabilised by prolonged serum deprivation. The 
importance of autophagy in maintaining cell fitness over this period is highlighted by 
the attempt of Atg7 knockdown cells to re-activate the autophagy pathway.  
The focus then turned to examining which molecular pathways were utilised to 
establish this senescent phenotype. Following three, seven, or fourteen days of growth 
in low serum media, cells were lysed and expression of cell-cycle regulators were 
analysed. Despite previous associations observed between autophagy and Tp53201,322, 
there was no stabilisation of either Tp53 or its transcriptional target p21 observed in 
Atg7-deficient cells following prolonged serum depletion (Figure 11.6E). Indeed, in 
both shLacZi and shAtg7 cells Tp53 levels decreased during culture in low serum. 
Alternatively, cell cycle arrest can be induced via the pRb/p27 pathway that inhibits 
cyclin/cyclin-dependent kinase 2 complexes as well as E2F transcription factors, 
which promote expression of key cell-cycle regulators. The retinoblastoma protein 
family is composed of pRb/p105, p107, and pRb2/p130 and is characterised by a 
common ‘small pocket’ transcriptional repressor domain. pRb undertakes several 
unique roles in cells, particularly with regards to the establishment of senescence, 
whereas pRb2 and p107 are believed to be associated with cycling or quiescent cells, 
respectively, by regulating different subsets of E2F complexes209,334. The activity of 
these proteins is regulated both by expression levels and phosphorylation by cyclin-
95 
dependent kinases, such that hyper-phosphorylated Rbs are inactive and hypo-
phosphorylated Rbs are active, which can be detected by an downward shift in 
migration on Western blots when the protein is active210. Here, serum depletion 
quickly resulted in a reduction of p107 expression and increase of p130 expression 
that was similar between shLacZi and shAtg7 cells. These levels were then unchanged 
during the course of the experiment, during which time senescence had become 
established (Figure 11.6E). Therefore, we can rule-out that p107 or p130 were 
influencing cell-cycle regulation in the induction of this senescent phenotype. The 
levels of pRb/p105, however, were more dynamic. pRb/p105 experienced a transient 
elevation in expression level in control and autophagy-deficient cells after three days 
growth in 0.1% FBS media, with this increase being more marked when Atg7 was 
knocked-down. Therefore, there is more pRb/p105 present to inhibit E2Fs and inhibit 
cell cycle. Following this early peak, control cells then reduced pRb/p105 expression 
back to levels similar to that of untreated cells. Conversely, hypo-phosphorylated 
active pRb/p105 remained high in Atg7-deficient cells after seven days cultured in 
low serum, suggestive of sustained cell cycle inhibition associated with senescence. 
Indeed, at this time-point there was also an increase in p27, the downstream 
transcriptional target of pRb/p105, in Atg7 knockdown cells. By fourteen days of 
serum starvation, the levels of pRb/p105 were lower than those found in untreated 
conditions for both cell lines, but hypo-phosphorylated pRb/p105 was still higher in 
autophagy-deficient cells relative to controls. Together, these results suggest that 
autophagy-deficient cells activate the pRb-p27 cell cycle inhibition pathway to arrest 
cells in the G1 phase.  
Autophagy has previously been implicated in the production of the senescence-
associated secretory phenotype (SASP), a phenomenon that reinforces the senescent 
state in both an autocrine and paracrine manner thereby helping to lock them into 
permanent growth arrest221,223,310. To identify whether the senescent phenotype 
observed here in autophagy-deficient cells instigated the production of key SASP 
regulators, KRasG12D-transformed cells were grown in serum-depleted media before 
lysis and Western blotting analysis. This revealed that the levels of the cleaved active 
form of the SASP member interleukin-1β (IL-1β) were consistently higher in Atg7 
knockdown cells following seven and fourteen days of nutrient-restricted growth, 
with production increasing exponentially over this time (Figure 11.6F). Contrastingly, 
whilst Atg7 knockdown cells have a greatly increased production of the SASP 
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member interleukin-6 (IL-6) after seven days cultured in 0.1% FBS, relative to 
control cells, by fourteen days culture in low serum there was elevated production of 
IL-6 in both control and knockdown cells. As all other markers firmly point towards 
Atg7-deficient cells exhibiting a senescent phenotype following fourteen days of 
serum starvation but control cells remaining in largely proliferation-competent state, 
the equal IL-6 production after fourteen days of treatment implies that this cytokine is 
either not important in establishing this form of senescence, or it is only functional 
when found in conjunction with other senescence regulators. Alternatively, the few 
senescent cells that are observed in control cells at this time-point may be particularly 
active in IL-6 production. 
Together, these data demonstrate that autophagy-deficient KRasG12D-transformed cells 
are particularly sensitive to prolonged nutrient restriction, resulting in an increased 
propensity to senesce relative to their autophagy-competent controls. This senescence 
is instigated by the pRb-p27 pathway and reinforced by the production of a pro-
inflammatory SASP, thereby inhibiting the expansion of cells following nutrient 
deprivation. 
11.5 Discussion 
The above studies illustrate an important role for autophagy in KRasG12D glial cell 
transformation and tumourigenicity. In a mouse model for gliomagenesis, autophagy 
was seen to be essential for tumour formation, potentially as a result of reduced pro-
growth signalling capacity during nutrient and oxygen restriction- conditions that are 
inherent in a rapidly expanding tumour. The prolonged exposure of cells to low 
nutrient conditions reveals that autophagy-deficient cells are more prone to 
senescence, thereby potentially putting a halt to cell proliferation in a vasculature-
defective tumour. But how representative are these results of the potential situation in 
patients? And how do these results fit into what is currently known about autophagy 
in the field of GBM as a whole? 
Firstly, regarding the KRasG12D-driven mouse model, this potent inducer of malignant 
transformation generated aggressive tumours with histological and proliferative 
markers resembling the human situation, as had previously been observed in this 
model281,308. Although over-active Ras is often observed in glioblastoma tumours, this 
mutation is not frequently observed in patients307. Therefore, KRasG12D may be 
predictive for the majority of cases but some mutations found in glioblastoma may not 
97 
have the same response when perturbed by autophagy inhibition. In this model we see 
that autophagy loss completely abrogates gliomagenesis, with cells even developing 
adaptations against shRNA knockdown in order to carryout autophagy and generate 
tumours. This therefore raises the question, would autophagy be similarly required for 
transformation with all the different driving mutations in GBM? I attempt to address 
this point in the next chapter utilising cell line models representing the four subtypes 
of GBM.  
The RCAS mouse model of GBM has advantages and disadvantages. The somatic cell 
gene transfer viral infection from DF-1 fibroblasts to the developing mouse’s Nestin-
expressing glial cells results in the transformation of the host’s own cells and the 
development of a tumour de novo. It is becoming increasingly clear that the immune 
system has a complex relationsip with tumours and studying tumour formation in the 
absence of a competent immune system is likely not to be representative335. In terms 
of tumour formation, therefore, the RCAS system is closer to how the pathology 
actually develops in patients, compared to a xenograft system that has to be 
performed in an immunocompromised animal and involves the introduction of a large 
number of foreign cells into the host336. In terms of autophagy, the interplay with the 
immune system is likely to play a large role given what has been seen previously, as 
well as in this study, with regards to the regulation of inflammatory signalling by 
autophagy.  
Xenograft experiments are beginning to become more sophisticated, however, with 
the cells introduced into the mouse that are derived directly from patients and carrying 
all their associated acquired mutations. Nonetheless, these cells are expanded in 
culture before xenografting into mice and therefore tend to have been passaged. These 
cells have therefore had time to acquire a number of mutations and adapt to a tissue 
culture environment. Contrastingly, the RCAS model is initiated with select 
perturbations and then can acquire further mutations with selection pressures similar 
to those that would occur in a patient tumour. Therefore, it can be argued that human 
tumours developing in patients could be more accurately modelled by: a) ex vivo 
human tumour cells xenografted into mice, b) mouse tumours developing in mice.  
These arguments consider the properties and pitfalls of different models of tumour 
formation but the more clinically relevant matter is how to mirror the application of 
potential pharmaceutical inhibitor to a tumour. Patients will not be treated with an 
anti-GBM agent prior to tumour formation; rather they will receive therapeutics to 
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target an already established tumour. In this regard, the RCAS model is not the ideal 
setting in which to test the role of autophagy. Whilst it can be used to investigate 
whether autophagy is required for malignant growth, the constitutive expression of 
shRNA against autophagy targets is unable to represent the application of a putative 
inhibitor against a pre-existing tumour. To develop this model further, a system to 
induce ablation of autophagy gene expression would be of greater value and 
potentially be more predictive of clinical outcome. Currently, inhibition of autophagy 
is most cleanly achieved by genetic means, as although there are a variety of known 
compounds that inhibit autophagy, none are specific to the pathway of autophagy 
alone.  
In order to better understand the results gleaned from the RCAS mouse model, cells 
were cultured under the stressful conditions which GBM cells experience in vivo that 
occur as a result of their poor vascularity and rapid growth. Specifically, cells were 
cultured in low oxygen and low nutrient levels and the activities of pro-growth and 
pro-survival pathways were analysed. The results showed that autophagy was 
required to maintain the phosphorylation and activation of Akt, ERK, and S6 
following exposure to these cell stressors. In the course of this study it was not 
possible to delve into the exact mechanisms by which autophagy maintained these 
signalling pathways, and it is also not something that has been previously documented 
in the field. Given what is known, however, one can hypothesise that there are a few 
possible mechanistic options. Firstly, the cellular building blocks generated by 
autophagic catabolism may promote the activity of metabolic pathways that then 
signal to proteins such as Akt to convey that the energy status in the cell is permissive 
for growth. Alternatively, it is known that hypoxia and low nutrients exert additional 
demand on the mitochondria to produce energy and endoplasmic reticulum to 
synthesise new proteins. The piecemeal degradation of mitochondria (mitophagy) or 
the endoplasmic reticulum (ER-phagy) by autophagy may help sustain the health of 
these organelles during such stress, thereby dampening stress signals that inhibit these 
pro-growth signalling pathways60,69,70,337. Finally, when the cell is stressed, 
upregulated autophagy may directly regulate a signalling player that is required for 
the activation of these cascades and maintains cell growth.  
Upon finding that signalling from Akt and S6 were reduced in autophagy-deficient 
cells following culture in low serum conditions for acute time-points, it was 
interesting to discover what the fate of cells were after sustained growth in low serum 
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media. We found that whilst autophagy-competent control cells were able to re-
expand in full-serum media after a period of starvation, autophagy-deficient cells had 
acquired a senescent phenotype. This halt in cell cycle correlated with the stabilisation 
of active, hypo-phosphorylated pRb and its downstream target p27, as well as the 
induction of a pro-inflammatory senescence-associated secretory phenotype (SASP). 
Others have previously documented connections between autophagy and the 
generation of a SASP. For example, the secretion of IL-1β has been reported to rely 
on the expression of key autophagy proteins316. However, others have seen that basal 
autophagy actually suppresses IL-1β inflammatory signal generation by the clearance 
of damaged mitochondria338. Furthermore, by means of degrading the NFκB regulator 
GATA4, autophagy is able to suppress the generation of SASP components until cells 
are assaulted with different senescence-inducers223. In support of this theory, here we 
see that autophagy loss promotes the production of SASP components IL-6 and 
cleaved, active IL-1β. 
But how might autophagy loss engage the pRb-p27 pathway? An interesting flurry of 
corroboratory papers in 2002 might provide the key to connecting the experiments 
undertaken here212–214. These papers show that Akt is able to directly bind and 
phosphorylate p27, which holds it in the cytoplasm thereby preventing its nuclear 
functions that inhibit the cell cycle. Here we have seen that the genetic ablation of 
autophagy reduces the activity of Akt during serum starvation, through mechanisms 
unknown, which may have the result of allowing the translocation of p27 to the 
nucleus and priming the cell for the induction of senescence. As well as lying 
downstream of pRb, p27 can feed back to stabilise and promote pRb activity205,339. 
Therefore, we can start to build up a model whereby: autophagy à Akt  –| p27 à 
pRb. To test such a hypothesis, a constitutively active myristoylated Akt mutant could 
be introduced into autophagy-deficient cells to test whether this is able to inhibit the 
induction of senescence340. Alternatively, Akt could be knocked-down in autophagy-
competent cells that could be then tested for a senescent phenotype following 
prolonged serum depletion.   
Senescence has been suggested to be paradoxically pro- and anti-tumourigenic 
according to the context. Early reports suggested that senescence is the brake on 
proliferation utilised by multicellular organisms to prevent the formation of cancers, 
whether this be following DNA damage, ageing (which highly correlates with a 
likelihood for DNA damage), or oncogene activation202,341. Then, key to the role of 
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senescence as an anti-tumour pathway, oncogene-induced senescent cancer cells 
could be actively cleared by the immune system342,343. The elimination of senescence 
regulators, such as Tp53 and p16, are some of the most frequently observed mutations 
in cancers, highlighting their importance as tumour suppressors. However, current 
research is showing that in an established tumour the influence of senescence can be 
conflicting, particularly with regards to the SASP. Whilst SASP does confer autocrine 
and paracrine senescence to cells, these pro-inflammatory factors can contrastingly 
promote the aggressive stem properties of cancer cells as well as inducing 
angiogenesis and the pro-metastasis epithelial to mesenchymal transition344. The 
study carried out here has drawn correlations between autophagy loss, induction of 
senescence, and inhibited tumourigenesis. As discussed above, the RCAS system 
provides a model for studying autophagy GBM formation but not maintenance. 
Therefore, it is not possible to assess whether autophagy inhibition might induce 
senescence and the SASP production in established tumours in vivo by this method, or 
what the consequences of this would be in the context of treatment. It would be 
interesting to use an inducible autophagy genetic ablation to test whether the poor 
vasculature and nutrient scarcity of GBM would cause a senescent phenotype in 
established tumours in mice and what the consequences of that would be. Previous 
reports have shown that senescence in GBM can either support stemness and tumour 
growth345, or halt cell proliferation and induce tumour cell clearance resulting in 
tumour regression346.  
Taken as a whole, this work utilising a KRasG12D GBM model presents a picture 
where autophagy can regulate the activity of key signalling cascades and cell cycle 
regulators during periods of stress in vitro, and is completely depended upon for 
gliomagenesis in vivo. The results gleaned here raise important questions regarding 
the role of autophagy in GBM and cell signalling, some of which I shall begin to 
address in the ensuing chapters. 
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12 GBM Cell Line Models Require Autophagy for 
Detachment-Induced Signalling and Anchorage-
Independent Growth 
12.1 Introduction 
12.1.1 Modelling Glioblastoma Multiforme 
Although the underlying epidemiology of glioblastoma multiforme (GBM) remains 
elusive it is generally considered to arise from an accumulation of sporadic mutations. 
GBM tumours exhibit a high degree of heterogeneity not only between different 
patients but also within a single patient’s tumour, thereby representing a significant 
challenge in developing effective treatment strategies. Such heterogeneity also 
hinders our ability to model this disease accurately in researching the fundamental 
biology underpinning the aggressive growth of GBM in vitro and using mouse 
models.  
The constitutively active KRasG12D mutant used in the previous chapter, whilst 
representative of MAPK pathway over-activity observed in the majority of 
glioblastomas, is not itself commonly observed in patients. Instead, the loss of the 
tumour suppressors such as NF-1 or TP53 and the over-expression and over-activity 
of receptor tyrosine kinases are observed most frequently in the clinic250,251. For 
example, one mutant of EGFR found in approximately 23% of tumours harbours a 
deletion of exons 2-7, generating a constitutively active variant called EGFRvIII347. 
GBM mutations can be grouped according to the genes that are most frequently found 
to be concurrently mutated and are designated ‘classical’, ‘proneural’, ‘neural’, and 
‘mesenchymal’. In order to study the role of autophagy in glioblastoma more 
accurately it was therefore necessary to develop a panel of cell lines with mutations 
more akin to those found in the clinic. Furthermore, in a different cancer type the 
reliance on autophagy for tumourigenic growth has been seen to be dependent on the 
mutational status201. Therefore, in modelling the different subtypes of GBM we can 
begin to tease apart whether certain mutations confer more dependence on autophagy. 
A mounting body of research suggests that GBM tumours may derive from a sub-
population of so-called ‘cancer stem cells’348–351. However, the importance of 
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autophagy in maintaining the oncogenic tumour-initiating properties of a glioblastoma 
stem cell model system remains unclear188,352.  
Mouse neural stem cells were transformed with constitutively active EGFRvIII 
mutant and Ink4a/Arf knockout to model the classical GBM subtype in a stem-like 
context, whilst mouse glial cell lines with Ink4a/Arf knockout, Nf-1 and Tp53 
knockdown, or the overexpression of Pdgfa ligand were used to model proneural, 
neural, and mesenchymal subtypes. CRISPR/Cas9 gene modification technology and 
shRNAs were then utilised to ablate the expression of essential autophagy players and 
therefore study the impact of autophagy loss on oncogenicity in glioblastoma model 
cell lines. The tumourigenic potential of cell lines could then be assayed in a variety 
of ways, including testing the ability of cells to grow independent of adhesion to 
basement matrices.  
12.1.2 Anoikis, Anchorage-Independence, and Autophagy 
A key step in cellular oncogenic transformation is acquisition of the ability to 
proliferate independent of anchorage, thereby facilitating their growth in a tumour227. 
To prevent this event, normal cells engage a form of caspase-mediated cell death 
called anoikis. Anoikis can be evaded by oncogenic transformation, epithelial-to-
mesenchymal transition (EMT), and exhibition of stem-like properties (see 
introduction section 8.3.3)228–233. In a wide variety of cancers, these perturbations 
have been seen to facilitate anchorage-independent growth by engaging the activities 
of signalling kinases Akt and ERK228,229,235–237.  
Once cell death is overcome, cancer cells must then upregulate certain metabolic and 
signalling pathways in order to proliferate without anchorage239,240. One means by 
which these processes can be fuelled is by upregulated autophagic flux170,244,245. 
Although several cell lines are known to rely on autophagy for anchorage-
independent growth, it is not known whether this is true for the four GBM subtypes or 
whether they have differential dependencies on autophagy in this regard. I therefore 
wanted to assess the influence of autophagy on the ability of different GBM model 
cell lines to grow without adherence. Further to this, I was interested to investigate the 
molecular mechanisms by which autophagy is able to influence cell fate following 




Research question: Is there a reliance of specific GBM subtypes on autophagy for 
malignant transformation? 
1. Generate cell models of glioblastoma multiforme subtypes with autophagy gene 
expression ablation 
2. Assay the oncogenicity of these cell lines by testing their capability for 
anchorage-independent growth in different settings: 
a. Soft agar assay 
b. Low-adhesion plates 
c. Acute suspension 




12.3 Generating Cell Lines 
12.3.1 Knockout of Key Autophagy Genes in Transformed Neural Stem Cells 
and Mouse Embryonic Fibroblasts 
CRISPR/Cas9 gene modification technology is finding a multitude of exciting 
applications from the bench to the clinic with the full potential of this technique still 
to be uncovered. To introduce CRISPR/Cas9 into our laboratory, single-guide RNAs 
(sgRNAs) targeting essential autophagy genes Atg3, Atg7, and Atg16l1 were cloned 
into a transient expression vector (sequence information summarised in section 
10.2.1). The efficacy of these ‘sgRNA vectors’ was then trialled by transfecting them 
into a mouse embryonic fibroblast (MEF) cell line using Lipofectamine 2000 and then 
cells were assayed for gene expression by Western blot. Whilst all guides were 
functional in reducing expression in a pool of transfected cells, single-guides against 
Atg16l1 were unexpectedly inefficient relative to the other genes (Figure 12.1A-C). 
Single colonies picked from these pools by my colleague Ainara González-
Cabodevilla were indeed knockout for Atg16l1, however, validating the use of these 
sgRNAs in further studies (Figure 12.1D). Alas, sgAtg7 #1 resulted in the rapid 
proliferation of transfected cells, which is highly suggestive of an off-target effect, 
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and therefore its use was discontinued during this study. This should be considered a 
reminder that CRISPR/Cas9 is not infallible and that multiple sgRNAs need to be 
used against one gene in order to discount the possibility of off-target effects.  
Having confirmed the functionality of these sgRNA vectors in MEFs, they were then 
transfected by Nucleofection into IENS cells kindly gifted by Dr Steve Pollard, which 
have been described elsewhere302–304. The IENS glioma-initiating mouse neural stem 
cell line has been transformed to model a ‘classical’ GBM subtype by the knockout of 
the Ink4a/Arf locus and the expression of the constitutively active EGFRvIII mutant. 
Fortunately, in these cells all guides were able to yield a good reduction in Atg gene 
expression without the necessity to select single clones, thereby avoiding clonogenic 
effects (Figure 12.1E-G). 
12.3.2 Modelling GBM Subtypes in XFM/tv-a Glial Cells 
The RCAS-XFM/tv-a system provides a highly adaptable and rapid method by which 
to knockdown genes or express exogenous proteins. Its use with KRasG12D expression 
proved to be a powerful tool with which to carry out our initial experiments and it was 
used again here to develop differently transformed glial cell lines. With a constitutive 
knockout of Ink4a/Arf, the XFM/tv-a glial cell line is immortalised and poised for 
transformation to an oncogenic phenotype with the addition of other drivers. 
In an effort to model both mesenchymal and neural classifications simply, cells were 
given a combined knockdown of Nf-1 and Tp53. To model the proneural subtype I 
used shRNA against Tp53 and overexpressed HA polypeptide-tagged PDGFA ligand, 
which over-stimulates the PDGFRA receptor to mimic its oncogenic amplification. 
Figure 12.1 CRISPR/Cas9 knockout of essential autophagy genes  
A-G: Western blotting for expression of autophagy players following CRISPR/Cas9 modification.  
A-D: sgRNAs against Atg3 (A), Atg7 (B), and Atg16l1 (C) were transiently transfected into mouse 
embryonic fibroblasts (MEFs), then single clones were selected of either Cas9 only control or sgAtg16l1#2 
knockout cells (D), E-G: Glioma-inducing Neural Stem Cells (IENS) were Nucleofected with sgRNAs 
against Atg3 (E), Atg7 (F), and Atg16l1 (G).  
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Following the generation of these XFM/tv-a cell lines, either control RCAS-shLacZi 
or RCAS-shAtg7 was applied to cells to knockdown expression of this essential 
autophagy player (Figure 12.2). 
12.3.3 Development of the RCAS-sgRNA System 
Whilst using XFM/tv-a cells with a combination of shRNAs against Nf-1 and Tp53, 
the shRNA against the key autophagy gene Atg7 was consistently selected against, 
with cells re-expressing the Atg7 protein at significant levels after just a few passages 
(Figure 12.3A). Whilst this evolution was interesting in its implication of Atg7 as an 
important mediator of cell fitness in this context, it made consistent and reliable 
experimentation challenging. In order to overcome this difficulty, the gene was 
suppressed by CRISPR/Cas9 knockout rather than knockdown with shRNA. 
However, XFM/tv-a cells do not transfect efficiently by either Lipofectamine 2000 or 
Nucleofection techniques to be able to use transiently expressing vectors. To 
overcome this, I developed a method by which the single guide RNAs could be 
extracted from the ‘sgRNA vector’ (previously used in the neural stem cell 
transfection) and then cloned into the ‘RCAS-Y vector’ so the sgRNA could be 
introduced virally, as described in the Material and Methods chapter (Figure 12.3B). 
This strategy combines the efficiency of the RCAS-XFM/tv-a system with the 
irreversibility of CRISPR/Cas9 modification.  
Successful cloning was confirmed by Sanger sequencing performed by the IGMM’s 
technical services team using a primer against a RCAS-Y sequence upstream of the 
NotI cloning site (e.g. RCAS-sgAtg7 #3 vector sequencing in Figure 12.3C). RCAS-
sgRNA viruses could then be produced in DF-1 chicken fibroblasts and used to infect 
XFM/tv-a cells. Three infections were sufficient to significantly reduce the expression 
of all the genes trialled (Figure 12.3D). This system therefore represents an efficient, 
Figure 12.2 Generation of XFM/tv-a GBM cell line models with Atg7 knockdown 
A: A Mesenchymal/Neural model with combined knockdown of Nf-1 and Tp53, B: A 
Proneural model with Tp53 knockdown and overexpression of HA-tagged PDGFA ligand. 
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rapid, and adaptable system by which genes can be knocked-out from a pool of 
XFM/tv-a cells. 
 
Figure 12.3 Development of the RCAS-sgRNA vector  
A: Western blotting demonstrating the re-emergence of Atg7 expression over time in XFM/tv-a cells 
with Nf-1 and Tp53 loss, B: Agarose gel of the PCR product of U6 promoter – sgAtg7#3 – NotI 
restriction site, which was amplified from the sgRNA vector, C: KpnI digestion products following 
cultivation of RCAS-Y vectors annealed with PCR products from B (properly orientated inserts 
generate a product of 6,000 bp and incorrectly orientated inserts give a product of 420 bp), D: Cloning 
strategy to insert single-guide RNAs into the RCAS-Y vector, E: Sanger sequencing file of the U6 
promoter and sgAtg7#3 sequences correctly inserted into the RCAS-Y vector, F: XFM/tv-a cells are 
tested for the successful knockdowns of Nf-1 and Tp53 and knockout of Atg7 using by Western 
blotting. 
12.4 Autophagy Gene Expression is Necessary for Anchorage-
Independent and Low-Adhesion Growth 
With these models in place, it was then possible to test the reliance of their 
oncogenicity on the expression of essential autophagy player Atg7 using the soft agar 
assay for anchorage-independent growth. The basis of this technique is to suspend 
cells in a low-agar semi-solid layer on top of a base layer of with a higher 
composition of agar, thereby sequestering cells from the bottom of the plate where 
they could adhere. Therefore, if a cell cannot resist anoikis or maintain its metabolism 
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and pro-growth signalling, it will not be able to proliferate to form a colony in the 
agar. This represents the capability of cancer cells to grow independently from the 
basement layer of their tissue of origin and form neoplastic groups of cells that can 
develop into a tumour. 
Figure 12.4 Growth of GBM subtype cell models under adhesion-restricted conditions 
A-C: Soft agar colony formation assay, D-E: Low-adhesion plates. A, B, D: Atg7 knockdown in 
XFM/tv-a cells transformed by a combined knockout of Ink4a/Arf and knockdown of Tp53 and Nf-1 
(A, D) or PDGF-A ligand overexpression and knockdown of Tp53 (B).  C, E: ANS4 (untransformed) 
and IENS (Ink4a/Arf-/-, EGFRvIII-expressing) neural stem cells with CRISPR/Cas9-mediated Atg7 
loss. n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
The GBM subtype models that I had developed here were all able to form colonies 
when harbouring the control empty vector, demonstrating that they were indeed 
transformed to a malignant phenotype. However, when expressing shRNA or sgRNA 
against Atg7 the formation of colonies was significantly inhibited in all cases (Figure 
12.4A-C).  
The soft agar assay establishes a complete loss of anchorage and I was interested to 
know whether Atg7 would be required for colony formation under a less stringent 
condition, where a small quantity of surface is available for a minority of the cells to 
adhere to. The mesenchymal/neural subtype (XFM/tv-a: Ink4a/Arf-/-, shNf-1, shTp53) 
and classical subtype (IENS: Ink4a/Arf-/-, EGFRvIII) were therefore cultured on low-
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adherence Alvatex scaffolds. These 200µm-deep honeycomb structures are made of 
polystyrene formed with ~40µm pores that allow cells to be cultured in 3 
dimensions353. Therefore, these scaffolds foster the growth of spheroids of cells; the 
efficient formation of which requires the capability for anchorage-independent 
growth. Equal numbers of shNf-1/shTp53 XFM/tv-a cells and IENS glioblastoma-
initiating neural stem cells, with or without Atg7 expression, were plated on these 
scaffolds in their respective growth media and cultured for 14 days. In both cell lines 
the loss of Atg7 expression correlated with a significant reduction in the formation of 
3D cell spheres (Figure 12.4D, E). Interestingly, IENS cells formed colonies with a 
much higher efficiency than XFM/tv-a cells in both the soft agar and low-adhesion 
assays (Figure 12.4). This could either be due to the expression of the constitutively 
active mutant EGFRvIII or the properties associated with their stemness, both of 
which are factors associated with colony formation354–358. 
Together, these results show that autophagy is required to support the proliferation of 
colonies of cells under both conditions of complete and partial anchorage restriction. 
12.5 Autophagy Supports Detachment-Induced Signalling But Does 
Not Influence Anoikis  
The soft agar assay is recognised to be a highly predictive model in cancer biology 
research227, but it simultaneously evaluates the initial oncogenic mutation, evasion of 
anoikis, as well as the secondary stimulation of metabolic and signalling activity 
required for prolonged anchorage-independent growth. To try to understand which of 
these stages relies on autophagy, a crude acute suspension method was used. Cells 
were seeded on plates with or without normal tissue-culture treatment in media 
without growth factors. When plates are not treated with a plasma gas to make the 
polystyrene surface negatively charged, cells are not able to adhere to the plates and 
so are kept in suspension. Cells can then be harvested for Western blot or stained with 
propidium iodide to measure anoikis cell death.   
Again, the IENS neural stem cell classical GBM subtype model (Ink4a/Arf-/-, 
EGFRvIII-expressing) and XFM/tv-a mesenchymal/neural subtype model (Ink4a/Arf-
/-, shTp53, shNf-1) were used to investigate the potential influence of autophagy in 
these adhesion studies. Upon suspending cells for four hours on plates not ionised for 
tissue culture use, there was a slight induction of cell death in IENS cells (~3%), 
which was slightly, but not significantly, increased by the knockout of Atg7 (~5%) 
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(Figure 12.5A). This was increased to ~8% and ~9%, respectively, after eight hours. 
However, the shNf-1/shTp53 cells had a dramatic stimulation of anoikis after just four 
hours, with approximately 30% of cells positive for P.I. staining, which was not 
influenced by Atg7 loss (Figure 12.5C). This supports the observations from the soft 
agar and low-adhesion assays that IENS transformed neural stem cells exhibit 
increased growth in comparison to XFM/tv-a glial cells following anchorage loss.  
As the initial induction of anoikis was not influenced by autophagy, I was interested 
to know whether a defect in cell signalling may contribute to the reduction in 
anchorage-independent growth observed in the soft agar assay caused by Atg7 loss. 
To assess signalling in this setting, the phosphorylation statuses of the key pro-
growth, anti-anoikis proteins ERK and Akt were tested. In both IENS and XFM/tv-a 
shNf-1/shTp53 cells there was an induction in ERK phosphorylation following 
detachment, relative to adhered cells cultured in serum-/growth factor-free medium 
(Figure 12.5B, D). However, there was only an induction of Akt phosphorylation, 
relative to adhered starved conditions, in XFM/tv-a shNf-1/shTp53 cells. Following 
IENS cell suspension for either two or four hours there was significantly less 
phosphorylation of Akt and ERK in cells with Atg7 knockout, although this was 
equalised to the level observed in control cells after sixteen hours in suspension 
(Figure 12.5B). XFM/tv-a shNf-1/shTp53 cells, similarly, have reduced Akt 
phosphorylation in Atg7-deficient cells following four hours of suspension (Figure 
12.5D). However, ERK phosphorylation was not influenced by Atg7 loss in this cell 
type. ERK remained active after sixteen hours in suspension, but both control and 
sgAtg7 #3 cells were defective in Akt phosphorylation after this time. In line with low 
cell death measurements in Figure 12.5A, following four and eight hours of 
suspension, anchorage loss did not induce any detectable cleavage and activation of 
caspase-3 in IENS cells (Figure 12.5B). Following sixteen hours of suspension, 
however, cells with and without Atg7 expression both had detectable levels of 
caspase-3 cleavage. Previous reports have shown that high EGFR levels facilitate 
anchorage-independent growth and that a reduction in EGFR levels following 
detachment results in anoikis229,237. To investigate whether EGFR may play a role in 
this context, its levels were measured during anchorage loss. Whilst EGFR expression 
decreased in XFM/tv-a shNf-1/shTp53 cells upon suspension, it remained stable and 
then increased in IENS cells (Figure 12.5B, D). This is likely to be mediated by the 
expression of EGFRvIII in these cells, which is known to be stably localised to the 
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plasma membrane where it avoids endocytic regulation and co-operates with the wild-
type receptor359–361. Indeed, I found that the exogenous expression of EGFRvIII 
stabilises wild-type EGFR in XFM/tv-a parental cells and in IENS cells, relative to 
ANS4 adult mouse neural stem cells, under untreated conditions (Figure 12.6). As 
EGFR signalling, via Akt/ERK activation, can facilitate anchorage-independence, this 
result may explain the disparities in growth rate between the two GBM model cell 
lines in soft agar and low-adherence assay. There was not, however, any influence of 
Atg7 on EGFR levels and, therefore, the influence of autophagy on Akt/ERK 
signalling and anchorage-independent growth are not due to the regulation of EGFR 
expression. 
 
Figure 12.5 Assaying the influence of Atg7 on anoikis and cell signalling following acute 
suspension 
A, C: Anoikis was measured by propidium iodide (red) staining of cells cultured on non-tissue culture 
treated plates in serum-/growth factor-free media for the indicated times (n=2 experiments), B, D: The 
activity of pro-growth signalling cascades was measured during either normal adhered growth, serum 
starvation, or serum starvation in suspension. A, B: IENS (Ink4a/Arf-/-, EGFRvIII-expressing) neural 
stem cells with CRISPR/Cas9-mediated Atg7 loss. C, D: XFM/tv-a cells transformed by a combined 
knockout of Ink4a/Arf and knockdown of Tp53 and Nf-1 with CRISPR/Cas9-mediated Atg7 knockout. 
n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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12.6 Discussion 
Anchorage-independence is a key step in the malignant transformation of cancer cells, 
but much of its regulation remains incompletely understood. Whilst it is known that 
oncogenic signalling pathways can prevent anoikis, it is becoming clear that more 
than the initial evasion of cell death is required to sustain anchorage-independent 
growth; cells must sustain pro-growth and pro-survival signalling as well as alter their 
metabolic configuration. The loss of attachment to ECM eliminates signalling from 
integrins and their cofactors, and this needs to be replaced by oncogenic signalling 
from pathways such as PI3K-Akt and ERK. These cascades prevent the activation of 
cell death players and stimulate metabolic programmes that promote ATP production 
and quench ROS.  
Whilst autophagy is known to be required for the anchorage-independent growth of a 
variety of cell lines, its influence on specific subtypes of GBM is unknown. Here I 
have shown that the essential autophagy player Atg7 is required for soft agar colony 
formation and the growth of 3D spheroid cultures on low-anchorage scaffolds in cell 
line models of different GBM subtypes (Table 12.1). Further investigation of two of 
these GBM subtype model lines reveals that the activity of Akt and ERK signalling 
pathways is significantly reduced in Atg7-deficient cells following acute anchorage 
loss. However, the phosphorylation levels of Akt and ERK did not correlate with 
induction of anoikis in these cell lines, which was unaffected by autophagy status. 
Crucially, all of the subtypes modelled here had a similar reliance on autophagy for 
anchorage-independent growth and detachment-induced pro-survival signalling. This 
is of interest in terms of a potential GBM therapeutic, where it is important to target 
an oncogenic pathway that is common between the different mutations exhibited 
across a tumour and between patients. However, producing a sufficient concentration 
Figure 12.6 EGFRvIII expression stabilises wild type EGFR expression 
A: Expression EGFRvIII in the MSCV vector in XFM/tv-a glial cells increases the levels of wild-
type EGFR, B: IENS transformed neural stem cells expressing EGFRvIII have higher wild-type 
EGFR levels than untransformed ANS4 adult neural stem cells. 
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of an autophagy inhibitor in GBM tumours is challenging due the low permeability of 
the blood-brain barrier and the difficulty in penetrating completely through the 
tumour mass. Therefore, an autophagy inhibitor may be more closely mimicked 
genetically by an shRNA against autophagy genes than by CRISRP/Cas9-mediated 
knockout. Results gleaned where autophagy genes were knocked out, such as the 
signalling studies in Figure 12.5, may not reflect how a tumour might respond to a 
putative pharmacological agent. However, as we find new ways to exploit 
CRISPR/Cas9 gene editing technology we may be able to develop a way in which 
autophagy genes can indeed be removed completely from patient tumours362. 
Table 12.1 Summary of the results of studies in different cell lines investigating the role of 
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• Autophagy loss does not 
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Furthermore, these results are confounded by studies that have described Atg5- and 
Atg7-independent means of autophagosome biogenesis, thereby suggesting that 
targeting these proteins may not prevent the degradation of autophagy substrates363. 
Moreover, although LC3 lipidation and completion of the autophagosome does 
expedite the fusion of autophagosomes with lysosomal compartment, the delivery of 
pre-autophagosomal structures to the lysosome can also occur in the absence of the 
ubiquitin-like LC3 conjugation players52. These means of bypassing the need for LC3 
lipidation machinery raise questions regarding the efficacy of ablating the expression 
of these players as selected cargoes may still find a way to be degraded in an 
autophagy-like manner. Therefore, the most comprehensive means of preventing the 
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degradation of targets selected by autophagy cargo receptors would be inhibiting the 
fusion of autophagosomal and lysosomal membranes. These studies exploring the 
alternative forms of autophagy are important to understand if we believe autophagic 
degradation to be important in the development of different diseases, such as cancer, 
as we may need to target them all. 
Although autophagy was seen to be similarly essential in all the differently 
transformed cells assayed in these studies, the variety of oncogenes/tumour 
suppressors that were manipulated were by no means exhaustive of the combinations 
that have been documented in the clinic. However, in terms of preliminary basic 
research, the number of perturbations that are used to transform cells to a malignant 
GBM subtype will always be limited and a degree of prioritisation must be employed 
according to the most frequently observed mutations. 
Also, here we have used a combination of studies in XFM/tv-a glial cells and IENS 
glioma-initiating stem cells to model different GBM subtypes but it is difficult to 
directly compare results obtained in these two cell lines. Firstly, they are cultured in 
media of differing compositions: whilst XFM/tv-a are grown in 10% FBS media, 
IENS require stem cell culture-like conditions with serum-free media supplemented 
with EGF, FGF, laminin, and B27/N2 supplements (see chapter 10 for full details). 
Therefore, the activity of the signalling pathways is likely to be significantly different 
between these cell types. Generally, modelling GBM in serum-free conditions is 
considered to be closer to the in vivo situation. Therefore, it would be more accurate 
to compare the influence of autophagy on GBM subtype models derived from glioma-
initiating cells transformed with driving mutations that are cultured in such serum-free 
media. 
Furthermore, it is important to consider that whilst generally believed good ways to 
assess the potential of a cell line to form tumours in vivo, the soft agar assay and other 
such techniques of anchorage-independent growth are only simple in vitro models. 
These conditions are unable to include all of the factors that GBM cells are exposed to 
in the human brain. The conditions of cell culture are highly favourable for cell 
growth, with abundant nutrients and growth factors and, crucially, lack the 
contribution of cross talk from resident brain cells, such as the microglia. Therefore, 
these assays cannot definitively show that autophagy would be required for 
tumourigenesis in vivo. 
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The results of the experiments described above, however, do lay the foundation for a 
range of future studies that might clarify the role of autophagy in anchorage-
independent growth. For example, whilst here it has been shown that detachment-
induced phosphorylation of Akt and ERK is hindered by autophagy loss, it is not 
known whether this is the cause of the reduced anchorage-independent growth 
capacity observed in autophagy-deficient cells. To address this, constitutively active 
mutants of these proteins (such as a construct of ERK2 fused to its upstream regulator 
MEK1 that confers constant activation364) could be expressed in Atg7-knockdown 
cells to test whether soft agar colony formation can be rescued, for example. 
It was also not explored here how autophagy regulates Akt and ERK phosphorylation 
following detachment. One possibility is that autophagic flux generates amino acids 
that stimulate mTORC1, thereby facilitating mTORC2 activation, and inducing Akt 
phosphorylation365,366. In this scenario, the activation of mTORC1 by amino acids 
would then exert feedback inhibition on autophagy via the inhibition of ULK1 
activity, preventing excessive activation of this cascade. Alternatively, autophagy 
may directly influence of activity of signalling pathways, via modulation of an 
upstream signalling molecule, such as has been proposed previously regarding c-
Met/β-integrin-ERK signalling170. On the other hand, the maintenance of 
mitochondrial and endoplasmic reticulum homeostasis by autophagy may reduce the 
production of ROS and PERK signalling; thereby helping prevent repression of Akt 
and ERK activity. The mechanism by which autophagy induces pro-growth signalling 
and anchorage-independent growth is important to understand before considering the 
use of an anti-autophagy pharmaceutical agent in patients in order to anticipate any 
potential side effects. 
Given the caveats outlined above, this study of autophagy function in anchorage-
independent growth can be considered as promising preliminary work that warrants 
further investigation. Together, these data demonstrate that, in the context of 
glioblastoma cell models, autophagy does not regulate anoikis but is important in 
promoting malignancy-related cellular signalling pathways that are required for 




13 Autophagy Supports Signalling from the Epidermal 
Growth Factor Receptor 
13.1 Introduction 
13.1.1 Receptor Tyrosine Kinase Signalling Cascades 
Receptor tyrosine kinase (RTK) signalling pathways are highly oncogenic and are 
elevated in 88% of glioblastoma multiforme (GBM) cases250,251. Moreover, the 
aberrant over-activation of RTKs is observed in a wide variety of cancers, leading to  
great interest in studying RTK signalling. However, much of their regulation is still 
unknown, largely owing to its highly context-dependent nature. Expression levels of 
different RTKs can differ between different tissue types and extra layers of 
complexity are added once one begins to consider pathological specificities and 
crosstalk between different pathways367.  
We do know, however, that a non-discrete set of interconnected signalling cascades 
can be induced upon activation of the kinase domains of different RTKs. These can be 
Figure 13.1 A simplified diagram of signalling cascades downstream of RTK activation 
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roughly grouped as: PI3K/Akt, mTOR, MAPK, and JAK/STAT (Figure 13.1)77. 
Adaptor proteins, such as Grb2/SOS, initiate the transmission of signalling from 
RTKs into these different pathways before the endocytic machinery is recruited and 
receptors are internalised and their activities moderated. The signalling pathways 
initiated by RTK activity generally result in the activation of pro-growth and pro-
survival pathways as well as the suppression of cell-death activators and cell-cycle 
repressors.  
It is interesting to note that RTKs, such as members of the HER family, can crosstalk 
with other each other as well as with other families of receptors (e.g. EGFR and 
VEGFR368). Furthermore, the same pathways can be activated by different RTKs. 
This represents a significant problem therapeutically, as pharmacological inhibition of 
one pathway can result in the compensatory activation of another. Understanding the 
regulatory mechanisms that are common between RTKs might lead us to uncovering 
a target that might prevent these adaptations. 
But how can we measure the activity of these pathways? The traditional, most 
frequently used method is using SDS-Page Western blotting, but this method is 
relatively low throughput, as only a select number samples can be run per membrane 
and only a few proteins can be probed for, thereby leaving much of the pathway 
untested. One method by which these limitations can be overcome is the the reverse 
phase protein array (RPPA) (Figure 13.2)369,370. This technique uses protein lysates 
applied to nitrocellulose membranes in a serial dilution of triplicate spots, which then 
can be probed for different protein abundances using small quantities of diluted 
primary and HRP-conjugated secondary antibodies. The HRP signal is then detected 
and can be normalised to housekeeping genes, such as β-actin, and thus the levels of a 
large number of proteins and protein modifications can be measured. This is 
Figure 13.2 Workflow of the high-throughput reverse phase protein array 
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particularly suited to cell signalling studies where the phosphorylation of known 
proteins in certain cascades can be measured relative to their expression.  
13.1.2 Regulation of Signalling From RTKs 
Although the majority of the downstream signalling pathways are relatively well 
characterised, the regulation of the RTKs themselves remains more elusive. Although 
the seminal review by Ullrich and Schlessinger outlined much of what is known 
regarding the activation mechanism of the RTK kinase domain nearly thirty years 
ago, how this signal is terminated is the subject of continued study371.  
Further to catalytic inhibition by the action of protein tyrosine phosphatases (PTPs), 
the primary method by which RTK signalling is regulated is by its endocytosis and 
subsequent endocytic trafficking. Briefly, following ligand binding and receptor 
activation, phospho-tyrosine residues in the cytoplasmic domains of the protein are 
recognised by adaptor proteins that tag the protein with ubiquitin and recruit 
endocytic machinery77,117. The receptor then becomes internalised into pre-early 
endosomes that mature into early endosomes. Receptors can then be sorted into either 
recycling or late endosomes, which are destined for return the plasma membrane or 
trafficking to the lysosome, respectively.  
13.1.3 Autophagy Influences RTK Signalling- The Current Evidence 
A recent review composed by my colleagues and myself has outlined much of the 
current evidence connecting autophagy and RTK signalling, with a particular focus on 
the role of autophagy in regulating RTK activity, which I shall summarise briefly 
here372.  
The majority of studies considering RTKs and autophagy focus on the regulation of 
autophagy by signalling cascades downstream of RTKs, such as EGFR33. However, 
some recent reports are revealing that autophagy can be just as influential in the 
modulation of RTK activity. For example, it has been shown that expression of 
autophagy proteins ATG5 and ATG7 is required for the phosphorylation and 
downstream activity of a variety of RTKs, including the c-Met receptor170,171,373. 
Autophagy proteins also mediate the trafficking of EGFR to the mitochondrion, 
where it can regulate cell fate decisions176. Alternatively, the Beclin-1 complex, 
which is involved in autophagy initiation, is also required for the maturation of RTK 
signalling-competent pre-early endosomes to signalling-repressed early endosomes182. 
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Moreover, RTKs and downstream MAPK signalling players have actually been 
directly localised on autophagy-related vesicles170,171,374.  
Together, these studies are starting to unfurl an interesting role for autophagy in 
promoting oncogenic RTK activity. However, there is currently no consensus 
regarding the underlying mechanism of this phenomenon. 
 
13.2 Aims 
Research question: What role does autophagy play in modulating signalling from 
RTKs, such as EGFR? 
This question represents an important detail not just in understanding normal cell 
homeostasis but also in terms of how cancers such as GBM regulate oncogenic 
signalling pathways to facilitate their malignant growth. To begin to answer it, a 
series of experiments were undertaken: 
1. Determine whether autophagy regulates signalling from different receptor tyrosine 
kinases (RTKs) in response to their cognate ligands 
2. Investigate the influence of autophagy loss on the activity of different signalling 
cascades downstream of EGFR  
3. Test whether these results can translate to different cell lines 
4. Assay the effect of autophagy-RTK cross-talk on cell survival  
5. Measure the activation and termination of EGFR signalling  
 
 
13.3 Signalling From the Epidermal Growth Factor Receptor is 
Perturbed Upon Autophagy Ablation in Glial Cells 
13.3.1 Investigation of the Influence of Autophagy on Signalling From Different 
RTKs 
To investigate the role of autophagy in a GBM cell model, XFM/tv-a glial cells with 
combined knockdown of Nf-1 and Tp53 had the expression of different essential 
autophagy genes ablated by CRISRP/Cas9, as described in chapter 12 above. To 
directly assay whether receptor tyrosine kinases (RTKs) in these transformed glial 
cells rely on autophagy for cell signalling, the activation of Akt and ERK were 
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measured following cell stimulation with a variety of growth factors. Under my 
supervision, Rosella Fontana (a visiting student) stimulated cells for fifteen minutes 
with either FBS (to stimulate a variety of different RTKs), EGF (for EGFR), IGF-1 
(for IGF-1R), or HGF (for c-Met), following four hours of serum withdrawal to 
synchronise receptors at the plasma membrane. Western blotting revealed that 
autophagy knockout resulted in significantly reduced the phosphorylation of Akt 
following stimulation with FBS, HGF, and EGF (Figure 13.3A, B, D). However, 
autophagy was not required for Akt signalling from IGF-1R (Figure 13.3A, D). ERK 
phosphorylation induced by treatment with FBS, HGF, and EGF was also marginally 
reduced in autophagy-deficient cells, although variability between experiments 
prevented statistical analyses reaching significance, except in the case of HGF 
treatment of sgAtg7 #3 cells (Figure 13.3A, B, D). These blots show that autophagy is 
required for the maximal signalling activity of a subset of RTKs, but not IGF-1R.  
Importantly, these experiments were optimised such that the stimulation of each 
receptor provided equal activation of Akt in control cells, thereby not over-saturating 
the pathways or receptors and making results comparable between growth factors. 
Of the RTKs tested here, EGFR is the most frequently perturbed in GBM. Therefore 
in exploring the mechanism by which autophagy facilitates signalling from these 
receptors, experiments were focussed on signalling through EGFR.  
13.3.2 Atg3, Atg7, and Atg16l1 Are Required for EGFR Signalling 
Data shown in Figure 13.3 utilised single-guide RNAs against Atg7 to inhibit its 
expression. To check that this phenotype depends on autophagy as a pathway rather 
that Atg7 specifically, Atg3 and Atg16l1 knockout cells were also used. Each of these 
genes is essential for LC3 lipidation and therefore for autophagic flux. Stimulation of 
these cells with EGF had the same results in all these knockout lines: Atg gene 
expression loss resulted in reduced Akt and ERK phosphorylation (Figure 13.4). 
These blots therefore show that the autophagy pathway is required for signalling from 
EGFR.  
13.3.3 Autophagy Is Required for Signalling to a Range of EGFR Downstream 
Targets 
Stimulation of EGFR by its ligand results in the activation of a variety of downstream 
kinase signalling cascades, of which Akt and ERK are members. These blots have 
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shown that autophagy is required for the activation of these proteins, but what about 
the other members of these cascades and the activity of other pathways? 
 
Figure 13.3 Signalling from a subset of receptor tyrosine kinases is regulated by autophagy 
A-C Western blots of growth factor stimulation in XFM/tv-a shNf-1/shTp53 glial cells with Atg7 
knockout following 4 hr serum starvation. Cells were stimulated with either 1% FBS (A), 2 ng/ml EGF 
(B), 0.1 ng/ml HGF (B, C), or 100 ng/ml IGF-I (C) for 15 min. D, E Densitometry quantification of 
phosphorylated and total proteins following cell stimulation with various growth factors. Graphs 
represent the ratio of p-Akt to total Akt (D) and p-ERK to total ERK (E), made relative to the value in 
control cells. n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
To undertake a more comprehensive study of protein abundances and modifications, 
the reverse phase protein array (RPPA) high-throughput screening platform was used. 
Samples consisted of Control or sgAtg7#3 XFM/tv-a shNf-1/shTp53 cells that were 
either untreated (‘10% FBS’), serum starved for four hours (‘-FBS’), or serum starved 
for four hours then stimulated with EGF or FBS (‘+EGF 15 min’, ‘+EGF 30 min’, 
and ‘+FBS 30 min’). Sample integrity and identity was then checked by Western 
blotting 
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 before submission for processing by Kenneth McCleod at the institute’s drug 
discovery facility (Figure 13.5A). I then analysed the results of the assay and sorted 
them from highest to lowest ratio of Control:sgAtg7 signal for each protein or protein 
modification (Figure 13.5B, Appendix 1). This study generated a wealth of interesting 
data, which I shall go through here in some detail. 
The top hits with the greatest fold difference of signal observed in control cells versus 
sgAtg7 cells following fifteen minutes EGF stimulation are almost all constituents of 
PI3K/Akt, mTOR, and MAPK signalling cascades (Figure 13.5, Appendix 1). The 
reduction in phosphorylation upon autophagy ablation is observed at fifteen and thirty 
minutes of stimulation with EGF and, to a lesser extent, in some cases at thirty 
minutes of FBS stimulation post-starvation. Although the phosphorylation of STAT5 
protein is a well-known readout of EGFR activity, its phosphorylation was not altered 
Figure 13.4 Autophagy gene expression is required for EGFR signalling activity 
A-C: XFM/tv-a shNf-1/shTp53 glial cells were serum starved for 4 hr before 15 min stimulation with 2 
ng/ml EGF, then were lysed for Western blotting analysis. A: Atg7 knockout cells, B: Atg16l1 knockout 
cells, C: Atg3 knockout cells. Experiments repeated at least 3 times. 
122 
here by serum starvation or EGF treatment (Appendix 1). However, its upstream 
regulator JAK was responsive to growth factors and did rely on autophagy for its 
activation, as did the other STAT proteins 1 and 6, although this was to a lesser 
degree than the other pathways (Appendix 1). 
On the other hand, autophagy-deficient cells displayed an increase in abundance of 
marks that are inhibitory of the cell cycle or inducers of cell death. For example, the 
mark with the highest sgAtg7:Control ratio following serum starvation was cleaved 
Caspase-3, a marker of cell death induction (Figure S17.15). Furthermore, whilst the 
cell cycle inhibitor pRb was phosphorylated and therefore inhibited upon EGF 
stimulation in control cells, cells lacking Atg7 did not induce its phosphorylation, 
thereby keeping it in an active state that can inhibit the E2F transcription factors and 
repress the cell cycle (Figure S17.2). The time points measured, however, were not 
sufficiently long enough to allow transcription and translation of the targets of E2F, 
such as Cyclin-D, in EGF-stimulated control cells (Figure S17.14). The protein XIAP 
inhibits members of the Caspase family and in this experiment its expression was 
increased in control cells following thirty minutes of EGF stimulation (Appendix 1). 
Similarly, inhibition of the pro-apoptotic protein Bad by phosphorylation was also 
increased in control cells following thirty minutes of EGF stimulation (Appendix 1). 
Furthermore, although these cells have knockdown of Tp53 (Figure 13.5A), there still 
appeared to be some degree of regulation of the cell cycle inhibitor p21 (downstream 
target of Tp53). Following thirty minutes of EGF stimulation the levels of p21 
decrease in control cells whilst remaining higher in autophagy-deficient cells 
(Appendix 1). This is in contrast to what has previously seen for this protein, where 
EGF was seen to increase p21 expression375. However, other factors known to 
regulate cell cycle or cell death were not affected, including Bcl-2; PUMA; Bim; 
ATM; PARP; and Bcl-x (all Appendix 1). Regarding the RTKs that lie upstream of 
these signalling cascades, autophagy also appears to have a role in promoting the 
activity of some and the expression levels of others following EGF stimulation (Table 
13.1). The receptors that are influenced by autophagy loss are those that are known to 
cross talk with EGFR; therefore it is possible that autophagy regulates their activities 
following EGF stimulation via EGFR. Furthermore, FBS stimulation did not activate 




Figure 13.5 Reverse phase protein array analysis reveals Atg7 loss reduces the activity of EGFR 
downstream signalling cascades I 
A,B: XFM/tv-a shNf-1/shTp53 cells were serum starved 4 hr then stimulated with FBS or EGF as 
indicated. A: Western blot confirming the identity of samples submitted for RPPA analysis and 
validating the Akt and ERK signalling defects observed by this method, B: The results of the RPPA 
(n=1) were ordered from highest to lowest signal ratio in Control over sgAtg7 for the condition ‘+EGF 
15 min’. Here are shown the top eight hits from this analysis, with the rest found in Appendix 1. 
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Influence of autophagy loss  
Graph in Figure 
15 min EGF 30 min EGF 
EGFR Lower Lower Figure S17.1 
EGFR pY1173 No change No change Figure S17.6 
EGFR pY1086 No change No change Figure S17.7 
Her2 Lower Lower Figure S17.2 
Her2 pY1248, Y1173 Lower Lower Figure S17.4 
Her3 Lower Lower Figure S17.5 
Her3 pY1289 Lower Lower Figure S17.6 
FLT3 pY591 Lower Lower Figure S17.2 
IGF-1R No change No change Figure S17.7 
IGF-1R  pY1162, Y1163 Lower Lower Figure S17.2 
VEGFR pY1059 Lower Lower Figure S17.3 
VEGFR pY1175 No change Lower Figure S17.9 
PDGFR pY1021 No change No change Figure S17.8 
PDGFR pY751 No change Lower Figure S17.9 
Met Lower Lower Figure S17.2 
Met pY1349 Lower Lower Figure S17.3 
Met pY1234 Lower Lower Figure S17.4 
 
above the levels found following serum starvation, supporting the idea that their 
activation is via the support of EGFR activation by autophagy. Unfortunately, the 
antibodies for EGFR phosphorylation sites Y1086 and Y1173 were not functional in 
this assay however, with no increase in signal between serum starved and EGF 
stimulated conditions, although this is known to be induced in this cell type (Figure 
13.3). Together, these RPPA results demonstrate that autophagy facilitates the activity 
of kinase cascades downstream of EGFR, as well as cross talk between EGFR and 
other RTKs, ultimately resulting in the suppression of cell cycle inhibitors and pro-
death factors. 
13.3.4 Autophagy Mediates EGFR in Different Cell Types 
Here we have seen that autophagy is able to regulate signalling from EGFR in 
XFM/tv-a transformed with shNf-1/shTp53, which represents a model of the 
‘mesenchymal’ and ‘neural’ subtypes of GBM251. But do other cell types also rely on 
autophagy for RTK signalling? To test this, CRISPR/Cas9 was used to ablate 
autophagy gene expression in either XFM/tv-a cells expressing constitutively active 
EGFRvIII, representing the ‘classical’ GBM subtype, or, in order to test this in a cell 
line that is far removed from GBM, mouse embryonic fibroblasts (MEFs) 
Firstly, my colleague, Joanne Simpson, carried out a careful analysis of the response 
of XFM/tv-a EGFRvIII cells to either EGF or FGF ligands. When cells were 
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stimulated with EGF for five, ten, or fifteen minutes the phosphorylation of Akt and 
ERK were comparable in control and sgAtg7 cells (Figure 13.6A). However, when 
EGFRvIII cells were stimulated with FGF it was clear that Atg7 was required for Akt 
phosphorylation (Figure 13.6B). This suggested that the effect of autophagy on RTK 
regulation is negated or over-powered when the receptor is constitutively active, 
although other receptors are still sensitive to the influence of autophagy. 
To test whether this is a universal mechanism in cells, a non-glial cell model was then 
interrogated: mouse embryonic fibroblasts (MEFs). sgAtg7 was introduced into these 
cells then I examined the expression levels of EGFR under untreated conditions. 
Although in XFM/tv-a cells I had not observed any consistent or significant change in 
EGFR levels, here in MEFs it was clear that EGFR expression was greatly reduced by 
Atg7 knockout (Figure 13.7A). To check that this was due to the loss of autophagic 
Figure 13.6 Autophagy is required for FGF-induced signalling but not EGF-induced signalling in 
glial cells with constitutively active EGFR 
A XFM/tv-a EGFRvIII cells were serum starved for 4hr followed by stimulation with EGF (2 ng/ml) for 
the indicated amounts of time before analysis by Western blotting, B XFM/tv-a EGFRvIII cells were 
serum starved for 4 hr followed by stimulation with FGF (10 ng/ml) for the indicated amounts of time 
before analysis by Western blotting. Experiments were repeated at least 3 times. 
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flux rather than loss of Atg7, Atg3 and Atg16l1 were also knockout out from MEF 
cells using CRISPR/Cas9. The loss of these autophagy players also reduced the levels 
of EGFR under untreated conditions (Figure 13.7B, C). In glial cells, we have seen 
that autophagy loss impacts signal transduction to Akt and ERK following RTK 
activation. Does the diminished EGFR expression observed here translate into 
reduced signalling downstream? 
A single-cell clone selected from sgAtg16l1 cells by Ainara González-Cabodevilla 
had complete loss of Atg16l1 expression. Along with wild-type MEFs, these cells 
were serum-starved for four hours then treated with EGF for fifteen or thirty minutes. 
The results show that whilst EGFR phosphorylation and levels are reduced by 
Atg16l1 loss, the activation of downstream players was similar following EGF 
stimulation (Figure 13.7D). Therefore, in MEFs the mechanism by which autophagy 
regulates of EGFR appears to impact its protein levels rather than perturbing its 
signalling activity. Alternatively, it may also be that autophagy-deficient MEFs have 
Figure 13.7 EGFR expression is reduced by autophagy knockout in MEFs 
A-C: Western blotting of untreated MEF cells expressing sgRNA against Atg7 (A), Atg3 (B), or 
Atg16l1 (C). D: Western blotting of single-clones selected from sgAtg16l1#2 transfected MEFs 
treated with 2 ng/ml EGF for 15 or 30 minutes. Experiments repeated at least 3 times. 
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acquired an alternative mechanism to compensate for EGFR deficiency that results in 
similar activation of Akt and ERK. 
13.3.5 Autophagy Loss De-Sensitises Transformed Glial Cells to EGF-Induced 
Cell Survival 
When grown under normal tissue culture conditions or when starved of serum for a 
short period of time, the growth rates of autophagy-competent and autophagy-
deficient XFM/tv-a shNf-1/shTp53 and EGFRvIII-expressing cells are comparable. 
However, we have seen that the activities of key cell growth and survival regulators 
are severely reduced in autophagy-deficient cells following stimulation with EGF, 
FGF, or HGF ligands. Is the regulation of RTK signalling by autophagy important for 
cell fate decisions? To address this point, I cultured my cells in serum-free media for 
twenty-four hours, which strongly induced cell death that could be measured by 
propidium iodide (PI) labelling. To test the influence of autophagy on the pro-survival 
capacity of RTKs, the mitogens EGF and HGF were added to the media376. Relative 
PI fluorescence was then measured using a high-throughput plate reader and made 
relative to the total cell number, as measured by DAPI. This value of cell death/total 
cell number was then made relative to the value of untreated cells.  
These analyses revealed that EGFRvIII and shNf-1/shTp53 cells have differing 
requirements for autophagy. shNf-1/shTp53 autophagy-competent cells experienced 
significantly less death when cultured with EGF or HGF than when serum starved, 
but autophagy-deficient cells did not, instead maintaining high levels of cell death 
(Figure 13.8A, B). Similarly, EGFRvIII cells control cells were able to rescue serum 
starvation-induced cell death when incubated with EGF or HGF (Figure 13.8A, C). 
However, although Atg7 loss did prevent a response to HGF, EGF-mediated rescue of 
cell death was autophagy-independent in this cell line. Therefore, EGFRvIII over-
rides the requirement for autophagy to facilitate EGFR signalling and mediate EGF-
induced cell survival. It is also interesting to note that EGFRvIII cells experienced a 
lessened induction of cell death, relative to shNf-1/shTp53 cells, during serum 
starvation, which corroborates with previous data suggesting EGFRvIII acts as a cell 
death repressor (Figure 13.8)377. 
13.4 Autophagy Mediates Maintenance of EGFR Signalling Activity 
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The results presented above have shown that autophagy positively regulates signalling 
from EGFR following EGF stimulation. To begin to understand what affects this 
change, a series of studies were undertaken to investigate whether autophagy  
 
Figure 13.8	Growth factors rescue cell death induced by serum starvation in autophagy-
competent cells 
A Graph representing the proportion of cell death (propidium iodide) relative to cell number (DAPI) in 
XFM/tv-a glial cells transformed with either shNf-1/shTp53 or EGFRvIII. Cells were either left 
untreated (10% FBS DMEM) or serum-starved for 24 hr, in the presence or absence of EGF (20 ng/ml) 
or HGF (10 ng/ml). Values made relative to that of untreated cells. B, C Representative images of 
propidium iodide staining of shNf-1/shTp53 (B) or EGFRvIII (C) cell lines either left untreated (10% 
FBS DMEM) or serum-starved for 24 hr, in the presence or absence of EGF (20 ng/ml) or HGF (10 
ng/ml). n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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influences the activation or termination of EGFR signalling. 
13.4.1 Autophagy Loss Does Not Affect EGFR Degradation Rates 
Autophagy is primarily a catabolic pathway in the cell that results in lysosomal 
degradation of various cargoes and EGFR signalling is known to be terminated at the 
lysosome32,90,378,379. Therefore, it is possible that autophagy loss influences EGFR 
lysosomal degradation to mediate its signalling response to EGF. Measuring EGFR 
levels after EGF stimulation for up to two hours in control and sgAtg7 XFM/tv-a 
shNf-1/shTp53 cells was used to test this hypothesis. Quantification of these blots 
reveals that EGFR degradation rates were not influenced by autophagy loss (Error! 
Reference source not found. 13.9).  There was, however, a clear reduction in EGFR 
phosphorylation (Error! Reference source not found. 13.9A). Therefore, autophagy 
is mediating the activity of EGFR rather than its protein levels. 
Figure 13.9 EGFR degradation rate does not rely on autophagy 
A: Example Western blot of XFM/tv-a shNf-1/shTp53 control and sgAtg7#2 cells stimulated with 20 
ng/ml EGF for up to 2 hr, B: Densitometry quantifications of EGFR levels following EGF 
stimulation in control and Atg7 knockout cells expressed as a percentage of the start material (t= 0 
min). n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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13.4.2 Autophagy Loss Shortens the Duration of EGFR Signalling But Does Not 
Influence EGFR Phosphorylation in vitro 
How is autophagy mediating EGFR activity? Is it reducing its initial kinase activation 
or something further downstream? Short time-points of EGF stimulation were used to 
try to distinguish between these possibilities. Stimulation up to five minutes shows 
that the initial activation of EGFR and its signal transmission to Akt, as measured by 
their phosphorylation levels, were both functional in autophagy-deficient cells (Figure 
13.10A-C). However, at time-points greater than seven minutes, EGFR and Akt 
phosphorylation were significantly reduced in Atg7 knockout cells. Therefore, 
autophagy seems to be required for the maintenance of EGFR signalling following an 
initial activation peak. 
To test whether the activation of the EGFR tyrosine kinase domain is impeded 
autophagy-deficient cells, an in vitro kinase assay was undertaken. This assay was 
performed by lysing cells in a kinase reaction buffer then incubating at 30°C for 
fifteen minutes in the presence or absence of EGF. Western blotting analysis showed 
that the addition of EGF induced the phosphorylation EGFR equally in control and 
Figure 13.10 Autophagy is required to maintain EGFR and Akt phosphorylation during EGF 
stimulation 
A-D: XFM/tv-a shNf-1/shTp53 control and sgAtg7 cells were serum starved 4 hr then stimulated with 2 
ng/ml EGF for the indicated time points. A, B: Densitometry quantification of EGFR (B) and Akt (C) 
phosphorylation relative to their respective total protein levels, expressed as a percentage of control cell’s 
maximum signalling time-point, C: Representative Western blot of control and sgAtg7#2 cells following 
different time-points of 2 ng/ml EGF stimulation, D: in vitro kinase reaction with cell lysates incubated 
at 30°C for 15 min in the presence or absence of 50 ng. n=3, error bars represent SEM, * p<0.05, ** 
p<0.01, *** p<0.001. 
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sgAtg7 cells (Figure 13.10D). This suggests that autophagy is likely not mediating an 
EGFR kinase inhibitor, but instead is regulating the maintenance of EGFR 
phosphorylation by another means in the cell.  
13.5 Discussion 
The data presented above have shown that autophagy is required to for the maximal 
of signalling downstream of a subset of receptor tyrosine kinases, including EGFR, in 
a cell model of GBM. Further study revealed that perturbed signalling as a result of 
autophagy gene ablation is caused by a failure to maintain EGFR phosphorylation 
following an initial peak in activity. 
RTK signalling targets Akt and ERK were directly measured following the growth 
factor stimulation of EGFR and c-Met, and were found to be significantly reduced by 
Atg7 knockout in XFM/tv-a glial cells transformed with Nf-1 and Tp53 knockdown. 
Although some reliance on autophagy has been implicated for these receptors before, 
this is the first study of its kind to evaluate equally ligand-stimulated RTKs under 
controlled conditions in the same cell line and therefore be able to directly compare 
downstream read-outs. In this manner, it is possible to show that whilst stimulation of 
Akt by EGF and HGF requires autophagy, stimulation with IGF-1 does not. In 
comparing autophagy-competent and -deficient cells that are stimulated with a 
mixture of growth factors (i.e. FBS), a requirement for autophagy to transmit general 
growth factor-to-Akt signalling was discovered. Furthermore, this was not specific to 
the expression of one autophagy regulator, but instead relied on Atg3, Atg7, and 
Atg16l1. Being able to demonstrate that this is a overall autophagy-dependent 
phenomenon is important due to evidence showing that different forms of so-called 
‘non-canonical autophagy’ can generate autophagosome-like structures and 
autophagy-related endomembranes, some of which have been seen to facilitate cell 
signalling170,363,380. 
These findings revealed by Western blotting were followed-up and substantiated by 
RPPA analysis. This technique showed that signalling cascades downstream of RTKs 
were perturbed from source to terminus by autophagy loss, following stimulation with 
either EGF or FBS. Unexpectedly, there was also reliance on autophagy for crosstalk 
between different RTKs, including other ErbB family members and VEGFR. The 
activities of these pathways are important with regards to GBM as ~88% of patient 
tumours are seen to have aberrant activity through different RTK pathways. If the 
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activity of a variety of RTKs can be similarly inhibited through the targeting of a 
common factor (e.g. autophagy) then it may be more effective at inhibiting the pro-
growth and pro-survival pathways that facilitate tumourigenesis. 
In chapter 11, low nutrient conditions induced an autophagy-deficient KRas-
transformed cell line to establish senescence, correlating with low Akt activity. This 
senescent phenotype was characterised by increased pRb activity and increased levels 
of the cell-cycle inhibitor p27. RPPA of EGF-stimulated cells here shows that Akt 
phosphorylation is lower in Atg7 knockout cells (Figure 13.5), correlating with a 
reduction in pRb phosphorylation (Appendix 1, Figure S17.2), thereby permitting its 
activity in repressing the E2F transcription factors and inhibiting the transcription of 
cell-cycle progression factors. This supports the pathway hypothesised in that chapter 
whereby: autophagy à Akt  –| p27 à pRb, although in that instance autophagy was 
maintaining Akt activity during serum starvation, whereas here autophagy is 
facilitating the activation of Akt following EGF stimulation. 
Upon investigating whether autophagy may be similarly required in other cellular 
contexts, XFM/tv-a cells with constitutively active EGFRvIII had Atg7 knocked-out 
then were stimulated with EGF and FGF. The activation of Akt by FGF did require 
Atg7, similarly to the shNf-1/shTp53-transformed XFM/tv-a cells. However, when 
stimulated with EGF, an elevated and sustained response in EGFR activity was 
observed, regardless of autophagy status. Therefore, this mutation of EGFR that 
renders it constitutively active can bypass its regulation by autophagy, but retains the 
reliance of other RTKs on autophagy for signalling activity. This was investigated 
further in an in vitro cell death assay that measured the response of cells to EGF and 
HGF ligands. In shNf-1/shTp53 cells, there was a reliance on autophagy to transmit 
pro-survival signalling from EGF and HGF during serum starvation stress, but 
EGFRvIII cells only relied on autophagy to transmit HGF signals, but not EGF, where 
Atg7 expression did not influence cell fate. Previous studies have shown that 
EGFRvIII signals primarily from the plasma membrane and has a low rate of 
endocytosis, resulting in exemption from endocytic regulation. Therefore, if 
autophagy mediates receptor signalling by a post-endocytosis process, then EGFRvIII 
would be rendered insensitive to it. 
Although relatively abundant in gliomas and head and neck squamous cell carcinomas 
(HNSCC), the constitutively active variant III mutant is not the only EGFR 
perturbation that is seen in cancers. Further work regarding the role of autophagy in 
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EGFR signalling capacity may explore the influence of autophagy on other EGFR 
mutations, such as the leucine to arginine mutation observed at position 858 in many 
lung cancers381. Most frequently observed in GBM, however, is the amplification of 
the EGFR gene locus251. Therefore, testing whether autophagy can also regulate 
signalling from an increased number of receptors would also be of clinical concern. 
Results from this study suggest that oncogenic constitutive activation of EGFR may 
render cells insensitive to autophagic regulation of signalling pathways, but perhaps 
the over-expressed wild-type receptor may still be vulnerable. This represents an 
opportunity for personalised therapy, with different inhibitors having different 
efficacy between patients depending on the specific mutational landscape. 
Why this modulation of RTK signalling is selective for EGFR and c-Met over IGF-1R 
is unclear. It may be that different regulatory mechanisms are employed for specific 
receptors by the cell, of which autophagy may only affect a subset. If this is the case, 
it is highly likely that the outcome of autophagic regulation of RTKs will vary 
between cell types, which have varied expression and activities of different RTKs 
respective to their differentiation status and tissue niche77,367,382. Alternatively, 
similarly to EGFRvIII expression, IGF-1R may have a low rate of endocytosis 
meaning it would not be influenced by potential endocytic regulation by autophagy.  
These results in XFM/tv-a cells with different oncogenic drivers have highlighted that 
the influence of autophagy on RTKs may depend on the mutational background of the 
cells. Furthermore, subsequent knockout of autophagy proteins in MEFs showed that 
the outcome of EGFR modulation by autophagy varies between cell types. Whilst 
glial cells utilised autophagy for EGFR signalling regulation, in MEFs autophagy 
seemed instead to divert EGFR from lysosomal trafficking but not influence cell 
signalling. It is possible that autophagy may be acting on the same process in these 
disparate cell types that generates different outcomes due to the cellular connect.  
But what is this mechanism? As outlined in the introduction, EGFR can be regulated 
either by modulation of its tyrosine kinase activity or by its endocytic trafficking. Cell 
lysates were tested for EGFR tyrosine kinase competency and found it to be equal in 
cells with or without Atg7. Regulators of the kinase domain, such as PTPs would be 
directly exposed to the receptor, irrespective of their cellular spatial regulation, by this 
method. Therefore, if they were targets of autophagic degradation and sgAtg7 resulted 
in the increase of their expression levels, EGFR activation would be lower when 
stimulated with EGF. However, no such difference was observed in this assay. 
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However, it does not rule out that autophagy can regulate the spatial regulation of 
RTK inhibitors like PTPs.  
EGFR activation by ligand binding occurs in an initial spike then is slowly dampened 
over the ensuing minutes by various regulatory mechanisms. To assay whether the 
activation of the receptor was influenced by autophagy loss, short time-points of EGF 
stimulation were used. It was possible to see that the peak of EGFR activation was not 
changed by autophagy loss then, following seven to ten minutes of stimulation, EGFR 
phosphorylation was reduced in autophagy-deficient cells. This is approximately 
within the timeframe during which EGFR recycling to the plasma membrane occurs78. 
The recycling of EGFR potentiates its signalling capacity as returning to the plasma 
membrane presents the receptor for another round of ligand binding to reinforce 
signalling pathway activity. Therefore, the recycling of EGFR may be how autophagy 
facilitates the maintenance of EGFR activity. 
Collectively these results suggest that autophagy may be involved in the regulation of 
a subset of RTKs, including EGFR, which is important in maintaining their activity 
and, consequently, the stimulation of downstream signalling cascades. The 
mechanism by which autophagy regulates these signalling pathways shall be explored 
in the next chapter. 
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14 Autophagy Regulates Endosomal Dynamics and 
Epidermal Growth Factor Receptor Trafficking 
14.1 Introduction 
14.1.1 Regulation of The Endosomal System 
Cells must constantly respond to the conditions in which they find themselves in order 
to mediate processes like proliferation, metabolism, and migration. To sense these 
conditions, cells can take up extracellular materials using processes like 
macropinocytosis, phagocytosis, clathrin-mediated endocytosis, or clathrin-
independent endocytosis (see introduction 8.2.1). Although it is important to consider 
the other types of endocytosis, it is known that EGFR is primarily regulated by 
clathrin-mediated endocytosis (CME) at the low concentrations of EGF that have 
been used in this and the previous chapter78,383. Therefore, here I will focus on 
introducing CME.  
Many of the adaptors that initiate clathrin-coated pit formation bind to the negatively 
charged plasma membrane that form around around clusters of activated RTKs. One 
such example is adaptor protein-2 (AP-2), which connects cargo (such as EGFR) and 
membrane lipids to multimeric clathrin to generate a nascent coat384. These clathrin-
coated buds are then pinched off from the plasma membrane in a dynamin-mediated 
fashion99. These pre-early endosomes are signalling active, negative for 
phosphatidylinositol-3-phosphate (PI(3)P), and characterised by the presence of 
adaptor protein phosphotyrosine interacting with PH domain and leucine zipper 1 
(APPL1)82,182. Maturation to early endosomes follows the recruitment the PI(3)P 
kinase complex, which is composed of PIK3C3, Beclin-1, and regulatory proteins 
UVRAG and Bim (Figure 14.1)385,386. These early endosomes then undergo a sorting 
process, with cargo destined for either: multivesicular bodies (MVBs) and late 
endosomes that fuse with the lysosome, or recycling endosomes that return to the 
plasma membrane. It has been suggested that although other means of endocytosis are 
primarily used to transport cargoes to the lysosome for degradation, CME chiefly 
results in sorting into the recycling route78. Whilst lysosomal degradation terminates 
signalling in a manner only replenishable by transcription and translation of new 
protein, recycling allows for the immediate replacement of receptors for renewed 
stimulation and re-enforcement of downstream signalling cascades78,129. 
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During endocytic maturation steps, regulatory and scaffold factors are exchanged or 
modified, such as phosphatidylinositol moieties and Rab GTPases. These can act as 
molecular markers for each stage of the endocytic pathway: 
• Early endosomes: PI(3)P, Rab5, EEA1 
• Late endosomes: PI(3,5)P2, Rab7 
• Recycling endosomes: PI(4)P, PI(4,5)P2, Rab4, Rab11 
• Multivesicular bodies: PI(3)P, PI(3,5)P2, Rab5, Rab7 
• Golgi apparatus: PI(4)P, Rabs 1, 2, 6, 8, 9, 18 
• Plasma membrane: PI(4,5)P2, PI(3,4,5)P3 
Furthermore, it is possible to inhibit transition between these compartments by 
preventing the catalytic production of each phosphatidylinositide or recruitment of 
each Rab. 
Whilst some RTK adaptor proteins mediate CME, others recruit initiators of 
signalling cascades. One such example is Grb2, which connects RTKs such as EGFR 
to the signalling molecule SOS that in turn activates Ras to initiate the MAPK 
signalling cascade387. Whilst CME adaptor molecules bind at the plasma membrane, 
signalling adaptors can also interact with RTKs after their endocytosis388.  
RTK endocytosis has been seen to have varying affects on signalling activity. 
Preventing endocytosis by inhibiting dynamin has produced conflicting and context-
dependent results, with different reports showing that the activities of downstream 
signalling pathways can be promoted389,390, inhibited391, or unaffected132,391,392. 
Alternatively, inhibition of endosomal maturation from pre-early endosomes results in 
prolonged signalling capacity, suggesting progression from these vesicles has an 
inhibitory effect on RTK signalling182. Given the importance of the activity of RTK 
downstream signalling pathways in diseases such as cancer, there is a need for 
increased clarity in this field.  
The signalling activity of EGFR relies on the activity of its tyrosine kinase domain, 
which is activated by phosphorylation and therefore can be inhibited by the action of 
protein phosphatases371,393,394. The binding of these phosphatases can occur at 




14.1.2 PI(3)P and the PIK3C3 Complex 
As described above, early endosomes are defined by the presence of PI(3)P that then 
acts to recruit the effectors EEA1 and Rab5. The PIK3C3 complex catalyses the 
synthesis of this lipid on endosomal membranes but also it also has a parallel role in 
autophagosome biogenesis. The apportionment of PIK3C3 between these two 
functions is specified by the binding of different regulatory factors: the autophagy-
specific complex sees it bound to Beclin-1, ATG14L1, and AMBRA1, whereas the 
endocytosis-regulatory complex relies on binding to Beclin-1, UVRAG, and Bim1 
(Figure 14.1)25,396. In these two different conformations, therefore, this complex lies at 
a nexus between autophagy and endocytic trafficking. 
14.1.3 Autophagy and Endocytic Trafficking Commonalities 
The PIK3C3 complex is not the only common factor between autophagy and the 
endocytic pathway, however. A multitude of commonalities exist between these 
processes including shared trafficking compartments, such as the Golgi and ER, and 
mutual regulators, like TRE2-BUB2-CDC16 (TBC) domain-containing RAB GTPase 
activating proteins (GAPs) (Figure 14.2).  
TBC Rab GAPs are master endocytic regulators can interact with a multitude of 
essential autophagy mediators, including ATG9 and LC324,144,397. The fact that LC3 
Figure 14.1 The Different Configurations of the PIK3C3/Beclin-1 Complex 
Green: Core complex components PIK3C3 kinase and regulatory partner Beclin-1, purple: Proteins that 
direct PIK3C3 activity to autophagosome biogenesis, grey: PIK3C3 endocytic regulators, red: Rubicon 
can inhibit the activity of the PIK3C3/Beclin-1 complex 
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and ATG9 are amongst the few known lipid-binding autophagy proteins may belie the 
convergence of autophagic and endocytic membranes.   
Indeed, autophagy proteins have been seen to trace along several lines of endosomal 
traffic. For example, essential autophagy players ATG16L1 and ATG9 can interact 
with clathrin and AP-2, respectively, at the plasma membrane31,398. ATG16L1 and 
ATG9 can then localise to recycling endosomes upon autophagy induction, mediated, 
in the case of ATG9, by the activity of ULK124,145. Furthermore, MVBs/late 
endosomes can co-localise with ATG9 upon autophagy induction, which is likewise 
associated with ULK1 but additionally requires PI(3)P142. Another connection with 
late endosome compartments is found in the fusion of autophagosomes with MVBs to 
form ‘amphisome’ structures that target to the lysosome379.  
Furthermore, by switching between its two different complexes PIK3C3 is able to 
provide feedback mechanisms between autophagy and RTK signalling. For example, 
preferential participation of PIK3C3 in autophagosome biogenesis would abrogate the 
addition of PI(3)P to pre-early endosomal structures, thereby holding them in a 
Figure 14.2 Diagram Representing a Simplified Version of the Endocytic Pathway and Where 
Autophagy Proteins Have Been Observed in that Pathway  
Green: receptor tyrosine kinases and their ligands, purple: constituents of the autophagy pathway, 
black/grey: components of the endocytic pathway. 
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permissive state for RTK signalling. Active RTKs then stimulate cascades that inhibit 
autophagy upstream, thereby making PIK3C3 complex components available to act in 
endosomal regulation16,18,19. On the other hand, RTK activity can instigate Beclin-1 
post-translational modifications that inhibit that activity of the PIK3C3 complex33,180. 
Alternatively, Rubicon-mediated inhibition of PIK3C3 sequesters UVRAG from its 
function with HOPS in activating Rab7181. As the final stages of autophagy rely on 
Rab7, its suppression by Rubicon therefore has the potential to inhibit both RTK 
endocytic degradation and autophagy181,399. These actions of Rubicon can thereby 
hypothetically promote RTK signalling and reinforce inhibition of autophagic 




Research question: How does autophagy facilitate EGFR signalling? 
In the previous chapter the reliance of sustained EGFR signalling on the expression of 
key autophagy proteins was demonstrated. Disrupting this signalling by autophagy 
loss reduced the phosphorylation of Akt and ERK and lead to insensitivity to EGF-
induced cell survival. The initial activation of the tyrosine kinase domain of EGFR 
was seen to be intact in cells and in vitro. Therefore, it is likely that, following its 
activation and endocytosis, EGFR is undergoing differential endocytic regulation. The 
current literature offers a complex picture of connections between autophagy and the 
endocytic trafficking pathways that regulate RTKs. To tease apart how autophagy 
facilitates the proper signalling of EGFR a series of points had to be addressed: 
1. Investigate whether autophagy players regulate EGFR signalling by affecting its 
endocytic trafficking 
2. Examine potential direct connections between autophagy proteins and EGFR or 
endocytic players  
3. Test which endocytic regulators are disrupted by autophagy knockout 
4. Finally, determine the molecular interactions by which autophagy can influence 




14.3 Autophagy Perturbs EGFR Endocytic Trafficking 
In the previous chapter it was shown that XFM/tv-a shNf-1/shTp53 transformed glial 
cells require autophagy for the maintenance of signalling from EGFR after 
stimulation for more than ten minutes with EGF, although the initial activation of the 
kinase was autophagy-independent. But a question mark remained regarding how 
autophagy was able to effect this change in signalling. As the kinase activity of the 
receptor was unchanged it suggested that autophagy might act upon its regulation by 
endocytosis. 
14.3.1 Autophagy Loss Alters EGFR Endosomal Residency 
Endocytic trafficking tightly regulates EGFR signalling and to begin exploring how 
autophagy was influencing EGFR its localisation in different endosomal 
compartments was tested. 
Once endocytosed, EGFR traffics to early endosomal compartments that are marked 
with Rab5 and EEA1. EGFR co-localisation with mCherry-tagged Rab5 and 
endogenous EEA1 was analysed by immunofluorescence (IF) following stimulation 
with EGF for either five or fifteen minutes. Image analysis showed that whilst after 
five minutes of stimulation there were similar amounts of EGFR in early endosomes 
in control of sgAtg7 cells, by fifteen minutes there was a marked accumulation of 
EGFR in early endosomal vesicles in autophagy-deficient cells (Figure 14.3). 
The EGF-EGFR complex that forms at the plasma membrane remains intact during its 
initial endocytosis and in early endosomes, but as the pH lowers during endosome 
maturation, the ligand detaches from its receptor49. Upon testing co-localisation 
between Alexa555-tagged EGF (denoted 555-EGF) and endogenous EGFR in these 
cells, it was possible to see numerous EGFR+/EGF- vesicles in control cells. However, 
autophagy ablation reduced the incidence of green EGFR+/EGF- puncta, instead 
showing increased yellow co-localisation between ligand and receptor, thereby 
suggesting that endocytic maturation was defective (Figure 14.4). 
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Early endosomes can sort cargo into late endosomes for trafficking to the lysosome 
for degradation. As EGFR was seen to accumulate in these early endosomes, was it 
possible that they were not maturing to late endosomes in autophagy-deficient cells? 
To investigate this, 555-EGF was applied for fifteen minutes before cells were stained 
for endogenous Rab5 or Rab7 to mark early and late endosomes, respectively. 
Figure 14.3 Atg7 Knockout Cells Have an Accumulation of EGFR in Early Endosomes Following 
15min of EGF Stimulation  
A, B: Representative images of EGFR staining with either endogenous EEA1 (A) or over-expressed 
mCherry-Rab5 (B) following 5 or 15 min (20 ng/ml) EGF stimulation in XFM/tv-a shNf-1/shTp53 
cells, C, D: Quantification of Pearson’s coefficient for EEA1/EGFR and mCherry-Rab5/EGFR 
colocalisation following 5 and 15 min EGF stimulation. n=3 experiments, ≥30 cells quantified per 
condition, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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These images showed that EGF was able to traffic similarly to Rab7-positive late 
endosomes in autophagy-competent and autophagy-deficient cells, whilst confirming 
that EGF accumulates in Rab5-positive early endosomes when Atg7 expression is lost 
(Figure 14.5). This data is in line with the results from the EGFR degradation assay 
presented in the previous chapter: EGFR trafficking to late endosomes and its 
subsequent lysosomal degradation is not influenced by autophagy status. 
Alternatively, EGFR can be sorted into recycling endosomes from early endosomes 
then returned to the plasma membrane. There are two classes of recycling endosomes, 
so-called ‘fast’ and ‘slow’, which are marked by Rab4 and Rab11, respectively. 
Although Rab4 co-localisation with EGFR was not affected by Atg7 knockout, EGFR 
trafficking to Rab11-positive recycling endosomes was significantly reduced by 
autophagy loss (Figure 14.6). Therefore, autophagy facilitates the delivery of EGFR 
to recycling endosomes, correlating with an enhanced signalling capacity. 
Figure 14.4 EGF/EGFR Co-localisation is Greater in Atg7 Knockout Cells 
A: Representative confocal images showing increased co-localisation between EGFR and 555-EGF in 
Atg7 knockout XFM/tv-a shNf-1/shTp53 cells (red: 555-EGF, green: EGFR, blue: DAPI), B: 
Quantification of the number of EGFR-positive, 555-EGF-negative vesicles per cell. n=3 experiments, 
≥30 cells quantified per condition, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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14.3.2 Atg7 Knockout Results in the Accumulation of Perinuclear EGFR+ 
Vesicles 
During the course of the above studies, it was clear that stimulation with EGF resulted 
in the accumulation of EGFR in a perinuclear region when Atg7 was knocked out. In 
order to quantify this phenomenon, ‘perinuclear’ vesicles were defined as within a 
fifteen-micron radius from the centre of the nucleus. Following five minutes of EGF 
stimulation EGFR was evenly distributed in autophagy-competent and deficient cells 
whilst in the process of early endosome trafficking (Figure 14.7A). However, 
following fifteen minutes of EGF treatment, although EGFR was still well distributed 
throughout control cells, over two-thirds of EGFR was perinuclear in autophagy-
deficient cells (Figure 14.7B). 
Confocal live cell imaging was then used to characterise this trafficking defect. 
Following four hours of serum starvation, fluorescently labelled EGF (555-EGF) was 
applied to control or Atg7 knockout shNf-1/shTp53 cells and imaged in dimensions of 
 Figure 14.5 Late Endosome Trafficking of EGFR Is Not Influenced By Autophagy Loss 
A: Quantification of co-localisation between endogenous Rab5 or Rab7 with 555-EGF, which was 
applied at 20 ng/ml for 15 min to XFM/tv-a shNf-1/shTp53 cells , B: Representative images of co-
localisation between 555-EGF and Rab5 or Rab7. n=3 experiments, ≥30 cells quantified per condition, 
error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001.  
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x, y, z, and time. Computational tracking of EGF-containing vesicles in this setting 
confirmed the fixed confocal data: autophagy loss results in the perinuclear 
accumulation of EGFR (representative example tracks A). There were a multitude of 
tracks continuously originating from the plasma membrane in control  
 
Figure 14.6 Atg7 Is Required For EGFR Trafficking to Rab11-Positive But Not Rab4-Positive 
Recycling Endosomes 
A, B: Representative images of EGFR staining with mCherry-Rab4 (A) or mCherry-Rab11 (B) 
following 5 or 15 min (20 ng/ml) EGF stimulation in XFM/tv-a shNf-1/shTp53 cells , C: Quantification 
of Pearson’s coefficient for EGFR with mCherry-Rab4/Rab11 colocalisation following 5 and 15 min 
EGF stimulation. n=3 experiments, ≥30 cells quantified per condition, error bars represent SEM, * 









cells, whilst autophagy-deficient cells EGF maintained a continuous circumnavigation 
of the nucleus (Figure 14.8). Furthermore, quantification of these tracks showed that 
each EGF+ vesicle has an increased duration when Atg7 is knocked-out (Figure 
14.8B). This suggests that EGF is most likely still bound to its receptor in early 
endosomes, rather than becoming dissociated and degraded, leaving EGFR free to 
return to the plasma membrane for renewed activation. This did not, however, 
 Figure 14.7 Live Cell Imaging Reveals Autophagy Facilitates EGF+ Vesicle Dynamics 
A: Representative rainbow-coded tracks of 555-EGF+ vesicles in XFM/tv-a shNf-1/shTp53 cells over 
time generated in Imaris, where t=0 is purple and the end of the experiment is red, B-D: 555-EGF+ 
vesicle tracks were analysed by Imaris software for duration (B), distance travelled (C), and speed (D). 
n=3 experiments, ≥30 cells quantified per condition, error bars represent SEM, * p<0.05, ** p<0.01, *** 
p<0.001. 
Figure 14.8 EGFR Accumulates in a Perinuclear Region of Atg7 Knockout Cells 
A: Representative images showing that after 5 min EGF stimulation (20 ng/ml) control and Atg7 knockout 
XFM/tv-a shNf-1/shTp53 cells show similar EGFR staining pattern but by 15 min Atg7 knockout cells 
accumulate perinuclear EGFR, scale bars=20 µm, B Quantification of EGFR staining within 15 µm of the 
centre of the nucleus at 5 and 15 min EGF stimulation. n=3 experiments, ≥30 cells quantified per condition, 
error bars represent SEM, * p<0.05, ** p<0.01 
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influence the speed at which vesicles moved or how far they travelled, perhaps 
indicating that the association between EGFR and the cytoskeleton is not affected 
(Figure 14.8C, D). Therefore, autophagy loss results in perturbed EGFR trafficking by 
preventing proper sorting into Rab11-positive recycling endosomes, instead causing 
its accumulation in early endosomes clustered close to the nucleus. 
14.3.3 EGFR Endosome-Plasma Membrane Recycling Is Facilitated By 
Autophagy 
Does this disruption of Rab11-positive endosomes in autophagy-deficient cells impact 
the plasma membrane recycling of EGFR? EGFR was still seen to traffic to Rab4-
positive ‘fast’ recycling endosomes, which may be able to compensate for the defects 
in Rab11 traffic. To assay whether EGFR recycling is affected, a cell-surface 
biotinylation-based method was utilised to track receptors following endocytosis 
(Figure 14.9). Following four hours of serum starvation, cell-surface proteins (e.g. 
EGFR) were conjugated to biotin on ice. Negative controls were generated by 
immediately stripping off this biotin label with a reducing solution on ice. 
Alternatively, ‘endocytosis’ and ‘recycling’ samples were incubated at 37°C for 
fifteen minutes with EGF to induce EGFR uptake before any non-endocytosed cell-
surface biotin label was then removed on ice. ‘Endocytosis’ samples were then lysed. 
‘Recycling’ samples were subjected to an additional round of fifteen minutes 37°C 
incubation with EGF, then were stripped for a final time. Thus, only protein that was 
Figure 14.9 Diagram of Biotinylation Recycling Assay 
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endocytosed would retain its biotin label in ‘endocytosis’ samples, and only 
endocytosed but not recycled protein would be labelled in ‘recycling’ samples. Pull-
down of biotin using streptavidin then allowed the relative quantities of biotinylated 
EGFR to be determined. 
XFM/tv-a shNf-1/shTp53 cells were treated as described above, then inputs and biotin 
pull-downs analysed by Western blotting. Firstly, we can see that the endocytosis rate 
Figure 14.10 Expression of EGFRvIII and Atg7 Influences EGFR Endocytosis and Recycling Rates 
A, B: Western blots of the biotinylation recycling assay in shNf-1/shTp53 (A) and EGFRvIII-expressing 
(B) XFM/tv-a glial cells. Cell-surface proteins were labelled with biotin then treated with either: surface 
biotin stripping buffer directly (Neg); EGF (2ng/ml) at 37°C 15 min and then stripping buffer (Endo); or 
EGF at 37°C 15 min, then stripping buffer, then EGF at 37°C 15 min, and then stripping buffer 
(Recycle), C, D: Graphs representing the percentage of endocytosed biotin-labelled EGFR (C) and 
quantity of endocytosed EGFR that is recycled to the plasma membrane (D). n=3, error bars represent 
SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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of EGFR is comparable in cells with or without Atg7 expression (Figure 14.10A, C). 
In comparing the protein that has been endocytosed to that which remains internalised 
after recycling is permitted, we can determine the relative recycling rate of EGFR in 
each cell line. In control cells, approximately three-quarters of EGFR was recycled 
back to the plasma membrane, leaving little biotin signal detected by Western blot 
(Figure 14.10A, D). However, a significant proportion of internalised EGFR remained  
in Atg7 knockout cells. Therefore, defective delivery of EGFR to Rab11-positive 
recycling endosomes does actually prevent its efficient recycling to the plasma 
membrane. The small proportion of EGFR that was recycled in cells without Atg7 
(~30%) may be attributed to recycling via Rab4-positive recycling endosomes. 
Atg7 was a useful control protein in this experiment: it confirmed the knockout 
efficiency in these cells as well as acting as a negative control. Atg7 is a cytoplasmic 
protein and therefore it should not be labelled with biotin and should not bind to the 
streptavidin beads. Indeed, pull-downs were clean of Atg7 signal, confirming the 
stringency of the pull-down conditions (Figure 14.10A, B). 
In the previous chapter it was seen that although shNf-1/shTp53 cells relied on 
autophagy for EGFR signalling, EGFRvIII-expressing cells did not. To explore this 
difference, EGFRvIII cells were tested for the rate of EGFR endocytosis and 
recycling. Due to the deletion of extracellular domains that confers the oncogenicity 
of this mutant, EGFRvIII was not able to be biotinylated. Therefore, here the 
influence of EGFRvIII on the wild-type receptor was assayed. As shown in chapter 
12, EGFRvIII expression stabilises the wild-type receptor and this was seen again 
here, with shNf-1/shTp53 cells expressing less EGFR. 
However, when EGF was applied, the quantity of endocytosed EGFR was similar 
between these cell lines (Figure 14.10B, C). Therefore, the fraction of wild-type 
receptor that was endocytosed was reduced in EGFRvIII-expressing cells, consistent 
with previous studies that showed EGFRvIII stabilises wild-type EGFR at the plasma 
membrane. Furthermore, wild-type EGFR that was taken up in EGFRvIII cells had a 
poor rate of recycling to the plasma membrane, and instead primarily remained 
internalised (Figure 14.10B, D).  Autophagy did not influence the rate of endocytosis 
or recycling in these cells. 
14.3.4  Atg7 Knockout Reduces the Quantity of EGF Ligand Taken Up By Cells 
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The recycling rate of EGFR has been seen to regulate the activity of downstream 
signalling cascades, most likely through the continued exposure of the receptor to 
additional ligand for continuous stimulation. If this were true, there would be a greater 
influx of EGF in recycling-competent than in recycling-defective cells. To test this in 
cells with or without Atg7, 555-EGF (whose fluorescence is stable at low pH) was  
Figure 14.11 Autophagy Loss Reduces Uptake of Fluorescent EGF 
20ng/ml of either Alexa555-EGF (555-EGF: A, B) or TexasRed-EGF (TxRed-EGF: C, D) was applied to 
XFM/tv-a shNf-1/shTp53 cells. A: Representative images from ImageXpress high-throughput 
microscope after 0, 5, 15, or 30 min 555-EGF, B: Quantification of 555-EGF fluorescence relative to cell 
number (DAPI), expressed as fold increase over background fluorescence levels (t=0 min), C: 
Representative confocal images of cells treated with TxRed-EGF for 30 min, D: Quantification of 
TxRed-EGF punta per cell, relative to the value in control cells. n=3 experiments, ≥30 cells quantified 
per condition, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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applied to cells for different lengths of time and then fluorescence signal was 
measured relative to cell number using high-throughput microscopy. These low 
magnification images show that control cells amass a large quantity of 555-EGF after 
thirty minutes of treatment, whilst autophagy-deficient cells take up less (Figure 
14.11A, B). To confirm the results obtained using the high-throughput method, cells 
were again treated with fluorescent EGF but were imaged instead by confocal 
microscopy. It was even more apparent at this magnification that autophagy-deficient 
cells had fewer EGF vesicles than control cells following thirty minutes of stimulation 
(Figure 14.11C, D). When considered in light of the trafficking data shown above, 
diminished uptake of EGF ligand in autophagy-deficient cells can be attributed to 
reduced EGFR recycling.   
14.3.5 Nuclear Translocation of EGFR Requires Autophagy 
EGFR is not just transported through the cytoplasm of the cell; however, it can also 
be translocated to the nucleus50. Once in the nucleus it can co-operate with various 
transcription factors, such as STAT3, STAT5, or E2F1, to promote the expression of a 
variety of proteins that promote cell growth and survival, as well as regulating 
chromatin components51,52. Autophagy has been seen here to regulate endosomal 
trafficking of EGFR and therefore its nuclear translocation was also investigated. 
Cells were fractionated with increasing detergent stringency to separate 
‘cytoplasmic’, ‘membrane’, and ‘nuclear’ matter. Western blotting of these fractions 
showed that under serum starvation conditions, there was a larger quantity of nuclear-
localised EGFR in control cells than in Atg7-deficient cells (Figure 14.12). Thirty 
Figure 14.12 Autophagy is Required for Nuclear Localisation of EGFR 
Western blotting analysis of cellular fractionation into cytoplasmic (marked by α-tubulin), membrane (β1-
integrin), and nuclear (PCAF) fractions, showing an accumulation of active EGFR in the nucleus only in 
control, not Atg7 knockout, XFM/tv-a shNf-1/shTp53 cells following 30 min of EGF treatment (20 ng/ml) 
after 4 hr serum starvation. Experiment repeated at least 3 times. 
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minutes of EGF treatment resulted in EGFR phosphorylation in the membrane 
fraction that was reduced by Atg7 loss, consistent with findings from the previous 
chapter. Furthermore, although this stimulation induced elevated EGFR translocation 
to the nucleus in control cells, this was not seen in cells lacking Atg7. This 
experiment presents a novel role for autophagy in promoting the nuclear translocation 
of EGFR to the nucleus, where is known to promote cell survival and proliferation.  
14.3.6 The Interacting Partners of EGFR Are Altered in Atg7 Knockout Cells 
As autophagy loss induces a significant redistribution of EGFR, I became intrigued to 
find out whether this results in a change in the EGFR interactome. To investigate this, 
cells were treated with EGF for thirty minutes before they were lysed, EGFR was  
Table 14.1 Mass Spectrometry Top Ten Hits Enriched in Control Over Autophagy-Deficient 
Cells 
Hits were identified by a greater than two fold enrichment of control samples over both sgAtg7#2 and 
sgAtg7#3 from triplicate samples and student’s T-Test value of less than 0.05. 
Gene 
Name 
Protein Name Function Summary 
(based on information from uniprot.org) 
Egfr Epidermal growth factor 
receptor 
Bait 
Arpc3 Actin-related protein 2/3 
complex subunit 3 
Involved in actin polymerisation associated with 
endosomal fission, specifically in association with the 
retromer. 
Sec61g Protein transport protein 
Sec61 subunit gamma 
Necessary for protein translocation in the endoplasmic 
reticulum  
Zfp91 E3 ubiquitin-protein 
ligase ZFP91 
Atypical E3 ubiquitin-protein ligase that mediates 'Lys-63'-
linked ubiquitination of MAP3K14/NIK. May also play an 
important role in cell proliferation and/or anti-apoptosis 
Usp7 Ubiquitin carboxyl-
terminal hydrolase 7 
Hydrolase that deubiquitinates target proteins such as 
FOXO4, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, 
PTEN and DAXX.  
Mob4 MOB-like protein 
phocein 
May play a role in membrane trafficking, specifically in 
membrane budding reactions 
Lrp1b Low-density lipoprotein 
receptor-related protein 
1B 
Cell surface protein that binds and internalizes ligands in 
the process of receptor-mediated endocytosis 
 
Ap2a2 AP-2 complex subunit 
alpha-2 
Component of the adaptor protein complex 2 (AP-2), 
involved in clathrin-dependent endocytosis, destined for 
fusion with the early endosome. Potentially mediates an 
interaction between clathrin and ATG16L1 in the context 
of membrane recruitment for autophagosomes 
Cttnbp2nl CTTNBP2 N-terminal-
like protein 
Binds protein phosphatase 2A (prevents EGF-induced 
EGFR degradation & sustains EGF-mediated signalling) 
Anxa2 Annexin A2 Calcium-regulated membrane-binding regulated by anionic 
phospholipids. May cross-link plasma membrane 





Catalyses the phosphorylation of phosphatidylinositol 4-




immunoprecipitated, and the resulting binding partners were analysed by the IGMM 
mass spectrometry facility. Several known EGFR-interacting proteins were equally 
enriched in control and knockout cells, such as Grb2, and, importantly, binding of 
EGFR kinase inhibitors, such as Mig6, were not altered by autophagy loss (Figure 
14.13A). However, several hits were identified as selectively enriched in control cells 
over both Atg7 knockout cell lines (Table 14.1). After discounting unlikely 
candidates, the top ten remaining hits were subjected to GO term analysis of reactome 
pathways that revealed a common pattern of interactors that were depleted by 
autophagy loss (Table 14.2). Intriguingly, this evaluation flagged several 
phosphatidylinositol (PI) regulatory processes as the most over-represented in the 
dataset. It is known that the conversion of PI species characterises the different stages 
of endocytic trafficking.  
































Synthesis of PIPs at the plasma 
membrane 34 2 0.02 + > 100 1.13E-04 9.03E-03 
PI5P, PP2A and IER3 regulate 
PI3K/AKT signalling 78 3 0.04 + 85.62 5.46E-06 8.26E-03 
PI metabolism 57 2 0.03 + 78.11 3.06E-04 1.32E-02 
L1CAM interactions 67 2 0.03 + 66.45 4.19E-04 1.63E-02 
PIP3 activates AKT signalling 102 3 0.05 + 65.48 1.19E-05 2.01E-03 
PI3K/AKT activation 105 3 0.05 + 63.61 1.30E-05 1.96E-03 
GAB1 signallosome 105 3 0.05 + 63.61 1.30E-05 1.79E-03 
Clathrin-mediated endocytosis 111 3 0.05 + 60.17 1.53E-05 1.93E-03 
Role of LAT2/NTAL/LAB on 
calcium mobilization 111 3 0.05 + 60.17 1.53E-05 1.78E-03 
Cargo recognition for clathrin-
mediated endocytosis 77 2 0.03 + 57.82 5.49E-04 2.08E-02 
Signalling by EGFR 300 3 0.13 + 22.26 2.79E-04 1.36E-02 
Membrane trafficking 440 3 0.2 + 15.18 8.45E-04 3.04E-02 
Vesicle-mediated transport 470 3 0.21 + 14.21 1.02E-03 3.60E-02 
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It was also seen that deletion of Atg7 reduced the binding of EGFR with known 
players in endocytosis (e.g. AP-2) and regulators of recycling endosome traffic (e.g. 
Annexin-A2, PI4P5K). However, STRING analysis was not able to identify one  
 
Figure 14.13 Autophagy Loss Alters the EGFR Interactome 
A: Graphs representing protein relative abundance as measured by label-free quantification (LFQ) 
mass spectrometry analysis of EGFR I.P.s from XFM/tv-a shNf-1/shTp53 control and Atg7 knockout 
cell lines, with LFQ given on a log10 scale. Colour coding refers to part N of the figure, whereas 
black/grey coding designated for proteins with no enrichment in control over autophagy-deficient 
samples, B: STRING analysis of the top ten hits enriched in control samples over Atg7 knockout, C: 
Schematic simplified diagram of the endocytic pathway labelled with mass spectrometry hits lost in 
autophagy knockout cells. n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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particular complex that is disrupted by Atg7 loss (Figure 14.13B). The loss of binding 
of some endocytic regulators, such AP-2, is likely due to the stalling of EGFR in early 
endosomes in Atg7 knockout cells thereby preventing its binding to players at the 
plasma membrane. These data are in agreement with EGF uptake analyses that 
suggest the reduced flux of EGFR to the plasma membrane in knockout cells dampens 
EGF/EGFR endocytosis rate. Other players which are known to act at the plasma 
membrane, such as Mig6 and Grb2, were not seen to be influenced by autophagy loss, 
likely because they actually also bind to EGFR throughout its passage through to 
early endosomes14,24 (Figure 14.13C).  
Collectively, these analyses show that autophagy loss results in the abrogation of 
EGFR binding to certain initiators of endocytosis, recycling endosome mediators, and 
PI-regulators.  
14.3.7 Inhibitors of Vesicular Processes Can Mimic Autophagy Loss 
EGFR activity is regulated is by its endocytic trafficking that can direct it either 
through recycling endosomes back to the plasma membrane or to the lysosome for 
degradation. If autophagy is mediating EGFR activity by its endocytic trafficking, 
using inhibitors of different stages of endocytosis should mimic or oppose autophagy 
knockout. To test this, inhibitors were used against dynamin (Dynasore), 
lysosomal/vesicle acidification (Bafilomycin A1), or PI(3)P production (PIK3C3 
inhibitor) in shNf-1/shTp53 control cells.  
Bafilomycin A1 inhibits the final step of autophagosome degradation in the lysosome, 
and therefore might be expected to mimic the loss of autophagic flux caused when 
Atg7 is deleted. However, inhibition of vesicle acidification resulted in an increase of 
EGFR activity following EGF stimulation, as measured by EGFR and Akt 
phosphorylation, possibly attributable to the lack of EGFR regulation by degradation 
(Figure 14.14A). EGFR induction was also enhanced by treatment with Dynasore. 
Inhibiting dynamin prevents the pinching off of clathrin-coated pits, thereby holding 
EGFR at the plasma membrane in the clusters that are formed prior to endocytosis. 
Therefore, EGFR is not endocytosed and instead remains active at the plasma 
membrane where is can signal to Akt. However, inhibition of PIK3C3 diminished 
signalling from EGFR following EGF stimulation, mimicking Atg7 knockout. PI(3)P 
is essential for both the formation of early endosomes and in autophagosome 
biogenesis, as evidenced here in the reduction of LC3-II when its production is 
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inhibited. Therefore, this inhibitor is unable to distinguish whether EGFR activity is 
being regulated by the influences of either autophagy or endosomal trafficking. The 
evidence presented thus far has indicated that autophagy plays a role in regulating the 
endocytic trafficking of EGFR. Furthermore, a mutant of EGFR with a reduced rate of 
endocytosis is insensitive to the influence of autophagy. To confirm this, Atg7 
knockout cells were treated with Dynasore to inhibit CME. Western blotting showed 
that the influence of autophagy loss on EGFR signalling could indeed be bypassed by 
holding EGFR at the plasma membrane (Figure 14.14B). Therefore, autophagy 
influences EGFR signalling subsequent to its endocytosis. 
14.4 Homeostasis of the Endosomal System Relies on Autophagy 
The above microscopic analyses regarding the influence of autophagy proteins on 
EGFR trafficking suggest that there is a direct interplay between these two processes. 
However, the precise molecular disturbances caused by Atg7 loss to perturb the 
Figure 14.14 The Influence of Atg7 Knockout on EGFR Can Be Mimicked By PIK3C3 Inhibition 
and Rescued By Inhibiting Endocytosis 
A: XFM/tv-a shNf-1/shTp53 cells were starved of serum for 4 hr then treated with 20 ng/ml EGF alone 
or in combination with either 20 µM Bafilomycin A1, 10 µM PIK3C3, or 30 µM Dynasore for 30 min, 
before analysing by Western blot, B: XFM/tv-a shNf-1/shTp53 control and sgAtg7 cells were serum 
starved for 4 hr then stimulated with 20 ng/ml EGF for 30 min with or without 30 µM Dynasore. 
Experiments repeated at least 3 times. 
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endocytic pathway are not clear. To try to address this, I undertook a series of 
experiments to characterise the disruption in endosomal maturation. 
14.4.1 Electron Microscopy Reveals Endosomal Compartments are Perturbed 
By Autophagy Loss 
Thus far, the majority of the experiments utilising imaging methods have been 
targeted to look at specific proteins as a read-out for the status of different endocytic 
compartments. To take a step back and view the wider situation in the cell, 
transmission electron microscopy was employed. Inspection of Atg7-deficient cells 
showed a striking disruption in two key aspects of the endosomal system. Firstly, 
there was a significant increase in the number of multivesicular bodies (MVBs: 
Figure 14.15A, C). These bodies are so named because they are composed of a 
number of distinct vesicles enclosed within a single larger structure. These are known 
trafficking sites for EGFR en route to the lysosome for degradation, particularly after 
stimulation with high levels of EGF2,54. Secondly, the average area of the endosome 
or endosome-like vesicles was more than doubled by Atg7 knockout (Figure 14.15B, 
C). Therefore, autophagy loss has a significant impact on the regulation of the 
endosomal system.  
14.4.2 EGFR Does Not Accumulate in Multivesicular Bodies in Atg7 Knockout 
Cells 
Electron microscopy demonstrated that Atg7-deficient cells have dramatically more 
MVBs than control cells. Previous studies have shown that MVBs can fuse with 
autophagosomes to generate ‘amphisome’ structures that are destined for the 
lysosome. Alternatively, MVBs have also been seen to have a role in exocytosis40,55–
57. Given the documented targeting of EGFR to MVBs, I was interested to understand 
whether autophagy may be regulating EGFR plasma membrane recycling via MVB 
structures. Using GFP-tagged CD63 as a marker of MVBs, EGF-induced trafficking 
of EGFR to MVBs was measured in control and autophagy-deficient cells. The 
formation of large MVBs was promoted in autophagy-deficient cells, confirming the 
observations from the electron microscope (Figure 14.16A). Furthermore, there was 
an increased co-localisation between EGFR and CD63 in Atg7 knockout cells (Figure 
14.16B). However, inspection of the images shows that the vast majority of EGFR is 
not in fact localised in these MVBs (Figure 14.16C). Instead, earlier IF studies 
demonstrate EGFR is primarily located in early endosomes when Atg7 is lost. 
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Figure 14.15 Transmission Electron Microscope Analyses of Autophagy-Deficient Cells Show 
Disruption of Endosomal Compartments 
XFM/tv-a shNf-1/shTp53 cells with Atg7 knockout were serum starved for 4hr then stimulated with 2 
ng/ml EGF for 15 min before fixation and sectioning for electron microscope analysis. 
A: Quantification of the number of multivesicular bodies (MVBs) per cell, B: Quantification of 
endosomal vesicle size, C: Representative images showing endosomal (green stars) and MVB (pink 
stars) disruption by Atg7 loss. 3 technical replicates, 1 biological replicate, error bars represent SEM, * 
p<0.05, ** p<0.01, *** p<0.001. 
 
Therefore, it can be surmised that the increase in MVBs is a side effect of autophagy 
loss, but not the cause of EGFR trafficking disruption.   
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14.4.3 Autophagy-Deficient Cells Have Increased Endosomal 
Phosphatidylinositol-3-Phosphate  
Evidence from these experiments has connected autophagy with the regulation of 
early endosomes and MVBs. All three of these vesicular structures rely on the lipid 
phosphatidylinositol-3-phosphate (PI(3)P) to form5,26,58,59. Therefore, might the 
deregulation of early endosomes and MVBs caused by autophagy loss be attributable 
to PI(3)P disruption?  
 
Figure 14.16 Autophagy-Deficient Cells Accumulate Large CD63-Positive Vesicles 
XFM/tv-a shNf-1/shTp53 cells expressing GFP-CD63 were serum starved for 4hr then stimulated with 
2 ng/ml EGF 15 min. Cells were then stained for EGFR. A: CD63-positive vesicles are larger in Atg7 
knockout cells, B: CD63-positive vesicles co-localise more with EGFR in Atg7 knockout cells, C: 
Representative images of GFP-CD63 expressing cells co-localising with EGFR. n=3 experiments, ≥30 
cells quantified per condition, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
The overexpression of fluorescently tagged PI(3)P-binding domains in cells can 
perturb normal trafficking processes. Therefore, a technique was used to detect levels 
of PI(3)P whereby cells that were permeabilised by liquid nitrogen and fixed with 
PFA were then incubated with a recombinantly expressed Alexa488-tagged FYVE 
domain (‘PI(3)P probe’)60. As in all of the assays outlined above, cells were serum 
starved for four hours then stimulated with EGF. In shNf-1/shTp53 XFM/tv-a glial 
cells the knockout of either Atg7 or Atg16l1 resulted in a striking increase in the levels 
of PI(3)P (Figure 14.17A,E). As loss of these downstream autophagy players may be 
causing an accumulation of PI(3)P+ autophagosome precursor structures, the 
endosomal localisation of this lipid was tested with concurrent EEA1 staining. This 
showed that loss of these essential autophagy proteins causes an increase specifically 
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in early endosomal PI(3)P (Figure 14.17C,E). The specificity of this probe was 
confirmed using an inhibitor of PIK3C3, 3-methyladenine (3-MA), which reduced 
PI(3)P levels and prevented its co-localisation with EEA1. 
The majority of the experiments investigating EGFR trafficking regulation by 
autophagy in this study have utilised XFM/tv-a shNf-1/shTp53 cells. However, in the 
previous chapter we saw that EGFR in mouse embryonic fibroblasts (MEFs) also 
relies on autophagy. The phenotype observed was slightly different, however, with 
EGFR expression, but not signalling capacity, significantly reduced by autophagy 
loss. Application of the PI(3)P probe in these MEF cells shows that Atg7 knockout 
also increases the endosomal levels of this lipid in an alternative cell line (Figure 
14.17B,D,F). 
Therefore, loss of expression of essential autophagy genes results in a marked 
increase in the levels of PI(3)P at early endosomes in two distinct mouse cell lines. 
Whilst in glial cells this results in perturbed signalling from EGFR, in MEFs EGFR 
experiences increased lysosomal targeting.  
14.4.4 Autophagy Does Not Influence PIK3C3 Catalytic Activity 
Autophagy and early endosomes share a common essential kinase player: PIK3C3. 
This kinase produces PI(3)P that acts as a docking site for downstream effectors in 
both of these pathways. The PIK3C3 complex has different regulatory players 
depending on whether it is functioning in an autophagic (Atg14l1+) or endocytic 
(UVRAG+) capacity7. One player that is common between these complexes is Beclin-
1. Therefore, to test whether the knockout of downstream autophagy players Atg7 and 
Atg16l1 influences the formation of either of these complexes, Beclin-1 was 
immunoprecipitated from cells and its binding partners were interrogated. Post-
translational modification of Beclin-1 by EGFR has been seen to regulate the kinase 
complex and direct its activity33. Therefore, it was isolated from either serum-starved 
cells or cells that were serum-starved then treated with EGF.  
However, co-immunoprecipitation of components from these complexes was not 
changed by either treatment with EGF or Atg7 knockout (Figure 14.18A). Binding of 
Rubicon, which inhibits the endocytic complex, was also not altered. This was 
confirmed by the reciprocal immunoprecipitation of PIK3C3 itself and testing for 
binding partner configuration. The binding of known partners of PIK3C3, UVRAG, 
and Beclin-1, were not changed by Atg7 loss, but an exciting novel association was 
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Figure 14.17 Autophagy Loss Increases Levels of Early Endosomal PI(3)P 
Control, sgAtg7, or sgAtg16l1 cells were serum starved 4hr then stimulated with EGF 15 min (with or 
without 30 min 3-MA pre-treatment) before probing for PI(3)P and EEA1.  
A, B: Quantification of the number of PI(3)P label per cell, made relative to control autophagy-
competent cells for either shNf-1/shTp53 XFM/tv-a glial cells (A) or MEFs (B), C, D: Pearson’s 
coefficient for co-localisation between PI(3)P probe and EEA1 in shNf-1/shTp53 (C) and MEF (D) 
cells, E, F: Representative images of EEA1 and PI(3)P staining in shNf-1/shTp53 (E) and MEF (F) 
cells. n=3 experiments, ≥30 cells quantified per condition, error bars represent SEM, * p<0.05, ** 
p<0.01, *** p<0.001. 
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uncovered with Atg16l1 (Figure 14.18B-E). As this is only observed when Atg7 is 
knocked-out, it is suggestive that this may only be a very transient or weak binding 
under autophagy-competent circumstances. Upon probing for Atg16l1 in the input, it 
was clear that it is severely destabilised when not in its complex with Atg5 and Atg12 
in Atg7-deficient cells. The binding of WIPI2 was also tested. WIPI2 is a PI(3)P-
binding autophagy protein and an interacting partner of Atg16l1 and therefore might 
bridge a PIK3C3-Atg16l1 association. However, it was not detected in the PIK3C3 
immunoprecipitation. 
To investigate the importance of the interaction of Atg16l1 with PIK3C3, Atg16l1 
knockout cell lysates were subjected to PIK3C3 immunoprecipitation. However, this 
did not change the co-immunoprecipitation of either Beclin-1 or UVRAG (Figure 
14.18F). Therefore, Atg16l1 is not mediating the formation of the PIK3C3 complex. 
To understand whether the Atg16l1-PIK3C3 association relies on Atg7 or on 
autophagic flux, full length or an Atg5 binding-deficient (autophagy defective ‘Δ5’) 
mutant of Atg16l1 were re-expressed in Atg16l1 knockout cells. However, due to the 
constitutive expression of sgRNA and Cas9 enzyme in XFM/tv-a cells, it is not 
possible to use re-expression constructs of Atg16l1. Consequently, MEFs were used 
to re-express Atg16l1 where the knockout of Atg16l1 was carried out using transient 
sgRNA/Cas9 expression vectors. This mutant should recapitulate Atg7 deletion, as 
Atg7 facilitates Atg16l1 conjugation to Atg5. However, Atg16l1 was not detected 
above levels of background non-specific binding to PIK3C3 in either full length or Δ5 
Atg16l1 lysates (Figure 14.18G). Therefore, the stabilised association of Atg16l1 with 
PIK3C3 that was observed may either be specific to glial cells or only occur in the 
context of Atg7 loss. However, it is clear that autophagy status does not influence the 
composition of either autophagy or endocytosis complexes of PIK3C3. Although 
known binding partners are not changed, it is possible that the loss of autophagy 
positively impacts the activity of the endocytic PIK3C3 complex by another means, 
such as post-translational modifications, resulting in an increase of PI(3)P. To analyse 
whether this is the case, PIK3C3 isolated from control or Atg7 knockout cells was 
used in an in vitro kinase reaction with phosphatidylinositol (PI). The PI(3)P 

























Interpolation from the resulting standard curve (Figure 14.19A) revealed that, rather 
than increasing its activity, Atg7 knockout actually marginally reduced PIK3C3-
catalysed production of PI(3)P (Figure 14.19B). However, it is difficult to interpret 
Figure 14.18 Compositions of PIK3C3/Beclin-1 Complexes are Not Changed By Atg7 Loss, But 
Does Reveal an Association with Atg16l1 
Cells were serum starved for 4 hr then stimulated with 2 ng/ml EGF for 15 min before lysis and 
immunoprecipitation. A: Beclin-1 immunoprecipitation from Atg7 knockout shNf-1/shTp53 XFM/tv-a 
glial cells, B: PIK3C3 immunoprecipitation from Atg7 knockout shNf-1/shTp53 cells XFM/tv-a, C-E: 
Quantification of co-immunoprecipitation of different PIK3C3 binding partners in XFM/tv-a cells, 
proportionate to their input, expressed relative to the binding observed in control cells, F: PIK3C3 
immunoprecipitation from Atg16l1 knockout shNf-1/shTp53 cells, G: PIK3C3 immunoprecipitation 
from Atg16l1 knockout MEFs re-expressing either full length (FL) or Atg5 binding-deficient mutant 
(Δ5) Atg16l1. n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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these results without further positive and negative controls, such as active 
recombinant enzyme and chemical inhibition of PIK3C3 (e.g. 3-MA), respectively. 
Also, although within the range of the standard controls for the assay, the PI(3)P  
conversion rate was quite low in this assay, suggesting some component may not be 
optimal. Additionally, it is possible that the process of PIK3C3 isolation disrupts its 
possible misregulation in Atg7 knockout cells, such as spatial regulatory mechanisms 
or a weak interacting partner. 
 
Figure 14.19 Atg7 Marginally Inhibits PIK3C3 Catalytic Activity  
A: Standard curve of PI(3)P levels in XFM/tv-a shNf-1/shTp53 read by Echelon’s PIK3C3 ELISA kit, 
B: Interpolation and data analysis allows inference of percentage of PI substrate converted to PI(3)P. 
n=3, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
 Figure 14.20 Autophagy Loss Reduces Rab11, But Not Rab5, Activity 
A, C: Western blots of Rab5-GTP (A) and Rab11-GTP (C) immunoprecipitation from shNf-
1/shTp53 XFM/tv-a control and Atg7 knockout cells that were serum starved 4 hr then stimulated 2 
ng/ml EGF 15 min (low exposure =LE, high exposure= HE), B, D: Quantification of the proportion 
of GTP- bound Rab5 (B) and Rab11 (D) levels, expressed relative to that of control cells. n=3, error 
bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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14.4.5 Autophagy Loss Reduces Rab11 Activity 
If the levels of PI(3)P are increased by autophagy loss but the production of PI(3)P is 
not influenced, then it stands to reason that the subsequent consumption of PI(3)P 
may instead be perturbed. In recycling endosome formation, early endosomal PI(3)P 
is first dephosphorylated to PI. Then it is phosphorylated at the 4’ by PI4K before a 
second phosphorylation at the 5’, likely in anticipation of fusion with the PI(4,5)P2-
enriched plasma membrane. This lipid switch occurs in parallel with the loss of Rab5 
and the addition of Rab11 GTPases. To assay whether autophagy loss influences the 
activity of these proteins, immunoprecipitation of specifically the GTP-bound active 
forms of Rabs were performed from lysates of control and Atg7 knockout cells treated 
with EGF. Rab5-GTP levels were marginally, but not significantly, higher in 
autophagy-deficient cells (Figure 14.20A, B). Conversely, Rab11-GTP levels were 
significantly reduced when Atg7 expression was lost (Figure 14.20C, D). This 
Figure 14.21 Autophagy Status Does Not Influence Transferrin Receptor Recycling 
A-D: 555-Tfn was applied to shNf-1/shTp53 XFM/tv-a cells with or without sgAtg7 for 15 min then chased 
with media without Tfn for 5 or 15 min. A: Representative low magnification images of 555-Tfn levels 
following -Tfn chase, B: Quantification of 555-Tfn levels per cell, relative to levels before chasing with -
Tfn media (i.e. t=0 is 100%), C: Co-localisation between 555-Tfn and endogenous Rab11 is maximised 
following 15 min chase with -Tfn media as 555-Tfn is localised to recycling endosomes, D: Quantification 
of Pearson’s coefficient between 555-Tfn and Rab11 following 15 min chase with -Tfn media. n=3 
experiments, ≥30 cells quantified per condition, error bars represent SEM, non-significant (NS): p>0.05 
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suggests that the defective processing of PI(3)P in autophagy-deficient cells results in 
a failure to engage the recruitment of Rab11. 
The archetypal recycled protein is the transferrin receptor (TfnR). Following the 
binding of Tfn ligand, endocytosed TfnR has a very low rate of targeting to late 
endosomes and is instead constitutively recycled via Rab11-positive endosomes to the 
plasma membrane. To test whether autophagy influences all Rab11 recycling 
endosome traffic, the recycling rate of TfnR was investigated. Unlike EGFR, which 
detaches from EGF during endosomal sorting, TfnR remains bound to Tfn during 
endocytosis and recycling then releases it into the extracellular space. Following a 
pulse with fluorescently labelled Tfn ligand (Alexa555-Tfn, denoted 555-Tfn), cells 
were chased with media without ligand to allow the expulsion of Tfn, meaning that a 
slower recycling rate would correspond to greater levels of 555-Tfn in the cell. 
However, analysis showed that cells with or without Atg7 expression were able to 
recycle TfnR at comparable rates (Figure 14.21A,B). To confirm that this was by the 
known Rab11-mediated recycling route, 555-Tfn was co-localised with endogenous 
Rab11. The Pearson’s coefficient between these two vesicles was similar between 
control and sgAtg7 cells (Figure 14.21C,D). Therefore, autophagy does not regulate 
the trafficking of all cargoes through Rab11-positive recycling endosomes, only a 
subset including EGFR. 
14.5 Autophagy Players Localise to Early Endosomes 
These results have shown that knockout of autophagy players, such as Atg3, Atg7, and 
Atg16l1, reduces signalling from EGFR and results in stalled EGFR trafficking from 
perinuclear early endosomes. But do autophagy players directly interact with the 
endosomal pathway and EGFR to affect this change? To investigate this, a series of 
microscopic analyses were undertaken. 
14.5.1 Live Imaging of EGF and Autophagy Players Reveals Their Transient 
Association 
To capture any potentially transient associations between autophagy and endosomes, 
direct interrogation of autophagy players and EGFR trafficking was undertaken using 
confocal live-cell imaging. GFP-tagged essential autophagy players LC3 and Atg16l1 
were stably expressed in cells, which were then serum starved for four hours then 
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 stimulated with Alexa555-tagged EGF (555-EGF). Full co-localisation was not 
observed between EGF and either of these proteins, but instead a transient contact 
was detected (Figure 14.22A,B). A ‘kiss-and-run’ style of association occurred for 
approximately 155 seconds between GFP-LC3 and 555-EGF, but only 86 seconds 
between GFP-Atg16l1 and 555-EGF, which might be suggestive of the mechanism of 
association (Figure 14.22C). LC3 recruitment to pre-autophagosomal membranes 
occurs upon its conjugation to phosphatidylethanolamine, which is catalysed by 
Figure 14.22 Live Imaging of GFP-Tagged Autophagy Players and 555-EGF Trafficking Reveals 
a Transient Association  
A, B: Representative time lapses of puncta from 555-EGF-treated GFP-Atg16l1 (A) and GFP-LC3 (B) 
XFM/tv-a shNf-1/shTp53 cells, C: Bar graph showing that GFP-LC3 puncta contact 555-EGF for 
longer than GFP-Atg16l1. n=3 experiments, ≥75 events quantified per condition, error bars represent 
SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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various ATG proteins, including Atg16l1. LC3 then remains on autophagosomes 
during their expansion/formation and until their fusion with the lysosome. As LC3 is 
associated with EGF for longer than Atg16l1, it implies EGF+ vesicles are recruited 
for longer than just the LC3 lipidation step. Furthermore, following its association 
with EGF, Atg16l1 converts from its punctate localisation to becoming diffuse in the 
cell (Figure 14.22A), whilst LC3 remains in puncta after contact with EGF (Figure 
14.22B). Together, this implies that autophagosome biogenesis may occur following 
contact with EGF+ structures. 
14.5.2 Imaging Interactions Between Autophagy Proteins and Endosomes By 
Structured Illumination Microscopy 
This association was then viewed in more detail using high-resolution structured 
illumination microscopy (SIM). This provided greater clarity in showing that EGFR 
Figure 14.23 Structured Illumination Microscopy (SIM) of Endosomal and Autophagy 
Structures 
A: XFM/tv-a shNf-1/shTp53 cells expressing either GFP-LC3 or GFP-Atg16l1 were serum starved for 
4 hr then stimulated for 15 min with 20 ng/ml EGF then stained for EGFR, B: XFM/tv-a shNf-
1/shTp53 cells overexpressing S-tagged Atg16l1 were serum starved for 4 hr then stimulated with 20 
ng/ml 555-EGF 15 min before staining for EEA1 and S-tag. Experiment repeated 3 times. 
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was truly contacting, but did not co-localising with, GFP-LC3 and GFP-Atg16l1, as 
detected by IF following fifteen minutes of EGF stimulation (Figure 14.23A). If these 
structures are becoming associated but not directly binding one another, then what 
was actually providing the connection? It has been previously seen that Atg16l1 is 
trafficked through the endosomal system and that endosomes can contribute to 
autophagosome biogenesis36,53. As autophagy has been shown here to regulate early 
endosomes it is possible that they might provide the link between autophagy players 
and EGFR. To test this, cells stimulated with 555-EGF for fifteen minutes were 
prepared for SIM analysis by staining for Atg16l1 and EEA1. The resulting images 
show that EEA1+ vesicles do in fact provide a link between autophagy and EGF+ 
structures and these hybrid compartments are stabilised by loss of Atg7 (Figure 
14.23B). 
14.5.3 Weak Localisation of Atg16l1 and WIPI2 at Early Endosomes is 
Stabilised by Atg7 Loss or Chemical Disruption of Endosomes 
The above studies have revealed a weak or transient interaction between autophagy 
proteins and early endosomes in untreated autophagy-competent cells and an early 
endosomal defect in autophagy-deficient cells. This therefore raises the question of 
whether autophagy proteins can directly play a role in regulating early endosomal 
homeostasis. To interrogate this possibility, the localisation of autophagy proteins to 
endosomes was tested under different conditions. 
Confirming the findings from live cell imaging and SIM, confocal microscopy of 
autophagy-competent cells revealed a poor co-localisation between Atg16l1 and 
EEA1 (Figure 14.24A). However, as Atg7 loss had been seen to disrupt different 
endosomal structures, I hypothesised that any potential weak or transient interaction 
of upstream autophagy players at early endosomes may be captured in Atg7-deficient 
cells. Indeed, in Atg7 knockout cells there is a strong co-localisation between Atg16l1 
and EEA1 (Figure 14.24A,C). Furthermore, quantification of the size of early 
endosomes that co-localised with Atg16l1 shows that they have a larger area than that 
of the population of EEA1+ vesicles as a whole, irrespective of cell line (Figure 
14.24B). This suggests that autophagy could have a role either in regulation of 
endosomal size by facilitating an early to recycling endosomal switch that occurs in 
larger ‘sorting endosomes’ or autophagy proteins may be specifically targeted to 
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perturbed endosomes for degradation. This goes hand-in-hand with the EM data in 
section 14.4.1, which showed that Atg7 loss increased endosomal size. 
To chemically mimic the effect of Atg7 knockout on endocytic trafficking, inhibitors 
of different endosomal functions were employed. Prior to immunofluorescence 
staining against Atg16l1 and EEA1, cells were treated with either monensin, which 
inhibits the generation of a proton gradient over endosomal membranes and thereby 
prevents recycling endosome traffic, or Dynasore, which inhibits the pinching off of 
recycling endosomes that is mediated by dynamin. Interestingly, preventing the early 
to recycling endosome transition with either of these compounds induces the 
Figure 14.24 Atg16l1 and WIPI2 are Targeted to Early Endosomes When Atg7 Expression is Lost 
and Atg16l1+ Early Endosomes Are Larger Than The General Endosomal Population  
A: Representative images of EEA1 and Atg16l1 co-localisation in serum starved XFM/tv-a shNf-
1/shTp53 cells with or without Atg7 expression or treated for 1 hr with 100 µM monensin or 50 µM 
Dynasore, B: Quantification of the size of EEA1+ vesicles that co-localise with Atg16l1 compared to the 
average vesicle size of the total EEA1 population, C: Quantification of the percentage of Atg16l1+ early 
endosomes in control and Atg7 knockout cells that were either untreated or treated for 1hr with monensin 
or Dynasore, D: Representative images of EEA1 and WIPI2 co-localisation in serum starved XFM/tv-a 
shNf-1/shTp53 cells with or without Atg7 expression or treated for 1 hr with 100 µM monensin or 50 µM 
Dynasore. n=3 experiments, ≥30 cells quantified per condition, error bars represent SEM, * p<0.05, ** 
p<0.01, *** p<0.001. 
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localisation of Atg16l1 to early endosomes (Figure 14.24A,C). This localisation was 
less than that observed for Atg7 knockout cells, possibly due to the cumulative effects 
that occur during successive passages. 
It has been previously observed that lipidation of LC3 can occur on single-membrane 
vesicles, known as ‘LC3-associated phagocytosis’ (LAP)400. This non-canonical form 
of autophagy occurs independent of the upstream regulator WIPI2 and so to 
determine whether the targeting of Atg16l1 to early endosomes is part of a LAP-like 
process the co-localisation of EEA1 with WIPI2 was tested. However, WIPI2 was 
similarly targeted to early endosomes, suggesting a canonical autophagic process 
(Figure 14.24D). 
14.5.4 Markers of Endosomal Damage Localise to Early Endosomes in Atg7 
Knockout Cells 
The localisation of these autophagy players at endosomes under conditions of 
endosomal disruption suggests that the autophagy machinery may target endosomes 
for degradation. By extension, the accumulation of Atg16l1 and WIPI2 at early 
endosomes in Atg7-deficient cells may represent stalled pre-autophagosomal 
structures that are endeavouring to encapsulate endosomes. Interestingly, the targeting 
of similar single-membrane vesicles for autophagic degradation has been described 
previously in response to bacterial infection58. In this regard, when Salmonella 
attempts to escape its vacuole in order to propagate, β-galactosides on the inner 
surface of the vesicle membrane become exposed to the cytoplasm. These are then 
recognised by the β-galactoside-binding lectins galectins-3, -8, and -9 and recruit 
active phosphorylated TANK-binding kinase 1 (p-TBK1). Galectin-8 was found to be 
the player required for the selective clearance of Salmonella by autophagy via its 
interaction with NDP52 that then recruits LC3C59. Conversely, the exact mechanisms 
by which p-TBK1 is able to mediate autophagosome biogenesis, for xenophagy or 
under other circumstances, are currently unclear. To investigate whether the same 
machinery is targeting early endosomes in the context of this study, the co-
localisation between these upstream autophagy regulators with EEA1 was tested. 
Accumulations of p-TBK1 puncta were observed in Atg7-deficient cells and, 




Figure 14.25 Markers of Selective Autophagy are Targeted to Early Endosomes in Atg7 
Knockout Cells 
A: Representative images of XFM/tv-a shNf-1/shTp53 control and Atg7 knockout cells that were 
serum starved 4 hr before staining against endogenous EEA1 and p-TBK1, B: Representative images 
taken from XFM/tv-a shNf-1/shTp53 control and Atg7 knockout cells that were transfected with 
YFP-Galectin-3, -8, or -9 constructs 24 hr prior to 4 hr of serum starvation followed by staining for 
EEA1, C: Quantification of the experiment outlines in part B. n=3 experiments, ≥30 cells quantified 
per condition, error bars represent SEM, * p<0.05, ** p<0.01, *** p<0.001. 
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Further to this, YFP-tagged galectins were over-expressed in control and sgAtg7 cells 
and their co-localisation with EEA1 was examined. Unlike results gleaned from 
galectin co-localisation with Salmonella, only galectin-8 exhibited an Atg7-dependent 
accumulation on these vesicles (Figure 14.25B, C). Some co-localisation between 
galectin-9 and EEA1 occurred but this was not increased upon Atg7 loss, suggesting 
it may not be part of the mechanism by which early endosomes are targeted by 
autophagy. Likewise, galectin-3 was ruled out as it had minimal co-localisation with 
EEA1 in either control of Atg7 knockout cells. This therefore led me to hypothesise 
that the autophagy machinery is recruited to early endosomes via a p-TBK1/galectin-
8-regulated mechanism.  
Figure 14.26 GFP-LC3 is Targeted to Early Endosomes Upon Monensin Treatment 
The percentage of GFP-LC3 positive EEA1 vesicles were quantified in XFM/tv-a shNf-1/shTp53 cells 
(A) and MEF cells (C) that were either serum starved 4 hr (-monensin) or serum starved 4 hr with 1 hr 
treatment 100 µM monensin. Representative images (green: GFP-LC3, red: EEA1) of untreated or 
monensin treated XFM/tv-a shNf-1/shTp53 (B) and MEF (D) are shown with overlaid panels of zoom 
areas. n=3 experiments, ≥30 cells quantified per condition, error bars represent SEM, * p<0.05, ** 
p<0.01, *** p<0.001. 
14.5.5 Early Endosomes are Targeted to Autophagosomes Upon Monensin 
Treatment 
As galectin-8 recognises damaged endosomes and the chemical disruption of 
endosomes had been seen to recruitment of autophagy players, I hypothesised that 
autophagy may selectively degrade damaged early endosomes, thereby maintaining 
the health of the endosomal system. To test whether autophagosomes are indeed 
generated at early endosomes, targeted damage of early endosomes was induced using 
monensin and recruitment of GFP-LC3 was monitored. A striking increase in LC3 
punctuation was observed upon monensin treatment, which was predominantly 
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localised to early endosomes (Figure 14.26). This was observed in both XFM/tv-a 
shNf-1/shTp53 and MEF cells, but, as expected, did not occur in Atg7-deficient cells. 
Alongside the previous results, this data suggests that autophagy selectively targets 
early endosomes, or parts of early endosomes, when they are damaged and inhibiting 
this process by knocking out Atg7 results in perturbed and dysfunctional endosomes. 
14.6 Discussion 
Previous studies have shown that signalling from certain RTKs, such as EGFR and c-
Met, relies on the expression of different autophagy proteins and that autophagy 
proteins can be localised to different endosomal compartments 170,171,174. However, the 
reasons behind these connections are largely unknown. During the course of the 
experiments described above, it was discovered that EGFR signalling relies on the 
mediation of its plasma membrane recycling by autophagy. Autophagy promotes the 
EGFR early-to-recycling endosome maturation step without influencing its 
degradation. Inhibition of this maturation step by the loss of autophagy results in the 
perinuclear accumulation of EGFR, defects in its nuclear translocation, and reduced 
uptake of its ligand. Knockout of Atg7 results in the accumulation of upstream 
autophagy players at early endosomes, correlating with increased endosomal vesicle 
size and elevated levels of the lipid PI(3)P. Further investigation revealed that 
selective targeting of damaged early endosomes by autophagy is critical for 
endosomal homeostasis. This is required for EGFR trafficking to Rab11-positive 
recycling endosomes and its subsequent return to the plasma membrane.  
Recent reports have suggested that signalling from the RTK c-Met and EGF-mediated 
activation of ERK occurs on LC3-positive so-called ‘autophagy-related 
endomembranes’170,174. Here, although relying on autophagy protein expression for 
signalling activity, EGFR was not seen to fully co-localise with autophagy players. 
Instead, Atg16l1 and LC3 had a juxta-EGFR localisation following EGF stimulation. 
This occurred in a transient manner and was seen in fact to be bridged by early 
endosomal membranes. Therefore, EGFR was still occupying canonical endosomal 
vesicles but was experiencing a brief association with autophagy proteins. Given that 
LC3 contacted these endosomal points for longer than Atg16l1, it is plausible that 
they represent sites of autophagosome biogenesis. The duration of these puncta also 
correlate well with the approximate 2-5 minute window estimated by others for 
autophagosome formation13,153. Subsequent studies revealed that upstream autophagy 
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players strongly localised to early endosomes when Atg7 was lost. Together, these 
data suggest that autophagosomes form at early endosomes containing EGFR. 
The regulation of endosomes by autophagy also appears to be critical for the nuclear 
translocation of EGFR. This may contribute to the autophagy-mediated EGF-induced 
promotion of cell survival during serum starvation that was documented in the earlier 
chapter. Whilst the signalling cascades triggered by EGFR activity can instigate 
changes in transcription and cell cycle regulators, recent studies have also outlined a 
key role for EGFR itself as a co-transcriptional regulator of cell survival genes, 
particularly during times of stress135,137. Therefore, in addition to the known roles of 
autophagy in cell health promotion during stress, here we see that it can facilitate 
EGFR nuclear translocation to aid cell survival. 
Atg7 knockout increased the vesicular co-localisation between EGF and EGFR and 
lengthened the duration of EGF+ puncta during live imaging. These represent early 
endosomal populations that were seen to accumulate in a perinuclear region. Mass 
spectrometry revealed that certain EGFR interacting partners were altered upon Atg7 
knockout. Complexes such as CME regulator AP-2, and ER-related proteins Sec61 
and Arp2/3 exhibited reduced binding to EGFR, suggesting that loss of autophagy 
sequesters EGFR from these sites. However, other known interactors were not 
affected by autophagy loss, such as Grb2. This adaptor connects EGFR to SOS, and 
so positively regulates Ras signalling from both the plasma membrane and early 
endosomes387,388,401. This seemingly conflicts with data presented in the previous 
chapter that showed autophagy loss reduced the activity of the downstream Ras target, 
ERK. If Grb2 adaptor binding was similar with or without autophagy, how can ERK 
phosphorylation be lower? One explanation might be that ERK can also be activated 
by Ras-GTP via the PI3K/Akt signalling axis402–404. Therefore, the reduced Akt 
signalling in autophagy knockout cells that is caused by restriction of EGFR in early 
endosomes may prevent the full activation of ERK, despite Grb2/SOS/Ras activity. 
The GO term reactome pathway analysis undertaken on the mass spectrometry hits 
highlighted a defect in PI metabolism pathway components in autophagy-deficient 
cells. This is given credence by the striking increase in the levels of the lipid PI(3)P at 
early endosomes following the loss of Atg7 and Atg16l1 in glial cells, as well as in 
Atg7 knockout MEFs. This suggests that autophagy loss is somehow disturbing the 
regulation of this lipid. However, the interactions of known regulatory partners of PI 
generating enzyme PIK3C3 were not influenced by autophagy loss and neither was its 
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in vitro catalytic efficiency. In fact, rather than increasing PIK3C3 activity, autophagy 
loss actually slightly diminished it. This may be a form of feedback inhibition 
instigated by PI(3)P accumulation in these cells. Therefore, these results suggest that 
it is the maturation from early endosomes and the processing of PI(3)P are defective 
in autophagy-deficient cells, rather than excessive synthesis. 
Interestingly, loss of Atg7 resulted in the co-immunoprecipitation of PIK3C3 with 
Atg16l1. This experiment was carried out under conditions of low detergent, 
however, with cell lysis buffer containing just 0.8% CHAPS. Therefore, the integrity 
of some biological membranes can be retained, suggesting that this binding may be 
indirect and occur over a membrane. Moreover, Atg16l1 is enriched at early 
endosomes, where the PIK3C3 functions, in Atg7-deficient cells. Therefore, it is 
possible that, instead of a direct interaction between PIK3C3 and Atg16l1, the 
abrogation of autophagy results in the accumulation of Atg16l1 at early endosomal 
membranes that can then be isolated by PIK3C3 immunoprecipitation.  
In contrast to previous reports, Atg16l1 was not seen to traffic to Rab11-positive 
recycling endosomal populations in either control or Atg7 knockout cells (data not 
shown)31,152. This was elucidated using both stable overexpression and endogenous 
staining of Atg16l1, whereas previous studies have primarily focussed on 
overexpression vectors. Additionally, a more recent study uncovered that transiently 
overexpressed Atg16l1 can be aberrantly targeted to recycling endosomes, but the 
endogenous protein is not prone to do so154. Therefore, my results regarding Atg16l1 
targeting to early rather than recycling endosomes agree with the finding of some 
groups but not with others. It is possible that this may demonstrate that the trafficking 
of this protein is cell type dependent.  
Instead, an alternative connection between autophagy and recycling endosomes was 
seen in this study: autophagy facilitated the sorting of EGFR into recycling 
endosomes. However, it did not regulate transferrin receptor (TfnR) recycling rates or 
its co-localisation with Rab11. Therefore, autophagy appears to be able to regulate the 
efficient sorting of a subset of receptors. This is supported by the observation that 
autophagy loss reduces the overall levels of active Rab11-GTP by approximately 45% 
but not completely. This evidence shows that other factors or mechanisms are at play 
that can mediate Rab11-positive recycling endosome formation for different factions 
of receptors, such as TfnR.  
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Investigation of the wider status of the endocytic system by electron microscopy 
revealed that disruption of early endosome maturation and PI(3)P levels by autophagy 
loss results in larger vesicle size and elevated formation of multivesicular bodies 
(MVBs). However, EGFR was not significantly trafficked to these MVBs upon 
autophagy inhibition suggesting that their production may be a secondary effect, 
potentially indirectly promoted by the elevated PI(3)P levels405.  
Moreover, enlarged early endosomal size may be attributable to increased PI(3)P as 
the homotypic fusion of early endosomes requires by EEA1, which binds PI(3)P83. 
Therefore, the increase in PI(3)P levels may result in promotion of early endosomal 
fusion. Immunofluorescence (IF) studies revealed that early endosomes have a larger 
size when co-localised with Atg16l1, thereby implicating this autophagy protein in 
the regulation of PI(3)P and endosomal homeostasis. However, these proposals are 
based on correlative evidence. To demonstrate that excess PI(3)P drives the formation 
of MVBs in autophagy-deficient cells, PI(3)P synthesis could be inhibited before 
undertaking EM or IF studies. Indeed it is possible that autophagy loss may instead be 
preventing the clearance of MVBs rather than promoting their formation as 
autophagosome-MVB fusion products, amphisomes, are known to be directed to the 
lysosome for degradation. Further study is required to clarify this point. 
Work outlined here has shown that the autophagy players Atg16l1 and WIPI2 target 
early endosomes and these associations can be clearly captured when autophagosome 
formation is prevented by Atg7 knockout. Furthermore, inducing endosomal 
disruption using monensin results in the recruitment of not only Atg16l1 and WIPI2 
but also, in autophagy-competent cells, LC3. This therefore suggests that endosomes 
are likely to be selective targets for autophagic degradation. Upstream, this is seen to 
mediated by galectin-8 and TBK1, which have previously been described to recruit 
the autophagy machinery to damaged endomembranes in the context of xenophagy58. 
Here we observe a parallel process under homeostatic conditions, where the 
autophagy machinery appears to be important in the targeting of damaged early 
endosomes (as induced with monensin or Dynasore and were found to accumulate in 
Atg7-deficient cells). Taken together with the data outlined above, preventing the 
targeting of endomembranes by autophagy can lead to the accumulation of PI(3)P-
positive early endosomes. However, in light of these findings many questions are 
raised, some of which I shall outline here. 
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Firstly, although these data uncover the targeting of early endosomes by the 
autophagy machinery, I have not demonstrated that autophagy actually degrades 
damaged endomembranes. To do this, it would be necessary to induce endomembrane 
damage then either show the localisation of early endosomal markers at the lysosome 
or demonstrate that the protein levels of these markers are reduced by Western 
blotting. Although we see accumulations of early endosomal lipid PI(3)P when 
autophagy is inhibited, currently we cannot be certain that early endosomes are 
actually degraded by autophagy. 
It is also unclear how endomembranes are damaged under normal conditions to 
require their selective removal. In the case of escaping bacteria, it is known that 
damage is induced by type III secretion systems, and that endolysosomal membrane 
damage can occur as a result of mineral crystals such as silica58,65. Here it is seen that 
inhibiting the formation of a proton gradient (monensin) or preventing dynamin-
mediated scission of budding vesicles (Dynasore) can result in the recruitment of 
autophagy players such as Atg16l1. These are quite disparate cues- what do they 
converge on? Do they result in membrane stress and rupture to be recognised by 
galectin-8? If so, might disruption of these processes in untreated cells be the cause of 
the membrane damage that fails to be cleared in Atg7 knockout cells? 
Furthermore, the role of TBK1 in mediating targeted autophagy remains somewhat 
elusive, with its upstream regulators and downstream targets not completely 
understood. This kinase has been seen to be required for the efficient recruitment of 
autophagy adaptors such as Optineurin and NDP52 to targeted cargoes, such as 
mitochondria or bacteria56,61. What adaptor protein might be responsible for early 
endosome membrane targeting in this study? If it were a comparable system to that 
for Salmonella clearance, it would be reasonable to suggest that it may be NDP52, 
which can bind galectin-8, co-ordinate TBK1 recruitment, and bind to LC3. However, 
this remains to be tested.  
Additionally, how can stalled canonical autophagosome biogenesis be distinguished 
from the targeting of endosomes by autophagy? It has previously been described that 
components of the COPI ‘coatomer’, which is required for Golgi-to-ER transport, are 
required for autophagosome maturation and depletion of these components induces 
LC3 co-localisation with early endosomal EEA1406. Might the loss of Atg7 or 
treatment with monensin or Dynasore actually be inhibiting autophagosome 
formation? To test this, a more targeted sterile rupture of early endosomes could be 
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achieved using an osmotic disruption method, which has been previously described58. 
If these membranes also co-localise with autophagy players, I would suggest that they 
are indeed being targeted by autophagy rather than acting as a membrane source for 
autophagosome biogenesis. 
Alternatively, the expression of the upstream damage recognition players could be 
inhibited and the consequential recruitment of the LC3 lipidation machinery tested. 
This is indeed how I aim to conclude this study; currently I am working to generate 
CRISPR/Cas9 constructs against galectin-8 and TBK1. The loss of these proteins 
would be hypothesised to prevent the recruitment of the autophagy machinery to early 
endosomes. This would therefore support a cascade of recruitment from damage 
recognition (galectin-8) and autophagy adaptor stimulation (TBK1) to recruitment of 
LC3 lipidation machinery (e.g. Atg16l1). Importantly, I will also test the influence of 
the knockout of these players on EGFR phosphorylation and signalling. However, 
many other avenues remain to be explored, particularly with regards to specificity of 
the endomembrane cargo. 
Together, the studies outlined above clearly demonstrate a key role for autophagy in 
facilitating the endocytic recycling of EGFR. Further results suggest this is promoted 
by autophagic clearance of perturbed early endosomes that thereby maintains 
endosomal homeostasis and allows progression of specific cargoes, such as EGFR, 
from PI(3)P+/EEA1+ early endosomes to Rab11+ recycling endosomes. Functional 
autophagy consequently promotes RTK signalling, EGFR nuclear translocation, and 
cell survival induced by EGF.   
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15 Final Discussion 
Throughout the course of this project I have endeavoured to elucidate whether 
autophagy can promote pro-growth properties of glioblastoma multiforme (GBM). 
The results gleaned during the course of experiments outlined above have uncovered 
a novel role for autophagy in regulating oncogenic receptor tyrosine kinase signalling. 
By delving into the cellular trafficking pathways that regulate such signalling it was 
possible to show that autophagy players are important in maintaining early endosomal 
function. These findings related back to my earlier work that showed that autophagy 
is important for oncogenic phenotypes of GBM cell line and mouse models. Here I 
shall discuss these results in the context of the existing literature, the relative 
problems and pitfalls of the experimental techniques, and how this work may be built 
upon in the future. 
15.1 Endosomal Regulation by Autophagy Proteins 
Endocytosis and autophagy are both vesicular trafficking mechanisms that regulate 
the abundance and activities of a variety of different cellular regulators. These 
pathways share a variety of common regulators, from lipid modifiers like 
phosphatidylinositol-3-kinase complex 3 (PIK3C3) to activators of Rab small 
GTPases. Several groups have described the localisation of autophagy proteins at 
different endosomal compartments and endosomal trafficking destinations, such as 
the Golgi. Whilst the contribution of these compartments to autophagosome 
biogenesis is beginning to be understood, the influence of autophagy proteins on the 
endosomal system is not known. By using a variety of microscopy analyses, here I 
have been able to show that inhibition of autophagic flux by genetic ablation of Atg7 
expression results in a significant disruption of endosomal homeostasis. Specifically, 
the loss of autophagy results in more multivesicular bodies (MVBs) and perturbs the 
maturation of early to recycling endosomes. Molecularly, this correlates with an 
increase in phosphatidylinositol-3-phosphate (PI(3)P) levels and the accumulation of 
autophagy proteins at early endosomes.  
15.1.1 Atg16l1 Localisation to Early Endosomes 
How does this fit into the larger picture of the endocytic and autophagy pathways? 
The plasma membrane and endosomal compartments have been shown to 
significantly contribute to autophagosome biogenesis, with certain autophagy players 
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localising there before re-distribution to pre-autophagosomal structures24,31,32,44. For 
example, Atg16l1 has been described to localise to recycling endosomal 
compartments31,146. However, during the course of the studies undertaken here in glial 
cells, I was unable to replicate this result, instead finding that this essential autophagy 
protein primarily tends to localise to early endosomes, particularly when recycling 
endosome formation was disrupted either chemically (monensin or Dynasore) or 
genetically (Atg7 loss). Further, a recent study reported in the Autophagy journal 
suggested that Atg16l1 targeting to recycling endosomes was only possible when 
transiently overexpressed Atg16l1 aberrantly targets there, but is not a common event 
for the endogenous protein154. 
These findings are interesting when considering that Atg16l1 can interact with the 
endocytic regulator clathrin-heavy chain at the plasma membrane: how does Atg16l1 
traffic from the plasma membrane to endosomes and on to autophagosomes? And 
therefore, by inhibiting autophagic flux in this study am I capturing an otherwise 
transient or minute intermediate of Atg16l1 transport? Current standard 
immunofluorescence techniques rely on a significant enrichment of a protein at a 
certain subcellular locale for detection above diffuse/background staining and 
therefore the trafficking of a small subset of protein cannot be detected, perhaps 
explaining why other groups have not observed Atg16l1 at early endosomes. By 
inhibiting its use in autophagy by deleting Atg7, we accumulate Atg16l1 at early 
endosomes to sufficient levels for detection by immunofluorescence staining. 
Alternatively, it is possible that Atg16l1 is targeted to early endosomes in Atg7-
deficient cells by virtue of a perturbation of the properties of those endosomes, like 
increased PI(3)P levels or changes in membrane curvature. I have shown that Atg16l1 
localises specifically to larger EEA1-positive early endosomes, and that this correlates 
with an increase in PI(3)P levels. Unpublished evidence from our laboratory group 
demonstrates that Atg16l1 can bind lipid moieties, with a specificity for PI(3)P 
(generated by Leo Dudley and Ainara González-Cabodevilla, data not shown here). 
Therefore, my data co-localising Atg16l1 with EEA1 may represent targeting of 
Atg16l1 to enlarged early endosomal compartments that have elevated PI(3)P.   
It is interesting to consider the purpose of Atg16l1 trafficking through the endosomal 
system, however, not just with regards to regulation of endocytic trafficking but when 
considering autophagic flux. For instance, autophagy proteins at endosomes may act 
as sensors for extracellular conditions – might the presence of Atg16l1 act as a sensor 
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of growth factor signalling? For example, under starved conditions Atg16l1 might be 
targeted to sites of autophagosome formation, whilst under fed conditions, when there 
is less demand for autophagy, it might transport via early endosomes to the lysosome. 
Alternatively, the localisation of autophagy players at early endosomes may indicate 
that autophagosome biogenesis requires membrane sourced from the endocytic 
pathway. Whilst these hypotheses are intriguing, further investigation suggested that 
Atg16l1 and other autophagy proteins are likely to be targeted to early endosomes as 
part of another mechanism, as described below. 
15.1.2 Autophagy Targets Early Endosomes For Degradation 
Although traditionally believed to be a largely random bulk degradation pathway, the 
discovery of multiple mechanisms that regulate the targeting of autophagy machinery 
to specific cargoes in a closely regulated manner has shown it to be a highly 
specialised degradation process. In particular, the targeting of organelles, such as the 
ER or mitochondria, by autophagy has garnered much attention in recent 
years60,66,70,407–409. Functionally, the selective clearance of damaged organelles, or 
parts of organelles, has is seen to be important for their overall function and 
consequently the maintenance of cell fitness60,69,410. Excitingly, for the first time here 
we show that autophagy proteins can also selectively target early endosomes. 
However, the work undertaken here has not shown that autophagosomes actually 
deliver these structures to the lysosome for degradation. As discussed in section 14.6, 
further experimentation is required to verify the final steps in this pathway. 
Early endosomal targeting seems to occur constitutively in cells as the loss of Atg7 
results in the accumulation of autophagy regulators, such as Atg16l1 and WIPI2, at 
early endosomesunder untreated conditions. However, it is likely to occur at a low 
level under basal conditions, as the co-localisation of these players with EEA1 in 
unstimulated autophagy-competent cells is infrequent. Instead, for significant 
Atg16l1-EEA1 co-localisation in wild-type cells, endosomal stress had to be induced 
using monensin and Dynasore, which disrupt membrane potential and prevent the 
dynamin-mediated budding off from vesicles from endosomes, respectively.  
15.1.2.1 How Does Endomembrane Damage Occur? 
Further investigation revealed that perturbed early endosomes are targeted by 
galectin-8, which recognises galactosides on the luminal face of endomembranes, and 
phosphorylated TBK1, which is known to function as part of the innate immune 
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response58,411. However, it is unclear how endomembrane damage might occur under 
basal conditions and accrue in Atg7-deficient cells. One possibility is that membrane 
remodelling processes that are undertaken as vesicles bud off from endosomes induce 
membrane stress and rupture that needs to then be cleared. This is supported by the 
localisation of Atg16l1 and WIPI2 to early endosomes following Dynasore treatment, 
which is known to cause elongated enlarged endosomes (as shown here and 
elsewhere412,413) and therefore could alter endosomal membrane integrity by 
increasing its curvature. Alternatively, the osmotic imbalance or disruption of the pH 
gradient over the endosomal membrane may result in membrane rupture and galectin-
8 recruitment. These perturbations are induced by monensin, the application of which 
resulted in the co-localisation of EEA1 with Atg16l1, WIPI2, and LC3. 
Further study to understand the exact cause of this damage is challenging due to the 
difficulty in controlling for the multitude of factors that can regulate early endosomes 
and can compensate for their disruption. A targeted approach would be required to 
test specific hypotheses and candidate processes. 
15.1.2.2 Selectivity of Autophagic Endosomal Targeting 
Deciphering the cause of this membrane disruption might also help address another 
question: why early endosomes? Several other endosomal types exist in the cell, yet 
early endosomes seem to be specifically targeted by the autophagy machinery in 
Atg7-deficient and monensin- or Dynasore-treated cells. Why do these factors not 
also induce late or recycling endosomal degradation? It is possible this selectivity is 
due to the enrichment of PI(3)P at early endosomes – a lipid known to be essential for 
autophagosome biogenesis by recruiting key factors including WIPI2414, DFCP1415, 
and Atg16l1 (unpublished data from our laboratory).  
It is also conceivable that targeting early endosomes over other forms is the most 
efficient means of controlling membrane quality throughout the endocytic system as 
other endosomes are derived from early endosomes. In one model, cargoes can be 
sorted into subdomains in a so-called ‘sorting endosome’ that then bud off as late or 
recycling endosomes416–418. Therefore, ensuring early endosome membranes are intact 
would promote the membrane integrity of any subsequent daughter vesicles. In the 
course of these experiments we have seen that loss of autophagic endosomal 
homeostasis does indeed perturb recycling endosome traffic, either by hindrance of 
formation or an inability to properly mature into Rab11+ recycling endosomes. 
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Therefore, it seems that maintaining endomembrane integrity is important for 
recycling endosome function. Conversely, ensuring late endosomal membranes are 
intact is a relatively futile task as they are destined to imminently fuse with the 
lysosome and be degraded. 
15.1.3 Multivesicular Bodies are Elevated in Autophagy-Deficient Cells 
As well as defects in early endosomes, immunofluorescence and electron microscopy 
revealed that Atg7-deficient cells have a striking increase in the numbers of MVBs. It 
has been known that endosomal structures such as MVBs can fuse with autophagic 
vesicles to mediate their degradation90. Therefore, the increased incidence of MVBs 
in autophagy-deficient cells may be as a result of one of two factors: either the 
increased formation promoted by elevated PI(3)P-positive early endosomes, or 
defective clearance of MVBs via autophagosome-fused intermediate structures called 
amphisomes419,420.  
Although the work undertaken here is unable to resolve whether it is the synthesis or 
degradation of MVBs that is influenced, it would be possible to address this point by 
acutely inhibiting these processes. One means of doing this may be by using PI3KC3 
inhibitors, like SAR405, to prevent PI(3)P synthesis and thereby abrogate the 
recruitment of the ESCRT complex to form MVBs91. The degradation rate of MVB 
structures could then be monitored in autophagy-competent and autophagy-deficient 
cells whilst preventing any fresh synthesis.  
In the light of the data gathered during this study, however, I would hypothesise that 
rather than blocking in their degradation, autophagy loss seems instead to result in the 
accumulation of PI(3)P at early endosomes that would promote MVB formation. To 
test this, blocking lysosomal function, such as by using bafilomycin A1, could inhibit 
MVB degradation and so the subsequent formation rate of MVBs could be calculated. 
Although not explored extensively in the context of this study, MVBs are known to be 
important organelles for several cellular processes, such as dampening RTK 
signalling and exosome release, which have been seen to have a role a wide-range of 
pathologies including cancer and neurodegeneration421–423. Therefore, the impact of 
autophagy loss on MVB biology warrants further investigation. 
15.1.4 Autophagy Regulates the Trafficking of EGFR to the Nucleus 
Away from endosomal vesicles, autophagy has been seen to be required for the 
homeostasis of and trafficking of various cellular components to organelles like the 
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Golgi and mitochondria. Trafficking of receptor tyrosine kinases to the nucleus is 
thought to occur via early endosomes that either sends cargo retrograde via the 
Golgi/ER or even by direct fusion with the nuclear envelope. Previous work has 
shown that autophagic flux is required for the trafficking of EGFR to mitochondria 
and here we have demonstrated that expression of Atg7 is required for EGFR 
trafficking to a nuclear marker-containing fraction of cell lysate176. However, whether 
this fraction represents solely the nuclear fraction was not proven- it was isolated by 
removing ‘cytosolic’ and ‘membrane’ fractions by increasing detergent stringency, 
leaving only constituents that are not soluble in 1% NP-40 but are soluble in RIPA 
buffer. Whilst lacking the membrane marker β1-integrin and enriched in the nuclear 
protein PCAF, the presence of other contaminating organelles, such as ER or Golgi, 
was not investigated. As the function of nuclear EGFR is known to be a potent driver 
of cell survival/growth but ER/Golgi-resident EGFR is not known to have a function, 
distinguishing these possibilities is would be important in determining whether this 
function of autophagy truly mediates nuclear EGFR.  
The nuclear localisation of EGFR is induced by its ligand-mediated activation137. 
Therefore, it is not clear whether the defect in EGFR nuclear translocation is due to 
the reduced EGFR activity or perturbed early endosome function or maturation. Alas, 
there is not enough currently known about the mechanism of plasma membrane-to-
nucleus trafficking mechanisms for molecules such as RTKs or integrins to be able to 
dissect this phenomenon easily108,109,135. 
Once in the nucleus, EGFR has been described to act as a co-transcriptional activator 
by binding to other transcription factors, such as STAT3, to initiate the expression of 
proliferative genes, such as c-Myc424. It would be interesting to test whether the 
apparent requirement for autophagy for EGFR nuclear translocation influences its 
ability to act as a co-transcriptional activator. In this scenario, the expression of gene 
products such as c-Myc, Cyclin-D, iNOS, and STAT1 could be measured by 
quantitative reverse transcription PCR (qRT-PCR) in autophagy-competent or -
deficient cells that are or are not stimulated with EGF for different time-points135.  
15.1.5 Autophagic RTK Endocytic Regulation is Selective 
This study has used EGFR trafficking as a model marker for the impact of autophagy 
on endocytic trafficking proficiency as a whole. However, we (and others170,171) have 
also seen that whilst this phenomenon also holds true for other RTKs, like c-Met, 
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others do not rely on autophagy for maximal signalling activity, such as IGF-1R. 
Alternatively, the transferrin receptor (TfnR) is a well-known model for Rab11-
mediated endocytic recycling but its endocytosis, recycling rate, and Rab11 
colocalisation were unaffected by loss of Atg7 expression, suggesting Rab11-positive 
recycling endosomes were functional.  
How can we align these data with those from experiments demonstrating the 
recycling via Rab11-positive and maximal signalling activity of some RTKs relies on 
autophagy? It has long been postulated that not all RTKs are handled equally by 
endosomes: whilst some seem to preferentially signal from the plasma membrane 
others can signal in endosomes, and although RTKs such as Trk kinases are 
preferentially recycled, others, like PDGFR are sorted to the lysosome117,425–427. What 
dictates these specificities is currently unknown and constitutes a field of active 
research. These RTK regulatory mechanisms are generally considered to be specific 
to cell type and likely help establish lineage-specific properties. Here we may suggest 
that glial cells have a high reliance on plasma membrane-localised EGFR that is 
maintained by Rab11-mediated recycling routes, whereas IGF-1R may either be 
directly sent to the lysosome, internalised at a reduced rate, signal from endosomes, or 
returned to the plasma membrane preferentially via Rab4-regulated ‘fast’ recycling 
endosomes. This would be an interesting point to pursue through further experiments 
localising IGF-1R to different endocytic compartments and utilising a cell surface 
biotinylation recycling assay, as described in section 14.3.3. Alternatively, these 
differences may be attributable to discrepancies in the efficiency of receptor sorting to 
Rab11-positive recycling endosomes that depends on autophagy. This, indeed, would 
be the most likely explanation of why the TfnR is recycled at a similar rate in 
autophagy-competent and autophagy-deficient cells: whilst TfnR is able to be sorted 
properly, EGFR, which has a drastically different set of binding partners and 
ubiquitination marks, is unable to be correctly sorted. 
To explore the importance of autophagy in endocytic trafficking and EGFR 
signalling, here I have manipulated the expression of three genes (Atg3, Atg7, and 
Atg16l1) that are essential for autophagy. Whilst these proteins are known to function 
in both canonical and so-called ‘non-canonical’ autophagy, other autophagy players, 
such as Atg13, have only been documented to participate in canonical autophagosome 
biogenesis428–431. To explore the possibility that this is a non-canonical 
autophagosomal process it would be necessary to ablate expression of Atg13 in these 
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cells and then assay the signalling response to EGF and the recycling capability of 
EGFR.  
On the other hand, an alternative form of LC3 lipidation has been described to occur 
on single membrane vesicles called LC3-associated phagocytosis (LAP)400. However, 
as this process is WIPI2-independent, the co-localisation of WIPI2 with EEA1 
observed here argues against the phenomenon observed here being LAP. To 
conclusively test this, however, a mutant of Atg16l1 has been described that can 
function in canonical autophagy but is unable to target to sites of LAP400. Therefore, 
the targeting of this mutant to early endosomal membranes would demonstrate that 
this is not LAP but rather a canonical form of autophagy. 
15.2 Autophagy as a Modulator of Receptor Tyrosine Kinase 
Signalling 
It is known that the endocytic trafficking of RTKs is a critical regulator of their 
activity. Indeed, the studies undertaken here show that the perturbation of endocytic 
homeostasis in autophagy-deficient cells correlates with an inability to maintain 
maximal signalling capacity, which is attributed to reduced plasma membrane 
recycling. Furthermore, Atg7 loss results in inhibition of EGFR nuclear translocation, 
where it is known to carry out a function as a co-transcriptional activator135,137.  Here I 
shall put this in the context of data gathered in chapters 11 and 12, as well as with 
regards to what has been described previously in the field. Additionally, I shall 
discuss some of the technical considerations when interpreting cellular signalling 
data. 
15.2.1 The Interpretation of Signalling Data 
In chapter 13 I uncovered a role for autophagy in promoting signalling from EGFR, 
specifically to Akt and ERK that lie in the interconnected PI3K/mTOR and MAPK 
cascades, respectively. Although these are both well-known read-outs of EGFR 
activity, interestingly I found a particularly striking defect in Akt signalling but a mild 
or inconsistent perturbation in ERK, as evidenced by the larger error bars in the 
quantification for p-ERK ratios. This may be due to the possibility of ERK to be 
stimulated from early endosomes, whereas Akt is widely believed to be primarily 
activated at the plasma membrane, where its upstream activator PI3K resides130–134. 
Subsequent endocytic trafficking studies showed that EGFR was stalled in early 
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endocytic compartments in Atg7 knockout cells and therefore was sequestered from 
being able to activate Akt but ERK signalling may still be possible. These findings 
highlight the importance of utilising more than one read-out of RTK activity to be 
able to clearly understand whether a process of interest is capable of influencing 
signalling. However, by the low-throughput process of Western blotting I was only 
able to investigate these two players whereas EGFR is known to signal to a wide 
variety of downstream pathways including JAK/STAT77,432. 
To test whether Atg7 loss also impacted these pathways I employed RPPA, which can 
measure the phosphorylation and total levels of proteins and thereby infer their 
activity. This demonstrated that in fact autophagy was important for the activation all 
known EGF-stimulated pathways. However, this technique is not without its 
limitations. For example, it is highly dependent on the accuracy of the RPPA robot in 
spotting protein lysates on slides as well as the specificity of the antibody of interest. 
As an illustration of this point, whilst Western blotting (confirmed with two different 
antibodies) showed that EGFR levels were not altered by Atg7 knockout, RPPA 
indicated reduced expression of the protein. However, due to time limitations, this 
experiment was only repeated once and therefore this study should only be considered 
as preliminary data indicating a wide-ranging effect of autophagy on EGFR signalling 
output. To further confirm this finding, RPPA would need to be repeated and key 
pathways checked by Western blotting. 
Furthermore, in section 13.3.5, cell death during prolonged serum starvation with or 
without growth factor co-culture was used as a read-out of RTK activity. However, 
other outputs, including proliferation rate and expression of co-transcriptional targets 
are also frequently used in the field to measure the activity of RTKs. In order to more 
comprehensively test the cellular impact of autophagy loss on RTK activity, these 
factors should also be tested following growth factor stimulation. Additionally, 
although unfortunately outside the scope of the present study, RTK activity could be 
measured in vivo. This could be achieved by immunohistochemical staining of against 
phosphorylated forms of proteins such as EGFR and ERK in tumours with or without 
autophagy protein expression, or by checking for the presence of RTKs in the nucleus 
of tumour cells.  
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15.2.2 Cell Line Specificity of the Effect Autophagy on RTK Signalling 
It is also of interest to understand whether autophagy is engaged in the quality control 
of early endosomes in other cell types.  
I observed that autophagy has differing effects on the RTK EGFR according to cell 
line. Whilst in XFM/tv-a glial cells EGFR steady-state levels were found to be similar 
but its recycling rate and downstream signalling activities were abrogated by Atg7 
loss, in MEF cells signalling in response to EGF stimulation was unaffected but 
overall expression levels of the receptor were significantly reduced. Encouragingly, 
this fits with data previously reported for EGFR levels in MEF cells with autophagy 
loss52,433. However, thus far, the cause of these differences has not been resolved. I 
propose that early endosomal defects that accumulate following autophagy loss result 
in a cell-type specific effect on EGFR. Whilst in glial cells the recycling route of 
EGFR is inhibited but degradation is unchanged, in MEFs when the receptor is unable 
to be recycled it is preferentially targeted via late endosomes to the lysosome. Studies 
of the endocytic pathway undertaken in both cell lines (e.g. elevated PI(3)P levels and 
early endosomal targeting by LC3) yielded similar results, supporting the notion that 
this mechanism may be common between different cell lines. However, more 
extensive testing is required to confirm this.  
Furthermore, I observed conflicting results of ERK and Akt phosphorylation 
following EGF stimulation in MEF and XFM/tv-a cells. It is possible that this is due 
to their capacities for RTK signalling from early endosomes. Conflicting evidence 
regarding the stimulation of downstream signalling from early endosomes has been 
widely discussed77,82,130–133. Studies undertaken here have shown that EGFR 
accumulates in PI(3)P+ early endosomes when autophagy is lost- a compartment that 
has been suggested to be signalling defective. However, EGF stimulation of MEFs 
generated similar levels of Akt and ERK phosphorylation. This may be because 
EGFR activity is not in fact inhibited in this compartment in MEFs and therefore its 
accumulation there instead of its recycling to the plasma membrane does not impact 
the signalling output. To test this hypothesis, immunofluorescence against phospho-
ERK or -Akt and intracellular EGFR puncta could be undertaken. If true, in XFM/tv-a 
cells there would be little co-localisation expected whilst in MEFs a strong co-
localisation may be found.  
However, both XFM/tv-a and MEFs are mouse-derived cell lines so to be able to 
assess the potential importance of this process in GBM oncogenicity it would be 
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necessary to repeat several key findings in a human-derived GBM model cell line. 
Additionally, it would be fascinating to test this mechanism in vivo, perhaps by 
utilising the GFP-LC3 mouse. 
15.2.3 Autophagy and RTK Signalling as Regulators of Senescence 
As outlined in chapter 11, the prolonged culture of XFM/tv-a KRas cells in low serum 
conditions caused shAtg7 cells to undergo p27/pRB-mediated senescence. In a 
parallel experiment, whilst autophagy-competent cells were able to maintain strong 
Akt and ERK signalling in low serum or oxygen conditions, Atg7-deficient cells were 
unable to so. Might these two observations be linked? And might they relate to the 
reduction RTK signalling capacity described in chapter 13?  
RTKs like EGFR are known to promote cell survival during stressful conditions, such 
as low oxygen326,434–436. Lying downstream of EGFR lie Akt and ERK, which are here 
seen to have reduced activation in shAtg7 cells. This may impact the susceptibility of 
these cells to senesce as Akt acts as a negative regulator of p27, a key cell cycle 
inhibitor and senescence modulator212–214. Therefore, a pathway may be envisaged in 
which autophagy promotes EGFR endocytic trafficking and signalling under 
conditions of low serum or oxygen, thereby maintaining Akt activity and keeping p27 
at bay to prevent the induction of senescence. To understand whether this mechanism 
might be occurring in these cells, chemical inhibitors of Akt and EGFR could be 
employed, which should mimic the senescent phenotype observed in Atg7-deficient 
cells. This finding could have an impact on a number of fields, including 
development, cancer, and ageing344,437,438. 
15.3 Autophagy as a Regulator of Glioblastoma: An Opportunity 
for Therapeutic Intervention? 
The results gleaned here from in vitro GBM model cell line models have elucidated a 
role for autophagy in maintaining signalling frequently found to be oncogenic in this 
aggressive brain cancer. But how useful is this information in the clinical setting?  
15.3.1 Autophagy as an Inhibitor of Resistance and Recurrence 
Throughout the course of this work I have assayed the influence of autophagy on the 
oncogenic properties of glial cells. However, the greatest challenge in treating patients 
is the recurrence of the tumour. Although I have not directly investigated the 
importance of autophagy following radiotherapeutic or chemotherapeutic insults, the 
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results gleaned can be interpreted in the context of known drivers of tumour 
resistance. 
For example, nuclear EGFR is believed to drive resistance to therapies, particularly 
with regards to GBM and in section 14.3.5 I demonstrated that the nuclear 
translocation of this receptor is significantly inhibited in Atg7-deficient cells135,359. 
Therefore, autophagy may promote resistance to therapies by facilitating EGFR 
trafficking to the nucleus. Alternatively, I found that the influence of Atg7 loss on 
signalling and wild-type EGFR trafficking can be overridden by the presence of the 
constitutively active EGFRvIII mutant which is found in approximately 23% of GBM 
cases251. This variant is also known to support the nuclear functions of EGFR347,439. 
Therefore any potential influence of autophagy on the signalling or nuclear 
translocation of EGFR would be overcome in cells expressing this mutant receptor. 
This result argues for the need for a personalised approach when targeting autophagy 
in GBM, as it may not be efficacious in patients with EGFRvIII mutation.  
15.3.2 Targeting Autophagy as a Broad-Range RTK Inhibitor in GBM 
How might we go about targeting autophagy in GBM? And what factors would need 
to be considered in light of the results gleaned here? 
One of the major considerations for any GBM therapeutic is the low permeability of 
the blood-brain barrier and the difficulty in penetrating completely through the 
tumour mass. Therefore, producing an efficacious concentration of an autophagy 
inhibitor in GBM tumours would require a potent and specific compound. Currently, 
the only clinically available inhibitors of autophagy are not specific to autophagy and 
have not been able to achieve high enough concentrations to properly inhibit the 
pathway in patients288. More specific compounds are in high demand in a clinical as 
well as basic research capacity. Some interesting compounds are starting to be 
developed in this regard, such as the ATG4B inhibitor NSC185058 which was used to 
target autophagy in combination with radiotherapy treatment in a GBM model40. 
However, further work is required to develop such compounds and provide options 
for trials in patients. 
In the meantime, of the genetic tools available to specifically target the autophagy 
pathway shRNA is likely to be the best representation of the situation in tumours, 
where there is unlikely to be a complete loss of protein function upon the application 
of an inhibitor. Therefore, although a quick and useful tool in the laboratory, 
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CRISRP/Cas9-mediated knockout may not be an accurate prediction of the effect of 
an autophagy inhibitor. Additionally, shRNAs in the RCAS/tv-a mouse model were 
constitutively expressed to a high level to achieve a very effective knockdown of 
autophagy gene expression, and so also be not be a good representation of a 
therapeutic agent. However, rapid advancements in the CRISPR/Cas9 field are raising 
the possibility of utilising this tool in the clinic440,441. If this technique can be 
developed in GBM, the direct targeting of autophagy players could be achieved. 
However, unlike acute treatment with a selective chemical inhibitor, the delivery of 
these agents would have to be targeted to tumour cells as studies in mice have shown 
that the systemic irreversible loss of autophagy causes a multitude of issues, including 
neurodegeneration and susceptibility to infection6,200. 
The results gleaned here also highlight a potential pitfall in targeting autophagy to 
simultaneously inhibit a variety of RTKs. Although several RTKs, such as EGFR and 
c-Met, are reliant on autophagy to achieve maximal signalling, others are not, such as 
IGF-1R and EGFRvIII. Therefore, as has been documented previously for targeted 
RTK inhibitors, a compensatory upregulation of non-inhibited receptors might make 
an autophagy inhibitor ineffectual as a treatement due to being prone to resistance and 
relapse442,443. However, a therapeutic window to increase patient survival may exist 
for those with tumours addicted to signalling from an RTK that is modulated by 
autophagy, thereby providing an opportunity to employ a personalised medicine 
approach.   
Furthermore, a number of reports are coming through that autophagy proteins can 
actively participate in cellular processes independently of their canonical function in 
the autophagy as a catabolic pathway. This includes regulating mitochondrial 
function, endocytic trafficking, and supporting RTK signalling, as also described 
here146,170,173,444. Therefore, even inhibition a single autophagy player to inhibit 







15.4 Conclusion and Graphical Abstract 
As a whole, the results of these studies highlight autophagy as an exciting therapeutic 
target in GBM. Initial experiments showed that this pathway is critical for tumour 
formation in a mouse model of GBM due to its ability to maintain pro-growth 
signalling pathway activity and inhibit senescence. Further work demonstrated that 
autophagy supports signalling and cell survival during anchorage loss, a key feature 
of oncogenic transformation. Finally, work focussing on EGFR has demonstrated that 
autophagy is able to directly regulate homeostasis of the endocytic system. This 
promotes efficient EGFR recycling to the plasma membrane to consequentially 
maintain maximal signalling and cell survival.  
 
Figure 15.1 Graphical Abstract 
Early endosomal membrane damage is recognised by galectin-8 and p-TBK1. Removal of such damage 
is important for the early-to-recycling endosome switch to mediate the recycling of RTKs, such as 
EGFR. This facilitates their downstream signalling to PI3K/Akt and ERK/MAPK pathways that 
promote cell growth, survival, and anchorage-independent growth, whilst suppressing senescence.  
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Appendix 1: Additional Quantifications of Reverse Phase Protein Array Data 
Continuation from Chapter X where XFM shNf-1/shTp53 cells were either left untreated or subjected 
to serum starvation for 4hr followed by 20ng/ml EGF stimulation or 1% FBS stimulation for 15/30min 
The results of the RPPA were ordered from highest to lowest signal ratio in Control over sgAtg7 for the 


















Figure S17.1 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 




















Figure S17.2 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 
EGFR Downstream Signalling Cascades III  
 
Figure S17.3 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 


















Figure S17.4 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 















Figure S17.5 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 

















Figure S17.6 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 















Figure S17.7 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 





Figure S17.8 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 
EGFR Downstream Signalling Cascades IX 
Figure S17.9 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 

















Figure S17.10 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 
















Figure S17.11 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 

















Figure S17.12 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 
















Figure S17.13 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 




Figure S17.14 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 















Figure S17.15 Reverse Phase Protein Array Analysis Reveals Atg7 Loss Reduces the Activity of 
EGFR Downstream Signalling Cascades XVI  
 
